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ABSTRACT 
 
 Obesity, a complex multifactorial disease, is a serious public health concern due 
to numerous obesity-related comorbidities thought to result from various hormones in 
combination with lifestyle and environmental factors.  At present, the role of only a 
fraction of the hormones involved in obesity have been well defined. The aims of this 
thesis were to investigate: 1) the association of appetite regulating hormones with obesity 
and obesity-related phenotypes in the Newfoundland and Labrador general population; 2) 
the response and interaction of appetite and energy regulating hormones on obesity 
development under a positive energy challenge; 3) the association of dietary magnesium 
intake with obesity and diabetes; 4) testing the validity of the body adiposity index (BAI) 
in a Caucasian population; 5) the association of BAI with cardiometabolic risk factors 
(CRF); 6) and the development of a novel and more accurate equation than body mass 
index (BMI)and BAI to evaluate adiposity.  All of these were achieved using data from 
two different studies - the large scale, population-based CODING (Complex Diseases in 
the Newfoundland Population: Environment and Genetics) study and an intervention-
based, 7-day positive energy surplus study. 
 We have discovered that circulating PYY (appetite suppressant) is not 
significantly associated with obesity status defined by either percent body fat (%BF) or 
BMI.  However, circulating PYY was influenced by age, smoking, medication use, and 
menopausal status in women.  We also sought to explore the endocrine response of 
normal-weight, overweight and obese individuals to a 7-day hypercaloric diet.  We 
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demonstrated that PYY increased in response to overfeeding, but was not associated with 
changes in insulin resistance and/or weight.  We also found that adiponectin (insulin 
sensitizer) was not associated with obesity status but the significant increase in 
adiponectin, due to overfeeding, was significantly associated with insulin resistance.   
 We also investigated the impact of dietary magnesium on obesity and obesity-
related co-morbidities and found that higher dietary magnesium intake is associated with 
improved insulin sensitivity and this effect is particularly beneficial for overweight and 
obese individuals in the general population along with pre-menopausal women.  
Therefore, our data would suggest that the beneficial effects of magnesium intake are less 
sensitive among post-menopausal women.   
 In addition, we explored the applicability of the BAI and found that it was a better 
estimate of adiposity than BMI in the non-obese Caucasian population. The BAI was also 
more closely associated with the relationship of %BF with CRFs than BMI.  However, 
this association is significantly attenuated when assessing the influence of increasing BAI 
on CRFs amongst men and women examined separately. 
 Lastly, we developed a sex-specific equation to overcome the gender related 
weakness of both BMI and BAI to predict adiposity.  The body fat index (BFI) sex-
specific equations we developed more accurately predict %BF than BMI and BAI in the 
general population and at various extremes of adiposity in men and women.  
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1.1 - Prevalence of Obesity and Obesity-Related Comorbidities 
 
 Obesity, defined by excessive fat accumulation, is associated with a number of 
serious health conditions and has become one of the leading risk factors for global 
mortality [1].  The World Health Organization (WHO) estimates that, globally, more than 
500 million men/women are obese and is projected to grow to over 700 million before the 
end of the decade[1].  In Canada, the prevalence of obesity has tripled from 1985 to 
2011[2].  The high prevalence of obesity and obesity-related comorbities have grown to 
epidemic proportions culminating in a significant fiscal burden to health systems across 
the globe [3].  Currently, 34.9% of the United States [4] and 18.3% of Canadians [2] are 
obese representing an annual health cost of ~$147 billion [5] and ~$7 billion [6], 
respectively.  These fiscal burdens are principally attributable to the mirrored rise in 
obesity-related chronic health conditions such as: type 2 diabetes, hypertension, 
cardiovascular disease, and various cancers[7-10]. Newfoundland and Labrador having 
the highest rates of obesity and diabetes in Canada makes these health conditions 
especially pertinent to this Canadian province [11, 12].  A report by Statistics Canada in 
2011, revealed that 29% and 40% of the Newfoundland and Labrador population were 
obese and overweight, respectively [13].  Currently, 69% of Newfoundlanders and 
Labradorians are overweight/obese [12] and approximately 10% of the general 
population struggle with diabetes [11], which corresponds to an annual cost of $254 
million dollars.  Data from the Canadian Community Health Survey (CCHS) and the 
Canadian Diabetes Association (CDA) project that by the year 2020 over 71% of 
Newfoundland and Labradorians will be overweight/obese and the prevalence of diabetes 
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will exceed 15%[11, 12].  Although a number of methods are used to determine whether 
an individual is normal-weight, overweight or obese; the most widely implemented is the 
body mass index (BMI).  The body mass index indirectly estimates adiposity by dividing 
a body weight in kilograms by the square of height in meters [kg/m
2
].  According to the 
World Health Organization, a BMI > 25 kg/m
2
 is classified as overweight, while a BMI > 
of 30 kg/m
2
 is classified as obese.  However, BMI often mis-classifies obesity status up 
to two obesity categories  due to its inability to distinguish fat from muscle and bone [14-
17].  More importantly, even though BMI has been heavily criticized for not accurately 
representing adiposity or defining obesity, the majority of epidemiology studies still 
utilize BMI due to accessibility, low cost, and simplicity.  Therefore, caution should be 
exercised whenever BMI is being utilized to establish obesity.  In fact World Health 
Organization now officially recognizes the issue [18] of false-negative classification of 
obesity status when defined by BMI. 
 
1.2 - Etiology of Obesity 
 
 Obesity is complex with a multifaceted etiology.  Generally, obesity is the result 
of weight gain due to a chronic positive caloric balance where the total daily energy 
intake is greater than the total daily energy expenditure.  Although a lack of physical 
activity and/or the increased accessibility/consumption of calorie dense foods are the 
primary contributing factors to obesity, genetics, diet composition and the environment 
also play important roles in energy regulation and body weight maintenance.  For 
example, the ob/ob mouse is deficient in leptin which is an energy regulating hormone 
4 
 
acting on the hypothalamus to regulate energy expenditure and eating behavior[19].  In 
addition, the administration of leptin to these mice ameliorated the reduction in energy 
expenditure and excessive food intake [20].  A study by Montague and Farooqi et al. [21] 
examined two severely obese children finding very low circulating leptin levels and 
found an homozygous frame-shift mutation where a single guanine nucleotide in codon 
133 of the leptin gene was deleted. A follow up study by Farooqi et al. also revealed that 
the administration of the recombinant methionyl leptin increased energy expenditure and 
significantly reduced food intake and body fat. These studies provided the first genetic 
evidence that leptin, an energy regulator adipose tissue derived cytokine, was an 
important player in body fat management.  A study by Frayling et al. [22] discovered that 
a common variant of the FTO gene was significantly associated with BMI in children and 
adults. The study found that adults who were homozygous for the risk allele weighted 
about 3 kilograms heavier. They also found that adults homozygous for the risk allele had 
1.67 greater odds of being obese compared to those without the risk allele.  Lastly, twin 
studies have also provided strong evidence that genetics plays an important role in 
obesity development [23-26].  In addition, twin studies have also revealed the significant 
influence of the environment on obesity development [24, 25]. Therefore, genetic and/or 
environmental disruptions can significantly affect the optimal performance of various 
energy regulatory pathways resulting in the increased susceptibility to weight gain 
leading to obesity and obesity-related conditions.  Therefore, endocrinology also has a 
significant influence on energy homeostasis, via hormones playing an integral role in 
appetite regulation and glucose/lipid metabolism.  For example, some of the energy 
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regulating hormones which enter circulation can act directly on the CNS and influence 
eating behavior [27, 28].  Peptide YY (PYY), released into circulation from the 
gastrointestinal tract, is one such hormone which can cross the blood brain barrier and act 
directly upon the hypothalamus to reduce appetite [29].  In addition, the adipose tissue 
derived cytokine adiponectin and leptin, when released into circulation, can also 
significantly affect insulin sensitivity, energy expenditure, and eating behavior.  Due to 
the significant influence of energy regulating hormones on metabolism and their potential 
role in the development of adiposity and adiposity-related health conditions we chose to 
investigate a number of such hormones suspected in the development of obesity/diabetes 
throughout my PhD work.  In addition, since BMI is a very weak predictor of adiposity 
we utilized a much higher resolution measurement of body fat via a Dual-Energy X-ray 
Absorptiometry (DXA) machine.  A DXA system can very accurately distinguish fat 
mass from fat-free mass which allowed me to evaluate the direct association of various 
gastrointestinal (PYY, GLP-1, and ghrelin) and adipose tissue derived cytokines 
(Adiponectin) with adiposity.  The DXA system also provided me the ability to directly 
explore the impact of nutrition on the development of adiposity and obesity-related 
conditions while also designing a new sex specific predictive adiposity equation for 
epidemiological researchers wishing to more accurately define and investigate human 
obesity at the population level. 
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1.3 - Central Nervous System, Gastrointestinal Hormones and Appetite 
Regulation 
 
Appetite, a key factor in energy homeostasis, is multifaceted and significantly 
influences the regulation of body weight through both neural and hormonal signals in the 
central nervous system (CNS) [30, 31].  Our brain is responsible for receiving and 
interpreting orexigenic/anorexigenic signals that can alter both behaviour and metabolic 
processes [31].  Specifically, the gastrointestinal tract is one of the largest endocrine 
organs in the human body secreting several appetite regulating hormones.  The brainstem 
and hypothalamus receive both neural and hormonal signals through a gut-brain 
communication pathway subsequently regulating food intake and energy 
homeostasis[31].  Since gut hormones influence appetite and play an integral role in 
glucose/lipid metabolism and insulin sensitivity through gut-brain communication [27, 
28]understanding the relationship between appetite regulating hormones and adiposity 
may provide valuable insight into the underlying mechanisms responsible for the 
development of obesity. 
 
 The hypothalamus, which coordinates many neuroendocrine inputs, is the primary 
control center for appetite.  The neurons critical to energy regulation and appetite located 
within the hypothalamus are the arcuate, paraventricular and ventromedial nuclei[31] 
which each contain a unique population of neurons.  Many gastrointestinal hormones like 
PYY, GLP-1 and ghrelin can freely cross over the blood brain barrier to exert a direct 
influence on neurons within the hypothalamus [31].  The arcuate nucleus neurons are the 
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most frequently studied and well known regarding appetite regulation.  The orexigenic, 
appetite stimulating, neurons of the arcuate nucleus are the neuropeptide Y (NPY) and 
agouti-related protein (AgRP) producing neurons [32-34].  The activation of either the 
NPY or the AgRP nuclei will result in the increase of food intake and a reduction in 
energy expenditure [35, 36].  For example ghrelin, an appetite stimulating hormone, 
binds to the growth hormone secretagogue receptor (GHS-R) in the arcuate nucleus to 
increase food intake  [37, 38].  The anorexigenic, appetite suppressing, neurons found 
within the arcuate nucleus are the cocaine- and amphetamine-regulated transcript 
(CART) and proopiomelanocortin (POMC) neurons.  The stimulation of either the CART 
or POMC will result in a decrease in food intake and the increase in energy expenditure 
[35, 36].  For example, the alpha-melanocyte-stimulating hormone (a-MSH) is a 
derivative of the POMC polypeptide which binds to melanocortin receptor 4 (MC4R) in 
the paraventricular nucleus reducing food intake and increasing weight loss [39].  In fact, 
6% of severe early-onset obesity can be attributed to MC4R mutations [40] which also 
makes it the most common obesity syndrome described to date, having a prevalence 
higher than cystic fibrosis [41].   
 
 The paraventricular nucleus contains neurons which synthesize and release 
corticotropin-releasing hormone (CRH) and thyrotropin-releasing hormone (TRH) 
influence energy expenditure and appetite [42].  For example, both the CRH and TRH, 
anorexigenic neuropeptides synthesis and secretion is significantly reduced in a fasted 
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state [43, 44].  Paraventricular nucleus neurons also have many projections from the 
arcuate nucleus influencing food intake.   
 
 The dorsomedial nucleus has a large number of NPY projections which influences 
appetite.  For illustration, α-MSH stimulation results in the activation of the dorsomedial 
nucleus neurons which in turn reduces food intake [45]and damage to the area of the 
hypothalamus results in overeating and weight gain [46].  In addition, studies have shown 
that the administration of Cholecystokinin (CCK), an appetite suppressant, reduces NPY 
activation in the dorsomedial nucleus which in turn inhibits food intake [47].  The 
ventromedial nucleus neurons are significantly influenced by α-MSH and receives 
neuronal projections from the arcuate nucleus [48].  Case in point, the MC4 receptor is 
very prevalent in the ventromedial nucleus and the administration of α-MSH significantly 
increases food intake in rodents [48].   
 
 The lateral hypothalamus is best known for extensive MSH terminals and the 
synthesis and release of the melanin-concentrating hormone (MCH) [49].  MCH, a 13 
amino acid appetite stimulating hypothalamic hormone, is a very important energy 
regulating peptide which is also involved in skin pigmentation.  For instance, MCH has 
been found to increase in the fasted state and its administration is found to increase 
feeding and weight gain [50]. Since obesity is one of the fastest growing health 
conditions worldwide and the underlying mechanisms of food intake and energy 
homeostasis are playing a significant role, investigating the hormones which directly 
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influence appetite is important. Since gastrointestinal hormones in circulation can act 
directly on the hypothalamus to affect eating behavior, our laboratory and I set out to 
investigate the influence of PYY, GLP-1 and ghrelin on the development of obesity and 
obesity-related comorbidities. 
 
1.3.1 - Peptide Tyrosine Tyrosine (PYY) 
 
 Peptide YY (PYY), a 36 amino acid appetite suppressing gut hormone, is secreted 
from the L-cells of the gastrointestinal tract which acts centrally on the hypothalamus to 
inhibit the orexigenic activity of the neuropeptide Y (NPY)[30, 51, 52].  PYY is released 
from the mucosa in the ileum and colon of the gastrointestinal tract existing in a PYY3-36  
and PYY1-36 form [53, 54].  PYY secretion increases in response to food consumption 
and is positively correlated with the calorie content of meals [55-57].  Both forms are 
physiologically active decreasing pancreatic secretions and suppressing gastrointestinal 
motility [58].  Circulating PYY increases satiety, decreasing food intake via gut-brain 
communication and PYY plays an integral part in energy homeostasis [53, 54,59].   PYY 
is cleaved within the peripheral circulation at the N-terminus by circulating dipeptidyl 
peptidase IV (DPP-IV), which results in the PYY3-36 form. PYY binds to the Y1, Y2, and 
Y5 receptors, although the PYY3-36 form has the highest affinity with the Y2 receptor 
highly expressed on arcuate NPY neurons [29].  Considering that the activation of the 
NPY neurons stimulates food intake, the anorexigenic effect of PYY is primarily thought 
to be mediated by the inhibition of NPY neurons through the Y2 receptor in the arcuate 
nucleus[30, 53,60].  Data from animal experiments indicate that endogenous PYY acts on 
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the arcuate nuclei through the gut-hypothalamic pathway blocking various orexigenic 
effects which results in increased satiety and decreased gastric emptying [30, 53, 60].  It 
was originally suggested that circulating PYY concentrations were lower in obese rodents 
as well as humans and that PYY infusion effectively reduces food intake and body weight 
[30, 51, 53, 60].  The initial studies on the potential role of PYY in obesity development, 
which were conducted on rodents, revealed that a diet-induced obesity would decrease 
circulating PYY [30, 61,62].  This would suggest that the circulating concentration of this 
appetite suppressing gut hormone may be linked with the development of obesity [30, 
61,62].  The initial PYY gene knockout studies in mice revealed significant hyperphagia 
and that the acute administration of PYY could significantly ameliorate this condition 
[30, 53,61].  This group also proposed that endogenous PYY concentration was lower in 
obese rodents and humans, inversely associated with obesity-related phenotypes[51], and 
the administration of PYY could effectively reduce food intake and body weight 
independent of obesity status [30, 51, 53].  Therefore it was hypothesized that a 
deficiency in circulating PYY could be a significant contributing factor toward the 
chronic over consumption of food and subsequent weight gain.  However, many 
successive PYY knockout [63, 64] studies have failed to reproduce the strong association 
of PYY with hyperphegia and diet-induced obesity.  A considerable number of studies 
have also been unable to replicate the original results [65, 66] along with demonstrating 
any significant association between circulating PYY and adiposity [58].   
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 The initial human based studies on PYY also found circulating levels to be lower 
in obesity and inversely correlated with body mass index (BMI), suggesting that PYY 
deficiency may contribute to human obesity [51, 61, 67, 68].  The early studies found that 
the infusion of PYY decreased the appetite of men/women subjects along with a 
subsequent reduction in food intake [51, 53].  Taken together, these data suggest that 
individuals with a lower concentration of PYY, such as overweight/obese, may have a 
weaker satiety signal subsequently leading to the over consumption of food and weight 
gain in humans.  However, like in rodents, many subsequent human studies with larger 
sample sizes could not replicate the relationship between PYY and obesity [69-71].  The 
administration of PYY was also found not to have any effect on appetite or weight loss 
[66, 71].  Additionally, an extensive review in 2005,exploring the anorexigenic effect of 
PYY, revealed 84% studies produced among 41 independent research groups were unable 
to reaffirm the claim proposed by the initial investigations [69].  Therefore, although 
PYY was thought to be involved in the development of obesity [51, 53], significant 
controversy exists regarding the definitive role that PYY plays in this regard [58, 66, 69-
71].   
 
 The inconsistency in PYY and its association with obesity, we believe, is 
primarily due to the utilization of modalities which cannot accurately measure adiposity 
or assess obesity like BMI.  Our laboratory [15-17] has shown that BMI cannot 
accurately distinguish fat mass from fat-free mass and is not an accurate predictor of 
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adiposity, suggesting that the inaccurate measurement of adiposity and the 
misclassifications of obesity status could be the factor attributing to the contradictory 
reports concerning the association of PYY with obesity.  Other potential reasons for the 
contradiction in reports for the association of PYY with adiposity may be gender and/or 
lifestyle related.  A study by Sandstrom et al [72] found that circulating PYY was higher 
in men compared to women, while another study found that PYY levels are higher in 
women [70].  Additionally, various studies have proposed that nicotine and [73-75] and 
medications [76-78] can significantly influence PYY concentration.  The involvement of 
PYY in the development of human obesity is unclear [66, 79, 80], the relationship 
between circulating PYY and adiposity/obesity-status is controversial [69], and very little 
data exists from large human population-based studies to help resolve the controversy.   
 Since few large cross-sectional studies, taking into consideration potential 
confounding factors and that the current results in the literature are controversial, there is 
a good reason to explore the influence of circulating PYY on adiposity and obesity-status 
at the population level.  Therefore the purpose of my first study, described in Chapter 2, 
was to investigate the association of circulating PYY concentration with adiposity 
measured by dual-energy x-ray absorptiometry, in a large population adjusting for major 
confounding factors. The detailed objectives were to: 1) test if PYY is associated with 
obesity status by comparing fasting serum PYY between normal-weight (NW), 
overweight (OW) and obese (OB) men and women; 2) examine the association of PYY 
with body composition among normal-weight (NW), overweight (OW) and obese (OB) 
men and women; and 3) determine the influence of age, sex, smoking, medication use 
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and menopausal status on circulating PYY. 
 
1.3.1.1 - Peptide Tyrosine Tyrosine (PYY) And Positive Energy Balance 
 
 Body weight is primarily maintained by the balance between energy intake and 
energy expenditure.  The disruption of this highly regulated energy balance system by a 
chronic positive energy surplus, leading to the accumulation of adipose tissue, allows 
researchers the ability to investigate the mechanisms which facilitate and/or attenuate 
weight gain.  Sims et al. [81] was among one the first to explore the effect of an positive 
energy surplus on humans.  These studies had participants increase food intake 300% 
(~8,000-10,000 kilocalories/day) for a 10-week period of time [81, 82].  Their 
investigation demonstrated a significant increase in adipose tissue and various hormones.  
Upon the completion of the intervention, participants experienced a minimum weight 
gain of 15% of their baseline weight with an average weight gain of 16.4 kg.  Another 
very important human overfeeding study was completed by Bouchard et al. [83] in 1990 
published in the New England Journal of Medicine.  This investigation overfed 24 
participants for 84 days with an energy surplus of 1000 kcal per day which equaled an 
excess of 84,000 kcal [83].  The novelty of this study was that it was performed on 12 
pairs of twins.  Upon the completion of the intervention the participants’ minimum 
weight gain was 4.3 kg with an average weight gain of 8.1 kg.  Another study on 
overfeeding (50% greater than normal caloric intake) by Brons et al. [84] 26 normal-
weight young men observed a significant increase in both glucose and insulin along with 
adiponectin, leptin and gastric inhibitory peptide (GIP).  They also reported that insulin 
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secretion preceded the development of insulin resistance. Although, the overfeeding 
stimulus was strong enough to affect the endogenous concentration of various hormones, 
the positive energy surplus was not long enough to evoke significant weight gain.  
Another study by Astrand et al. [85] discovered that after a 4-week positive energy 
challenge body weight significantly increased 9.5%. The 18 young normal-weight adults 
(12 male and 6 female) also had elevated concentrations of insulin but resistin and 
adiponectin remained unchanged.  Due to the fact that obesity is generally understood to 
be the result of a chronic energy surplus where energy intake exceeds energy expenditure 
[86]which is triggered by many complex hormonal changes [87, 88], I also chose to 
investigate PYY under these conditions to elucidate its potential contribution to the 
development of obesity.  Previous studies having investigated the role of PYY during the 
disruption of energy balance have only examined the response of this gut hormone during 
a negative energy balance.  Essah et al [89] demonstrated that an 8-wk low-fat and low-
carbohydrate hypocaloric diet on obese participants significantly reduced body weight by 
9% along with a 10% reduction in circulating PYY.  It would seem that during periods of 
food intake reduction that the appetite suppressing effects of PYY are reduced to 
potentially increase food intake.  At the present time there is no data regarding the effect 
of weight gain, through a chronic energy surplus, on PYY or the potential differential 
effect of obesity status.  Our laboratory, [90-92] and others [57, 83-85,93], have 
demonstrated that changes in nutrition through overfeeding can have major effects on 
energy regulating hormones.  The response of PYY to our short term positive energy will 
provide valuable insight regarding the potential role of PYY in the development of 
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obesity as well as other related phenotypes including insulin resistance and serum lipid 
profiles. Therefore the primary objective of the study, thoroughly described in Chapter 
3, was to investigate whether PYY levels are affected by a short-term positive energy 
challenge and if obesity status (normal weight, overweight and obese) influences this 
response.  
 
1.3.2 - Glucagon-Like Peptide 1 (GLP-1) 
 
Glucagon-like peptide-1 (GLP-1), a 30 amino acid appetite suppressing hormone,   
is secreted from the L-cells of the distal gastrointestinal tract which acts through the 
hypothalamus to inhibit orexigenic activity [94].  GLP-1 also acts peripherally to reduce 
gastric motility, the secretion of glucagon and various gastrointestinal secretions[95, 96].  
The active form of GLP-1 is produced from the posttranslational modification of the 
proglucagon gene product by prohormonecovertase [94]and binds to the GLP-1 receptor 
(GLP1R) which acts both centrally and peripherally [97].  Although, GLP-1 is known to 
influence appetite it has also been found to facilitate glucose-dependent insulin secretion 
[98].  In addition, treatment with GLP-1 or GLP-1 receptor agonists are being 
investigated as treatments for diabetes and appetite regulation among obese [99, 100].  
During my PhD work Danny Wadden and I investigated the association of GLP-1 with 
body composition, obesity status and obesity-related biomarkers before and after 
overfeeding (the intake of 70% more calories for 7-days).  Our manuscript entitled 
"Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in 
men" published in the Journal of Nutrition & Metabolism (DOI:10.1186/1743-7075-10-
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33) discovered that circulating GLP-1 is not associated with adiposity at baseline, but 
GLP-1 significantly increased after a short-term positive energy challenge independent of 
obesity status.  Since GLP-1 is an appetite suppressant, the up regulation during 
overfeeding may be acting as a protective mechanism to reduce appetite and subsequent 
weight gain.  My work on GLP-1 will not be further discussed throughout this document 
as this work was used for Mr. Danny Wadden's Master's of Science (MSc) thesis. 
 
1.3.3 - Ghrelin 
 
 Ghrelin, the only gastrointestinal appetite stimulating hormone, is a 28-amino acid 
peptide secreted from the stomach lining which binds to the growth hormone 
secretagogue receptor (GHS-R) [37].  Ghrelin stimulates hunger and increases food 
intake and weight gain [101].  Like PYY, ghrelin acts directly on the CNS via the arcuate 
nucleus of the hypothalamus [102]. However unlike PYY, the administration of ghrelin 
results in the stimulation of the orexigenic NPY neurons in arcuate nucleus increasing 
appetite[103-106].  Since the peripheral administration of ghrelin stimulates 
hypothalamic NPY mRNA expression in the arcuate neurons the orexigenic effect of 
ghrelin is mediated predominantly through these neurons [107].  In addition, when 
growth hormone secretagogue receptor for ghrelin is knockout in mice food intake is 
reduced and weight loss is observed [108].   
 During my PhD work Danny Wadden and I investigated the association of 
circulating ghrelin with body composition, obesity status and obesity-related biomarkers 
before and after overfeeding.  Our manuscript entitled "Serum Acylated Ghrelin 
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Concentrations in Response to Short-Term Overfeeding in Normal Weight, Overweight, 
and Obese Men" published in the PLoS One Journal (DOI: 0.1371/journal.pone.0045748)  
discovered that there was no significant difference in ghrelin concentration among 
normal weight, overweight, and obese young men.  Additionally, to our surprise, fasting 
circulating ghrelin significantly increased in response to our 7-day positive energy 
challenge.  However, although ghrelin was not associated with adiposity, baseline ghrelin 
was negatively associated with baseline BMI and the change in BMI due to overfeeding.  
In addition, during my PhD work Peyvand Amini and I investigated the association of 
ghrelin and PYY with bone density in the general population of Newfoundland and 
Labrador.  Our cross sectional study entitled "Beneficial Association of Serum Ghrelin 
and Peptide YY with Bone Mineral Density in the Newfoundland Population" published 
in BMC Endocrine Disorders discovered that there is a positive association of ghrelin 
with bone density in women independent of BMI, physical activity, age, alcohol 
consumption, and smoking.  However, PYY was not associated with bone density in the 
Newfoundland population.   
 Lastly, during my PhD work Peyvand Amini, Danny Wadden and I also 
investigated the association of ghrelin with body composition, obesity status and obesity-
related biomarkers in the general population of Newfoundland and Labrador.  Our 
manuscript entitled "Serum Acylated Ghrelin Is Negatively Correlated with Insulin 
Resistance In the CODING study" published in PLoS One (DOI: 
10.1371/journal.pone.0045657) discovered that high circulating levels of ghrelin are 
associated with low levels of insulin resistance in the Newfoundland population. Ghrelin 
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was significantly negatively associated with circulating insulin level and measurements 
of insulin resistance in the general population and among men and women separately.  
However, ghrelin concentration was not associated with adiposity.  My work on ghrelin 
will not be further discussed throughout this document as the above work was used for 
the Masters of Science (MSc) thesis for Mr. Danny Wadden and Dr. Peyvand Amini. 
 
1.4 - Adiponectin and Obesity 
 
 Adiponectin, an insulin sensitizing and anti-inflammatory hormone, is a 244 
amino acid peptide secreted primarily from adipose tissue and binds to the ADIPO1 and 
ADIPO2 receptors [109].  White adipose tissue (WAT), once only regarded as a site for 
energy storage, is now known to play an integral role in human energy homeostasis [110-
112]secreting a large number of physiologically active proteins [113-115].  Specifically, 
adiponectin has been shown to attenuate insulin resistance and effectively increase the 
disposal of circulating glucose [116-118].  Considering that adiponectin has been 
recognized as a significant insulin sensitizer it would be consistent to anticipate that 
circulating adiponectin levels would be considerable in the presence of an insulin 
resistant state such as obesity.  However, the puzzling actuality suggests that adiponectin 
is inversely associated with obesity [119-124] and insulin resistance [122, 125-127].  The 
majority of human cross-sectional studies show that circulating adiponectin is diminished 
among the obese population [119, 122-124],  and significantly promoted after weight 
reduction [124, 125, 128, 129].  Since white adipose tissue is the primary location for the 
adiponectin production and secretion it would seem logical to assume that circulating 
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adiponectin may be regulated by adiposity feedback inhibition [124].  Although, evidence 
suggests that adiponectin is strongly associated with glucose and lipid metabolism, the 
role of adiponectin in the development of obesity and insulin resistance remains unclear.  
The ob/ob obese mouse model has shown that adiponectin secretion is significant reduced 
[127, 130, 131], however the adiponectin transgenic ob/ob mice can effectively 
ameliorate insulin resistance but not obesity [132, 133].  In fact, adiponectin knockout 
mice have been shown to severely attenuate glucose disposal and facilitate insulin 
resistance without affecting weight or adiposity [126, 134].  Additionally,  the 
administration of adiponectin to ob/ob, db/db, and adiponectin knockout mice can 
ameliorate the development of insulin resistance without significantly influencing 
adiposity [127, 135].  It would seem that adiponectin may not be mediated by adiposity, 
but rather the increase in insulin insensitivity.  Since, body weight regulation 
interventions decreasing excess body fat have been shown to increase circulating levels 
of adiponectin and improve insulin resistance [124], lifestyle interventions have become 
an appealing treatment for insulin resistance potentially due to hypoadiponectinemia 
found among obese [136].  In addition, hormones like TNF-α have been found to inhibit 
adiponectin release, while adiponectin has been shown to inhibit TNF-α in adipose tissue 
[134].  Adiponectin also reduces the expression of adhesion molecules in endothelial 
cells and elicits its anti-inflammatory properties by decreasing cytokine production from 
macrophages [137].  Furthermore, it promotes insulin sensitivity and the inhibition of the 
inflammatory mediators [124].  Esposito et al.[138] showed a significant improvement in 
adiponectin levels following a comprehensive multidisciplinary approach towards 
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lifestyle including nutrition guidelines proposed by the “Mediterranean Diet”.  The study 
found that reducing body weight in obese women through lifestyle variations such as diet 
were associated with increases in adiponectin and a reduction in insulin resistance 
markers.  Current human based overfeeding studies are controversial regarding its 
influence on adiponectin concentrations.  A study by Brons et al. [84] found after a 5-day 
high-fat (60% fat, 32.5% carbohydrates and 7.5% protein) of overfeeding (50% greater 
calories per/day) that circulating adiponectin increased by 13.4%.  They provided the first 
evidence that up regulation of adiponectin is likely due to significant increase total 
caloric intake rather than macronutrient composition of the diet.  Since the subjects in this 
study were only normal-weight young men their findings cannot be extrapolated to 
normal-weight women or overweight and/or obese men and women [84].  However, a 4-
week overfeeding study by Astrand et al [85] on 12 male and 6 female normal weight 
subjects did not find a significant increase in adiponectin concentration.  Again, since this 
study only consisted of normal-weight individuals’ assumptions cannot be made about 
the effect of overfeeding on adiponectin concentration among obese individuals.  Lastly, 
a 100 day overfeeding (840 kcal more calories per day) study by [93] on 12 pairs of male 
identical twins found that adiponectin concentration actually decreased.  In addition, no 
correlation was found between adiponectin at baseline and adiposity before or after 
prolonged overfeeding.  However, like the previous studies the aforementioned results 
can only be applied to normal-weight individuals.  In addition, recent studies have 
hypothesized that the potential negative association of adiponectin with obesity is in fact 
more dependent upon the development of insulin resistance [116, 120, 123, 139].  
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Although some studies have indicated that the reduction in adiponectin is primarily due 
to a concomitant increase in insulin resistance during obesity [120, 121, 139], no study to 
date has investigated the potential paradoxical correlation of adiponectin with the 
increase in adiposity and insulin resistance due to short-term overfeeding.  As 
aforementioned our laboratory and others have demonstrated that a short-term positive 
energy challenge significantly affects glucose and lipid metabolism, which results in 
significant body weight gain and insulin resistance [83-85, 90-92].  Moreover, changes in 
nutritional status have also shown to influence circulating adipokines [83-85, 90,91].  
However, to date, very few overfeeding studies have explored the influence of stressor, 
short term positive energy challenge, which is significant enough to increase both insulin 
resistance and body fat.  The publication described in Chapter 4 is the first study of its 
kind to investigate the effect of a 7-day positive challenge (70% above normal energy 
requirements) on circulating adiponectin among normal-weight, overweight and obese 
individuals defined by BMI and body fat percent measured by DXA.   
 
1.5 - Dietary Intake of Magnesium and Obesity 
 
 Magnesium, a cofactor required in over 300 enzymatic reactions, is the fourth 
most abundant cation in the human body involved with both glucose metabolism and 
insulin homeostasis [140, 141].  Magnesium has been proposed to be functionally related 
to glucose metabolism through an interaction with tyrosine-kinase activity on the insulin 
receptor which is associated with the development of insulin resistance and type 2 
diabetes [142]. More specifically, phosphorylation of the tyrosine kinase enzyme of the 
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insulin receptor, required for post-receptor insulin sensitivity and subsequent insulin-
mediated glucose uptake, are dependent on magnesium [143]. The apparent protective 
role of magnesium on IR and type 2 diabetes has not been fully explained but is likely 
due to enhanced insulin sensitivity through multiple mechanisms. Although recent 
evidence has suggested that dietary magnesium intake may play an important role in 
enhancing insulin sensitivity, population based studies have found conflicting evidence 
regarding the potential benefit of dietary magnesium intake.  Obesity, as a disorder, can 
place individuals at a significantly elevated risk for impaired insulin action [144]and 
various metabolic abnormalities such as hypertension, dyslipidemia, and glucose 
intolerance [144].  For example, type 2 diabetes comprises 90% of all diabetic cases and 
has become an ever increasing healthcare challenge as the number of people affected 
reaches epidemic proportions [1].  The prevalence of this condition is expected to reach 
over 438 million people globally by the year 2030 and carries with it a significant fiscal 
burden [145].  The functional relationship between various hormones and obesity-related 
conditions is a significant focus of my obesity research, however diet composition is also 
a heavily studied area of work [145, 146].  Although there is currently no medical 
intervention capable of preventing the development of diabetes, simple lifestyle 
modifications (such as increased physical activity, moderate weight loss, and eating 
behavior modifications) have been shown to attenuate the onset of type 2 diabetes [1, 
146].  A number of studies revealed a significant correlation of low dietary magnesium 
intake [147-149] with increased insulin resistance [150-152].   
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 Villegas et al. [151] designed a study to assess the risk of type 2 diabetes in 
women and found a negative correlation between magnesium intake and type 2 diabetes 
risk.  Guerrero-Romeo et al, [153] found that dietary magnesium intake is positively 
associated with improvements of insulin resistance.  Additionally, studies by Villegas et 
al. [151] and Kim et al. [150] have shown that dietary magnesium is beneficially 
associated with markers of insulin resistance and is more pronounced in overweight 
patients [150, 151]. These studies provide strong evidence that overweight/obese 
individuals could potentially benefit from an increase in magnesium intake [150, 151].  
These findings would suggest that individuals with excessive adiposity may be able to 
better absorb and metabolize magnesium resulting in enhanced insulin action.  Although 
controversy exists regarding whether dietary magnesium intake can attenuate the 
development of diabetes [154-156], none of the above studies adequately controlled for 
adiposity in their analysis.  In fact the majority of studies evaluating the association 
between dietary magnesium and insulin resistance have used BMI when attempting to 
control for adiposity.  Percent body fat and BMI likely represent different physiological 
entities, and that adiposity is the parameter most closely linked with the development of 
insulin resistance [157]. It is therefore, critical that accurate measurements of body fat be 
used when assessing the influence of adiposity on the relationship of magnesium intake 
with insulin resistance.  This is an important point to consider when the relative amount 
and distribution of adipose tissue, both important determinants of insulin sensitivity, 
cannot be determined by the BMI [158-160].  Due to the lack of a large cross-sectional 
population based study systematically controlling for body fat when investigating the 
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association of dietary magnesium intake on insulin resistance, we designed a study to fill 
this gap.  The manuscript described in Chapter 5 is the first largest cross-sectional study 
to systematically control for major confounding factors (age, gender, caloric intake, 
physical activity, medication use, smoking status, menopause), including body fat 
percentage, to investigate the influence of dietary magnesium intake on insulin resistance. 
 
1.6 - Measuring Adiposity and Defining Obesity Status 
 
 Obesity, defined by the excessive accumulation of adipose tissue, and obesity-
related comorbities have grown to epidemic proportions resulting in a critical global 
health issue [18, 161].  In fact the significant rise in obesity is mirrored by a rise in 
cardiometabolic risk factors [7-10].  Considering that Newfoundland and Labrador have 
the highest prevalence of both obesity and diabetes among the Canadian provinces[12, 
162], the development of obesity and its comorbidities are especially relevant. However 
as mentioned earlier in the "Prevalence of Obesity and Obesity-Related Comorbidities" 
section, due to the over usage of BMI to define obesity in previous studies, caution must 
be taken assuming that the associations found with cardiometabolic risk factors have to 
do with adipose tissue accumulation.  Moreover, since BMI cannot differentiate fat mass 
from fat-free mass the association of adiposity with health risk factors has come into 
question [15, 16]. Although,  air-displacement plethysmograohy (ADP), underwater 
weighing, magnetic resonance imaging (MRI) and/or dual-energy X-ray absorptiometry 
(DXA) are among the most precise measurements of body fat, conversely these methods 
are both expensive and impractical to assess obesity at the population level [163-165]. 
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1.6.1 - The Body Mass Index (BMI) and Obesity 
 
The body mass index (BMI), calculated as weight divided by height squared 
((Weight-kg)/(height-m)
2
), was designed over 100 years ago [166] and due the low cost 
and simplicity of implementation it is the most widely known and commonly used 
classification measure used by obesity health professionals.  BMI is currently the method 
utilized for the World Health Organization’s (WHO) annual reports regarding obesity and 
also utilized in the majority of population based studies investigating obesity and health 
risk factors relating to obesity. In fact, the World Health Organization (WHO) still 
defines obesity as the abnormal or excessive fat accumulation represented by a BMI 
value greater than or equal to 30 kg/m
2 
[18].  Although BMI is the most cost effective 
method to evaluate adiposity, it has been shown to have significant weaknesses in 
accurately determining adiposity.  The primary weakness of BMI is that it cannot 
distinguish fat mass from and fat-free mass [15, 16].  Another significant weakness of 
BMI is that it does not account the sexual dimorphism of adiposity, although gender 
differences for body fat percentage have been well documented [167-169].  The lack of 
sex criteria for BMI is a significant limitation to its ability to properly predict body fat. 
The body mass index also does not account for the variation of accumulation of body fat 
with age nor the inter-individual difference of body fat percentage among people within 
the same BMI category [15].  Considering that studies by our laboratory, and others, have 
shown that a BMI score can mis-classify by one or even two obesity categories [14, 15] 
caution must be exercised when utilizing BMI for obesity research.  In fact, due to the 
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abundance of data strongly supporting the weakness of BMI in predicting adiposity, the 
WHO now admits that caution must be exercised when utilizing BMI to classify obesity 
status [18].  With the rapid increase of obesity prevalence worldwide, attempts to develop 
a simple and low cost method to estimate adiposity more accurately than BMI are being 
made [170-172]. 
  
1.6.2 - The Body Adiposity Index (BAI) and Obesity 
 
 Due to significant limitations of BMI to accurately predict adiposity and the 
impracticality of direct percent body fat measurements from magnetic resonance imaging 
(MRI) and dual-energy x-ray absorptiometry, a study by Bergman et al. [170] proposed a 
new equation to calculate adiposity.  Utilizing regression analysis the aforementioned 
study found that height and hip circumference, measured in meters (m) and centimeters 
(cm) respectively, were sufficient to produce an equation to accurately predict the body 
fat measured by DXA.  The Body Adiposity Index (BAI) equation was derived from the 
concordance between the body fat percentages of an Mexican-American population.  
Unlike BMI, the BAI (hip circumference (cm)/[(height (cm)
1.5
)-18]) derived from this 
investigation did not involve the measurement of body weight.  Bergman et al. [170] 
reported that their BAI equation could more reliably predict body fat than BMI and 
required no statistical correction for gender or ethnicity [170].  However, the predictive 
of BAI for %BF remains inconclusive and it remains unclear whether BAI is a better 
predictor of %BF than BMI [170, 173-179].  Moreover, it is also unclear if BAI will 
reflect the gender differences of height and hip circumference measurements [180, 181] 
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along with various dynamic anatomical measurements utilized to evaluate adiposity.  
Lastly, caution must be exercised when interpreting the association of BAI with %BF as 
not all studies have employed a high resolution measurement of body fat, such as DXA.  
A letter to the editor by Barreira et al. [182] was the first published material regarding the 
validation of the BAI equation on a Caucasian population. They found that the correlation 
between body fat percentage with BAI was very similar to that with BMI (r = 0.82 and r 
= 0.83 respectively) in women.  However, the correlation of %BF with BAI was not as 
similar as BMI (r = 0.75 and r = 0.81) for men.  Barreira et al. concluded that BAI 
equation was an effective method for predicting %BF for a Caucasian population, 
although further studies are required to support these findings.  Since very few studies 
had attempted to validate the BAI equation on a Caucasian population our group became 
interested in doing so in the Caucasian Newfoundland and Labrador population.  The 
purpose of the work described in Chapter 6 was to validate the predictive power of BAI 
for %BF, measured by DXA and to investigate the potential influence of adiposity and 
gender on the accuracy of BAI.  Our manuscript was among the first of its kind to attempt 
to validate the accuracy of the BAI in its prediction of %BF, measured by DXA, among 
normal-weight, overweight, and obese Caucasian men and women. 
 
1.6.3 - The Association of the Body Adiposity Index With Obesity-Related 
Cardiometabolic Risk Factors 
 
The association of cardiometabolic risk factors (CRF) with obesity is not well 
established.  The majority of epidemiological studies/reports attempting to evaluate the 
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association of CRFs with obesity are based upon the assumption that BMI accurately 
predicts adiposity.  However over the past few decades, especially with the advent of new 
high resolution measurements of adiposity, our laboratory [15-17, 178] and others [14, 
15, 167-169, 183-186] have demonstrated that BMI is a very poor predictor of adiposity 
and obesity status.  More importantly, the false-negative classification of BMI defined 
obesity status reduces the identification of those at higher risk of cardiometabolic 
diseases with lower body fat content [187].  Therefore, as mentioned in the previous 
section " The Body Adiposity Index and Obesity", recent focus has been placed on 
developing more accurate and cost effective methods of assessing adiposity to determine 
the more precise link between body fat accumulation and its associated disease risk [170, 
188, 189].  To date a small number of studies to date have attempted to validate the 
effectiveness of BAI to predict body fat, and an even smaller number of studies have 
investigated the association of BAI and BMI with CFRs [190-194] and even fewer 
studies have included both insulin resistance and heart disease risk factors in their 
investigation [190, 191].  Despite the current criticisms of the use of BAI equations to 
predict %BF, an equally important question is; Does BAI more closely represent the 
association of %BF with obesity-related CFRs than BMI.  The current literature 
demonstrates that [190-192, 195-198], BMI significantly over estimates the association of 
obesity with CRFs.  However, since a number of studies have shown that weight is more 
associated with CRF than hip circumference independent of sex, it is not surprising that 
BMI was found to be more strongly associated with CRFs than BAI.  A study by Snijder 
et al. [198] and Freedman et al. [199] both found that BMI and waist circumference were 
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more strongly correlated than BAI with LDLc, HDLc, TG, glucose, systolic blood 
pressure and diastolic blood pressure.  An investigation from the Salzburg 
Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) study 
found that BMI was a better predictor of circulating lipids and glucose than BAI.  BMI 
was more strongly associated with HDLc, TG, glucose, insulin, and HOMA-IR than BAI 
[192].  Another study reported that BMI was more significantly associated with glucose, 
systolic blood pressure and diastolic blood pressure [195].  A weight loss study on obese 
post-menopausal women by Elisha et al. [196] found that the reduction in BAI was not 
associated with that the changes of CRFs (cholesterol, HDLc, TG, glucose, systolic blood 
pressure and diastolic blood pressure).  None of the above studies evaluated whether BMI 
or BAI was more closely associated with %BF.  Therefore, it would be equally important 
to evaluate whether the association of BAI or BMI with CRFs was more concordant with 
that of %BF. The majority of studies seem to indicate that BAI is an inferior predictor of 
CRFs than BMI.  However, to the best of our knowledge no large cross-section study has 
compared the association of insulin resistance and cardiovascular disease risk factors 
with BMI and BAI against their associations with a high resolution measurement of body 
fat while also taking into considering both gender and adiposity.  Currently, there is no 
consensus as to which method, the BAI or BMI can be more closely associated with 
CFRs. This might be more important in clinical practice. Therefore, the purpose of the 
manuscript in Chapter 7 was to determine 1) the association of BAI and BMI with CRFs 
against the association of DXA %BF with CRFs while taking into consideration both 
gender and adiposity and 2) whether BAI, or BMI, is more closely associated the 
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relationship of adiposity (%BF measured by DXA) with cardiovascular disease and type-
2 diabetes risk factors.  We hypothesize that BMI may be more strongly associated with 
CFRs, but the association of BAI with CFRs will more accurately reflect the association 
of CFRs with body fat independent of gender.  
 
1.6.4 - Designing a New Sex Specific Predictive Adiposity Equation 
 
 Even though a number of studies have shown that BAI is as good or better a 
predictor of %BF [173, 175, 178, 189, 194, 197, 200, 201], these studies have also 
revealed that this association is significantly reduced when attempting to predict 
adiposity with BAI among men and women separately.  The BAI tends to over-estimate, 
and underestimate DXA %BF among men and women, respectively [174, 189,201].  
Additionally, the waist circumference of men had stronger concordance with DXA %BF 
than that of the hip circumference measurement used in the BAI equation [178, 197].  
Recent, studies have also revealed that the predictive power of BAI significantly 
decreases among underweight and obese individuals [173,174,178,201-204].  As the 
incidence of obesity and obesity-related diseases continues to increase, the need for an 
inexpensive and accurate assessment of adiposity has become of great importance to both 
clinical and epidemiological research.  To have an equation that can accurately estimate 
adiposity for both men and women in the general population would be ideal due to the 
inherent gender differences.  However, considering that hip circumference, the primary 
measure in the BAI equation, is larger in females than in men [15] it could potentially 
reflect gender differences to some degree.  To date very few sex specific adiposity 
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equations, which accurately predict high resolution %BF measured by DXA, have been 
developed.  Since the recently BAI does not overcome the weakness of the BMI in 
predicting adiposity, the purpose of the study described in Chapter 8 was to develop an 
equation(s) to more accurately predict body fat percentage among men and women to 
better define obesity status.  An equation such as this would be of critical importance to 
determine the biomarkers related to obesity development and obesity-related 
comorbidities. 
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2.1 - INTRODUCTION 
 
Peptide YY (PYY), a 36 amino acid appetite suppressing gut hormone, is secreted 
from the L-cells of the gastrointestinal tract. Low levels of PYY have been reported to be 
associated with higher BMI and obesity [53]. Circulating PYY increases satiety and 
subsequently decreases food intake via gut-brain communication [53, 54, 59],inhibits 
gastrointestinal motility[205]and pancreatic hormone secretion[58, 206].In addition, it 
hasbeen documented that PYY plays an integral part in maintaining energy homeostasis 
[27, 28]. However, the involvement of PYY in the development of human obesity is 
unclear[66, 79, 80],the relationship between circulating PYY and adiposity is 
controversial[69],and very little data exists from large human population-based studies. 
Appetite, a key factor in energy homeostasis, significantly influences the 
regulation of body weight [51].  Therefore investigating appetite regulating hormones, 
such as PYY, may provide valuable insight into the underlying mechanisms responsible 
for the development of obesity. Initial PYY knockout studies revealed that mice 
developed significant hyperphagia and that the acute administration of PYY could 
significantly ameliorate this condition [30, 53,61].  This group also proposed that 
endogenous PYY concentration was lower in obese rodents and humans, inversely 
associated with obesity-related phenotypes [51], and the administration of PYY could 
effectively reduce food intake and body weight independent of obesity status [30, 51, 53].  
Therefore it was hypothesized that a deficiency in circulating PYY could be a significant 
contributing factor toward the chronic over consumption of food and subsequent weight 
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gain.  However, many successive PYY knockout [63, 64] studies have failed to reproduce 
the strong association of PYY with hyperphegia and diet-induced obesity.  A 
considerable number of studies have also been unable to replicate the original results in 
rodents or obese humans [65, 66, 71] along with any significant association between 
circulating PYY and adiposity [58, 70, 207].   
Considering that very few cross-sectional studies with large sample sizes have 
been performed considering confounding variables and that the current results in the 
literature are controversial; there is a necessity to explore the association of circulating 
PYY with obesity at the population level.  Therefore the purpose of our study was to 
investigate the association of circulating PYY concentration with obesity status and body 
composition, measured by dual-energy x-ray absorptiometry, in a large population 
adjusting for major confounding factors. The detailed objectives were to: 1) test if PYY is 
associated with obesity status by comparing fasting serum PYY between normal-weight 
(NW), overweight (OW) and obese (OB) men and women; 2) examine the association of 
PYY with body composition among normal-weight (NW), overweight (OW) and obese 
(OB) men and women; and 3) determine the influence of age, sex, smoking, medication 
use and menopausal status on circulating PYY. 
2.2 - SUBJECTS & METHODS 
 
Ethics Statement 
 This study was approved by The Health Research Ethics Authority (HREA) for 
the Faculty of Medicine, Memorial University of Newfoundland and Labrador, St John’s, 
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Canada.  All subjects provided written informed consent. 
 
Subjects 
 A total of 2094 subjects from theComplex Diseases in the Newfoundland 
population: Environment and Genetics (CODING) study (Male 523, Female 1571) was 
used for this investigation[15-17, 208,209].All participants of this current study were 
from the Canadian province of Newfoundland and Labrador.  Eligibility of participants 
for the CODING study was based upon the following inclusion criteria: 1) > 19 yrs of 
age; 2) at least a third generation Newfoundlander; and 3) healthy, without any serious 
metabolic, cardiovascular, or endocrine diseases.  The primary method of subject 
recruitment for the CODING study was the use of posters and handouts.  This literature 
was distributed throughout public facilities (offices, and hospitals) in the city of St. 
John's, Newfoundland and Labrador. Each individual completed a number of 
questionnaires to obtain information regarding lifestyle and physical activity.  
Anthropometric, body composition and biochemical measurements were performed 
following a 12-h fasting period.  
 
Anthropometric and body composition measurements 
 Height (cm) and weight (nearest 0.1 kg) measurements were collected and Body 
Mass Index (BMI) calculated.  BMI was defined as weight divided by height squared 
(kg/m
2
).  Waist circumference (cm) was measured as the horizontal distance around the 
abdomen at the level of the umbilicus, and hip circumference (cm) was measured as the 
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largest circumference between the waist and thighs.  Height, waist and hip measurements 
were recorded to the nearest 0.1 cm.  Percent body fat (%BF), percent trunk fat (%TF), 
percent android(abdominal) fat (%AF) and percent gynoid (lower abdominal-thigh)fat 
(%GF) were measured, in a supine position, utilizing dual-energy X-ray absorptiometry 
(DXA, Lunar Prodigy; GE Medical Systems, Madison, WI).The Lunar Prodigy software 
system determines automatically the regions for the assessment of %TF, %AF, %GF.  
%TF region is from the top of the shoulders to the top of the iliac crest, while the %AF 
region is the top of the second lumbar vertebra to the top of the iliac crest and the %GF 
region extends down iliac crest twice the height of the android area.  The current version 
of the enCORE software for the DXA data presented within this manuscript cannot 
differentiate visceral from subcutaneous fat. Therefore the %TF, %AF, and %GF regions 
represent the summation of both subcutaneous and visceral fat relative to theseregions.  
DXA produces an accurate measurement of adipose tissue within the body with a low 
margin of error.  For this reason, DXA is considered to be one of the most reliable 
measurements of adiposity and is commonly used as a standard compared to less accurate 
field methods such as BMI.  The enCORE (Ver 12.2, 2008, GE Medical Systems, 
Madison, WI) software package was used for DXA data acquisition.  Quality assurance 
was performed on the DXA scanner daily and the typical CV during the study period was 
1.4%.  
 
Total PYY Measurement 
 Fasting blood samples were obtained and serum was stored at -80 °C for 
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subsequent analyses.  Serum total PYY concentration was determined via an enzyme-
linked immunosorbentassay (Millipore Corporation Pharmaceuticals, Billerica, MA, 
USA).Due to the large number of participants in this current investigation samples were 
measured in singlet.  However the intraassay (range of 4.8% to 5.4%) and interassay 
(5.1%) variation from our previous study, [207]and the measurements of PYY in the 
current study, were performed by the same research assistant.  The detection limit of the 
PYY enzyme-linked immunosorbent assay used was 10 pg/mL for a sample size of 20 
µL.  
 
Lifestyle Assessment 
 All participants completed a self-administered screening questionnaire, which 
queried covariates including smoking (smoker, non-smoker) and medication (medication 
user, non-medication user).  Female subjects were screened for menopausal status (Pre-
menopause, Post-menopause) by questionnaire.  
 
Data Analysis 
 Data are presented as means ± standard deviation (SD) unless otherwise stated.  
Participants with PYY concentrations falling outside the range of ± 3SDs (n = 27) were 
considered outliers and excluded from analyses. The influence(s) of sex (Men vs. 
Women) environmental factors(smoking vs. non-smoking, medication vs. non-mediation 
user) and menopause (pre-menopause vs. post-menopause)on PYY concentration were 
assessed using independent sample t-tests.  Pearson correlation analysis was also 
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performed to assess the association of circulating whole PYY with body composition 
measurements for the entire cohort along with males and females separately.  Obesity 
status (normal-weight, overweight, and obese) for participants (n = 2094) was determined 
based on %BF according to the, age and sex specific, criteria recommended by Bray 
[3].Obesity status was also grouped based on BMI as normal-weight (NW; 18.5–24.9 
kg/m
2
), overweight (OW; 25.0 – 29.9 kg/m2) or obese (OB; > 30 kg/m2) according to 
criteria of the World Health Organization[210]. To further explore the association of 
PYY with body composition we stratified subjects into tertiles according to waist 
circumference, hip circumference, waist-hip ratio, BMI, %BF, %TF, %AF and %GF.  
Participants were also divided into tertiles according to fasting serum PYY 
concentrations (pg/ml) to examine differences in adiposity measurements.  Subsequently, 
adjusted and unadjusted multiple regression analyses were used to further explore the 
associations found between body composition measurements and circulating PYY 
concentration. The effect of age on the relationship between PYY and adiposity was also 
thoroughly explored. PYY concentrations were compared among normal-weight, 
overweight, and obese participants, defined by %BF according to the Bray Criteria, from 
four different age groups: 1) younger than 30 years of age (<30 yrs); 2) 30years of age 
and greater but less than 40 years of age (> 30 yrs - <40 yrs); 3) 40 years of age and 
greater but less than 50 years of age (>40 yrs - <50 yrs);and  4) 50 years of age and 
greater (> 50yrs). 
 
 Differences in PYY concentration among obesity statuses (NW,OW,OB), body 
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composition tertiles (low, medium, high),were analyzed by one-way analysis of 
covariance (One-way ANCOVA) controlling for age, sex, smoking, medication use, and 
menopause.  Multiple regression analysis also included age, sex, smoking, medication 
use, and menopausal status as potential covariates.  R statistical software package version 
2.15.2 (R development core team) was used for all analyses. Statistical analyses were 
two-sided and a P value <0.05 was considered to be statistically significant. 
 
2.3 - RESULTS 
 
PYY concentration and body composition measurements among male and female 
participants 
 Body composition characteristics and PYY concentration from both male and 
female subjects are shown in Table 2.1. Independent t-test analysis revealed that PYY, 
weight, height, BMI, waist circumferenceand waist-hip ratio were significantly greater 
for men than women. Women were significantly greater than men for age, hip 
circumference, %BF, %TF, %AF, and %GF. Sex differences for body composition 
measurements among Newfoundland and Labradoreans have been previously described 
by us [15-17]. Fasting serum total PYY concentrations were found to be approximately 
9%, or 11pg/ml, higher in men than in women (Table 2.1).   
 
Association of lifestyle/environmental factors with PYY concentration 
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 The influence of lifestyle and environmental factors such as smoking, medication 
use, and menopause on circulating PYY concentration were explored. None of these 
factors had an influence on PYY concentration for men. Female smokers had a 9.7% 
higher fasting PYY concentration than female non-smokers (120.50 ± 77.6 pg/ml vs 
109.87 ± 73.5 pg/ml, p < 0.04).  PYY concentration was significantly higher for female 
medication users (114.51 ± 75.5 pg/ml) over non-medications users (106.71 ± 72.4 
pg/ml) (p = 0.04).  With regards to menopausal status, PYY concentration was 10.3% 
greater for post-menopausal women over pre-menopausal women (117.78 ± 78.3 pg/ml 
vs106.70 ± 71.5 pg/ml, p < 0.006). Age, weight, BMI, waist circumference, hip 
circumference, %BF, %TF, %AF and %GF were all significantly greater for post-
menopausal women compared to pre-menopausal women (p < 0.004).  Lastly, to 
investigate the potential compound effect of smoking, medication use, and menopausal 
status on fasting PYY concentration for women we compared post-menopause smoking 
medication users (n=53) with pre-menopause non-smoking non-medication users 
(n=376). The post-menopause smoking medication users group (139.40±93.7 pg/ml) had 
a 38.6% higher fasting PYY concentration than pre-menopause non-smoking non-
medication users (100.60±67.7)(p < 0.005) independent of age, BMI and %BF.  
 
Pearson correlation analysis of body composition measurements with circulating PYY 
Pearson correlation analysis of weight, height, BMI, waist circumference, Hip 
circumference, waist-to-hip ratio, %BF, %TF, %AF, %GF with circulating PYY are 
shown in Table 2.2. Although no association was found between any of the body 
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composition measurements with PYY (pg/ml) in men, age (y), weight (kg), height (cm), 
waist circumference (cm) and the waist-to-hip ratio were significantly positively 
associated with circulating PYY (pg/ml) in the entire cohort.  Additionally,  age, waist 
circumference, hip circumference, %BF, and %TF were significantly positively 
associated with circulating PYY (pg/ml) in women. 
 
PYY concentration and body composition among normal-weight, overweight and  
obese for male and females participants 
 Body composition characteristics and PYY for NW, OW and OB men and women 
are shown in Table 2.3. Fasting total PYY concentration was not significantly different 
among NW, OW, and OB subjects within the entire cohort or for either sex(Table 
2.3).Weight, BMI, waist circumference, hip circumference, waist-hip ratio, %BF, %TF, 
%AF and %GF all significantly increased with the concomitant increase in adiposity 
status within the entire cohort and for both sexes. There was also no significant difference 
in circulating PYY when these adiposity groups were classified by BMI according to the 
WHO criteria (Figure 2.1). 
 
PYY concentration and body composition measurements among tertiles (low, medium, 
and high) according to body composition measurements and PYY concentration 
To further explore the potential relationship between PYY and body composition, 
PYY concentrations were compared among subjects stratified into tertiles according to 
obesity-related phenotypes (waist circumference, hip circumference, BMI, %BF, %TF, 
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%AF and %GF).  We found no significant difference in PYY concentration among any of 
the body composition measurement tertiles, or a difference in any of the body 
composition values among the PYY tertiles, in men (Table 2.4 & 2.5).  However, PYY 
concentrations were significantly associated with the increase in waist circumference, 
%BF, and %TF and these same body composition measurements were significantly 
associated with the concomitant increase of PYY concentration in women (Table 2.4 & 
2.5).PYY concentration was also significantly associated with the increase in waist 
circumference and waist-hip ratio before and after adjustment for the entire cohort.  Hip 
circumference and waist-hip ratio are also positively associated with the increase in 
circulating PYY before and after adjustment for the entire cohort and women (Table 2.4 
& 2.5).  Lastly, %AF was significantly associated with the increase in circulating PYY 
concentration in females (Table 2.4 & 2.5). 
 
Multiple regression analysis of body composition measurements with circulating PYY 
Unadjusted and adjusted linear regression analysis results of %TF, %BF, and 
waist circumference on circulating PYY are shown in Table 2.6.  No association was 
found between %TF (%) or %BF (%) with PYY (pg/ml) in the entire cohort or among 
men.  Although waist circumference (cm)was not associated with circulating PYY in 
men, it was positively correlated with the entire cohort before and after the adjustment for 
age, smoking, medication use and menopausal status.  Circulating PYY was positively 
associated with waist circumference (cm), %TF (%), and %BF (%) in women before 
adjustment for confounding factors.  However after the adjustment for age, smoking, 
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medication use and menopausal status only %TF (%) and waist circumference (cm) 
remained significantly associated with PYY in women(Table 2.6). 
Association of age with circulating PYY concentration 
 Circulating PYY were also analyzed among normal weight, overweight and obese 
men and women for 4 different age ranges(< 30 yrs,>30 yrs - <40 yrs,>40-<50 yrs, and > 
50 yrs).No sex differences for PYY concentration were found among normal-weight, 
overweight and obese for any of the 4 age groups(Data no shown) and circulating total 
PYY concentration was not significantly different among adiposity groups within any of 
the 4 age ranges (Data no shown). However, PYY concentration was 15.2 %,17.1% and 
11.8% greater among men than women within the < 30 yrs, > 30 - < 40 yrs, and > 40 - < 
50 yrsgroups respectively (Figure 2.2.). Additionally, the > 50 yrs group from women 
had 12.2% higher circulating PYY than women in the < 30 yrs group (118.1 ± 77.1 vs. 
105.3 ± 63.9)(Figure 2.2).   
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2.4 - DISCUSSION 
 
One major finding for the present study is that serum PYY is not inversely 
associated with obesity status defined by BMI or %BF adjusting for age, sex, smoking, 
medication use, and menopause.  Contrary to the current literature we have demonstrated 
for the first time that fasting serum PYY is positively associated with %BF, %TF, and 
waist circumference in women.  Additionally, circulating PYY was greater among men 
compared to women, and is affected by age, smoking, medication use and menopausal 
status in women only. 
 
 PYY is an anorexigenic peptide, released from the L-cells of the lower intestine, 
which acts centrally within the hypothalamus to inhibit the orexigenic activity of the 
neuropeptide Y (NPY) [30, 52]. The initial investigations involving PYY, conducted in 
rodents, revealed that a diet-induced obesity state decreased PYY concentrations. 
Suggesting that the circulating concentration of this appetite suppressing gut hormone is 
associated with the development of obesity [61, 62].  Studies conducted on a small 
sample of humans showed that endogenous PYY concentrations were lower in obese 
subjects and inversely correlated with obesity-related phenotypes [30, 61, 67, 68].  
However, other rodent [66] and human based [70, 71, 89, 207] studies have failed to 
reproduce the strong inverse relationship between circulating PYY and adiposity. 
Additionally, an extensive review in 2005,exploring the anorexigenic effect of PYY, 
revealed 84% studies produced among 41 independent research groups were unable to 
reaffirm the claim proposed by the initial investigations [69].Data from human studies are 
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limited, inconsistent, contain small sample sizes and have utilized less accurate obesity 
measures(like BMI)in place of more accurate measures of body fat.  Moreover, our 
laboratory and others have shown that BMI cannot accurately distinguish fat mass from 
fat-free mass and is not an accurate predictor of adiposity [15, 16]. Therefore the 
inaccurate measurement of adiposity and the misclassifications of obesity status could be 
the factor attributing to the contradictory reports concerning the association of PYY with 
obesity.  The first important finding from the present study is that circulating PYY was 
not significantly different among normal-weight, overweight and obese participants and 
these findings were consistent whether obesity status was defined either by %BF or BMI.  
Additionally, a recent study by our laboratory was also unable to detect an association of 
circulating PYY with obesity status (defined either by BMI or %BF) in a cohort 
consisting of young men[207].Considering the power of the present study, with over 
2000 subjects, our results indicate that circulating PYY concentration is not likely a 
significant factor affecting obesity status at the population level.  However, after 
extensive analysis we have shown that circulating PYY is positively associated with 
obesity measures related to body fat in women.  PYY concentration was 10.5%, 8.3%, 
and 9.2% greater among women with the highest waist circumference, %BF and %TF, 
respectively, compared to women with the lowest aforementioned body fat measures.  
This finding was also supported by the fact that waist circumference, %BF and %TF 
were greatest among women with the highest tertile according to PYY concentration and 
that unadjusted multiple regression analysis revealed a significant positive influence of 
waist circumference, %BF and %TF.  The positive relationship found in our study 
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between PYY and body fat measures are in direct opposition to the negative association 
theory.  However, among the results of a study [211]designed to investigate various 
metabolites in insulin resistance, we discovered that PYY concentration was greater 
among obese subjects compared to normal-weight subjects.  Although the primary 
objective of this study was not investigating PYY and obesity status, their results are 
consistent with our current findings. The increased level of PYY in circulation is likely a 
protective response of human body to the obese state. Nevertheless, more studies are 
needed to verify our findings in other populations.  
 
The potential influence(s) of sex, age, smoking, medication use and menopause 
on fasting serum PYY concentration were also examined.  Studies have reported gender 
differences in circulating PYY levels. One study found that PYY was higher in men 
compared to women [72], while others found that PYY levels are higher in women 
[70].In the present study we discovered that fasting serum PYY was 9% higher in men 
compared to women. Findings from our current study, along with those of others, suggest 
that circulating PYY concentration is not significantly affected by age [67, 70,72].  
However, when evaluating the influence of age on PYY among females, a positive 
association was found.  Smoking and medication use did not affect PYY concentration in 
men, but these factors did significantly increase circulating PYY levels in women. 
Circulating PYY concentration was 9.7 and 7.3% greater among female smokers and 
medication users over non-smoker and non-medication users, respectively. Currently, 
there is very little evidence to suggest that smoking and medication use affect circulating 
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PYY. However some data, from animal models, does propose that nicotine [73-75] and 
various medications [76-78] can increase circulating PYY.  Specifically, rodent studies 
have shown that nicotine can significantly increase mRNA expression and the production 
of PYY protein [74] along with the significant attenuation of neuropeptide Y (NPY) 
mRNA expression and production of NPY protein [73, 75].Therefore, it is probable that 
the inhibition of appetite, due to smoking, could be partially attributed to the stimulation 
of PYY and the inhibition of NPY in women. Lastly, post-menopausal women had 
significantly greater PYY than pre-menopausal women. However, since more than 70% 
of our post-menopausal women are medication users and that menopause is strongly 
associated with age, the up regulation of PYY could be an age and drug related 
interference.  Therefore we investigated the potential compound effect of smoking, 
medication use, and menopausal status on fasting PYY concentration for women. The 
analysis revealed that post-menopause, smoking, medication users had a 38.6% higher 
fasting PYY concentration than pre-menopause, non-smoking, non-medication users.  
This compound effect was unchanged after controlling for age, BMI and %BF. Our study 
provides strong evidence that there is an obvious sex difference regarding fasting PYY 
concentration and that age, smoking, medication use and menopausal status all 
significantly influence circulating PYY concentration in women and not men.  
 
The primary limitation of the present study is that we only investigated total PYY 
rather than only PYY3-36which has been suggested to be the more significantly active 
form of PYY.  However, total levels of PYY are well correlated with PYY3-36[61] and 
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both PYY3-36 and PYY1-36  have been found to decrease gastrointestinal motility [58]. 
Secondly, due to a significant number of subjects in the current study, singlet 
measurements of PYY were collected from a single serum sample for each subject. 
However, due to the fact that the intraassay (range of 4.8% to 5.4%) and interassay 
(5.1%) variation from our previous study[207] were low, and that the measurement of 
PYY in the current study was performed by the same research assistant, we are confident 
that our data is accurate.  Moreover, the large sample size further strengthens the 
reliability.  Thirdly, although our findings strongly suggest that PYY is not a significant 
player in determining obesity status, it must be acknowledged that our samples were 
collected in a fasted state. Population studies, monitoring the dynamic postprandial 
response of PYY concentration to various standardized diets, should be performed. 
 
In summary, the association of fasting serum PYY concentration with obesity 
status and body fat measures was investigated among 2094adultsfrom the Canadian 
province of Newfoundland and Labrador. To the best of our knowledge this is the largest 
cross-sectional study to systematically evaluate the relationship between peripheral 
circulating PYY concentrations with adiposity.  Our results indicate that PYY is not 
significantly associated with obesity status defined by either %BF or BMI.  However, 
circulating PYY is influenced by age, smoking, medication use, and menopausal status in 
women.  Moreover contradictory to previous studies, fasting serum PYY in the present 
study was significantly associated with waist circumference, %BF, and %TF in women.  
Although the effect size of the positive association of PYY with adiposity in women is 
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small, and potentially negligible, it may in fact represent a protective response to extreme 
weight gain.  
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3.1 - INTRODUCTION 
 
 It has been documented that gut hormones influence appetite and play an integral 
part in maintaining energy homeostasis through gut-brain communication [27, 28].  
Peptide YY (PYY), a short 36 amino acid protein with structural homology to 
neuropeptide Y (NPY) and pancreatic peptide (PP), is a gut hormone that increases 
satiety consequently decreasing food intake [59].  PYY is released from the mucosa in 
the ileum and colon of the gastrointestinal tract existing in a PYY3-36 and PYY1-36 form 
[53, 54]. Both forms are physiologically active decreasing pancreatic secretions and 
suppressing gastrointestinal motility [58].  PYY secretion increases in response to food 
consumption and is positively correlated with the calorie content of meals [55-57].  
However, at the present time it is not clear whether or not PYY concentration is 
dependent upon adiposity status or if it plays an important role in the development of 
obesity.  
The majority of PYY studies conducted to date have been performed on rodents.  
It was initially observed that PYY concentrations were decreased after a diet-induced 
obese state in mice suggesting that altered PYY secretion is associated with the 
development of obesity [61, 62].  In some human studies endogenous PYY 
concentrations were found to be lower in obese subjects and inversely correlated with 
body mass index (BMI), suggesting that PYY deficiency may contribute to obesity [51, 
61, 67, 68].  In addition, the infusion of PYY was found to decrease the appetite of both 
lean and obese subjects along with a subsequent reduction in food intake [51, 53].  Taken 
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together, these data suggest that individuals with a lower concentration of PYY, such as 
overweight/obese individuals, may have a weaker satiety signal subsequently leading to 
the over consumption of food and weight gain.  In contrast to these studies many other 
studies in rodents [66] and humans with larger sample sizes [70, 71,89] could not 
replicate the relationship between PYY and adiposity status. The administration of PYY 
was also found not to have any effect on appetite or weight loss [66, 71].  At the present 
time data regarding the role PYY plays in determining adiposity status is contradictory.  
In addition, there is no data concerning the effect of a positive energy balance on PYY 
and the potential difference among normal weight, overweight and obese subjects.  
Our laboratory and others have demonstrated that changes in nutritional status, 
such as overfeeding, have major effects on adipose tissue metabolism [91, 92], 
circulating concentrations of adipokines [212] as well as gene expression profiles [90].  A 
positive energy balance may also influence circulating levels of gut hormones such as 
PYY and subsequently affect appetite.  Although recent studies have suggested that PYY 
plays an important role in energy homeostasis [58, 89], no study has yet investigated the 
regulation of PYY after a short-term positive energy challenge.  The response of PYY to 
changes in nutritional status will provide insight regarding the potential role of this gut 
hormone in the development of obesity as well as other related phenotypes including 
insulin resistance and serum lipid profiles.  The objective of the present study was to 
investigate the role that PYY plays in the development of obesity by investigating the 
following: 1) fasting serum PYY levels in normal weight, overweight and obese healthy 
young men at baseline before overfeeding; 2) the response of PYY to short-term 
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overfeeding between different adiposity statuses; and 3) the correlations of PYY with 
phenotypes of insulin resistance, glucose, and lipid metabolism.  
 
3.2 - SUBJECTS & METHODS 
 
 Subjects were recruited from an overfeeding study investigating the effects of a 
positive energy balance on endocrine factors as well as parameters of glucose and lipid 
metabolism [90-92].  A total of 69 young men were recruited from the city of St. John’s 
(Newfoundland and Labrador, Canada) and the surrounding areas. Inclusion criteria were 
as follows: 1) male; 2) 19–29 yr of age; 3) at least third-generation Newfoundlander; 4) 
healthy, without any serious metabolic, cardiovascular, or endocrine disease; 5) not 
receiving medication for lipid metabolism; 6) reported stable weight (±2.5 kg) in the 
previous 6 months and 7) subjects abstained from any alcoholic or additional calorie-
containing beverage consumption during the study period.  No study participants took 
any drugs/medications throughout the duration of the study.  Initial data collection for 
this study began October 2003. This study was approved by The Human Investigations 
Committee for the Faculty of Medicine, Memorial University of Newfoundland and 
Labrador, St John’s, Canada.  All subjects provided written informed consent. 
 
Serum measurements 
Fasting blood samples were obtained from all subjects before and after the 
completion of the overfeeding intervention.  Serum was stored at -80 °C for subsequent 
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analyses.  Whole PYY (Millipore Corporation Pharmaceuticals, Billerica, MA, USA) 
concentrations were measured in duplicate utilizing enzyme-linked 
immunosorbentassays.  The intra-assay variation ranged from 4.8 – 5.4% and the inter-
assay variation was 5.1%. The detection limit of the PYY ELISA kits used was 10pg/mL 
when using a 20 μL sample size. Serum insulin concentrations were measured with the 
use of an immunoassay analyzer (Immulite; DPC, Los Angeles, CA).  The homeostasis 
model assessment (HOMA) was used as a measure of insulin resistance [HOMA-IR= 
insulin (µU/mL) × glucose (mmol/L)/22.5)] and β cell function [HOMA-β = 20 × insulin 
(µU/mL)/(glucose - 3.5)] [213].  Serum concentrations of glucose, triacylglycerols (TG), 
high-density lipoprotein (HDL) cholesterol and total cholesterol were measured by an 
Lx20 analyzer (Beckman Coulter Inc, Fullerton, CA).  Low-density lipoprotein (LDL) 
cholesterol was calculated with the following formula: Total cholesterol – HDL 
cholesterol – (TG/2.2). The LDL cholesterol calculation is reliable in the absence of 
severe hyperlipidemia.  
 
Measurement of body composition  
Height and weight measurements were collected and BMI calculated.  BMI was 
defined as weight divided by height squared (kg/m
2
).  Percent body fat (%BF), percent 
trunk fat (%TF), and percent android fat (%AF), were measured utilizing dual-energy X-
ray absorptiometry (DXA, Lunar Prodigy; GE Medical Systems, Madison, WI).  
Measurements were performed on subjects in a supine position, after the removal of all 
metal accessories, as previously described by us [91, 208].  Version 12.2 of the encore 
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(enCORE,Ver 12.2, 2008, GE Medical Systems, Madison, WI) software package was 
used for DXA analysis.  Subjects fasted for 12 hours before data was collected.  All 
measurements were collected on the first day of data collection and one day after the 7-
day overfeeding intervention.  
 
Overfeeding protocol 
A 7-day overfeeding protocol was chosen for this study to ensure that the 
intervention would induce metabolic changes.  Participants consumed 70% more calories 
than their normal energy requirements (hypercaloric), which consisted of 15% protein, 
35% fat, and 50% carbohydrates to mimic the common daily diet in North America. 
Baseline energy requirements were determined from three 24-hr diet recalls and a 30-d 
dietary inventory.  The average caloric intake per day was as follows: energy (baseline: 
2969 kcal; overfeeding: 5471 kcal), protein (baseline: 106 g; overfeeding: 178 g), 
carbohydrates (baseline: 394 g; overfeeding: 713 g), fiber (baseline: 19 g; overfeeding: 
33 g), total fat (baseline: 105 g; overfeeding: 221 g), saturated fat (baseline: 38 g; 
overfeeding: 71 g), and cholesterol (baseline: 304 mg; overfeeding: 735 mg). Subjects 
were offered meals at 0900, 1200, and 1700 every day, and energy values and 
macronutrient content of the food were measured by using FOOD PROCESSOR SQL 
software (version 9.5.0.0; ESHA Research, Salem, OR). The actical physical activity 
monitor (Mini Mitter Co, Inc, Bend, OR) was used to determine the total energy 
expenditure.  Physical activity levels were controlled below 15% between the baseline 
and overfeeding period. Full details of our overfeeding protocol have been previously 
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described and all of the participants in this study were members of these studies [90-92].  
On average, subjects gained 2.4 ± 1.3 kg body weight, of which 43.2 ± 31.6% (0.830 kg 
± 0.542) was body fat.  
 
Statistical analysis  
Data are presented as means ± SDs unless otherwise stated.  Before any statistical 
analysis was performed, data that were not normally distributed were logarithmically 
transformed (TG, insulin, HOMA-IR and HOMA-β) to approximate normal distribution.  
Subjects were classified on the basis of %BF as either normal weight (8 – 20.9%), 
overweight (21 – 25.9%) or obese (> 26%) according to criteria recommended by 
Bray[3].  Statistical analyses were also performed according to BMI as normal weight (≤ 
24.9 kg/m
2
), overweight (25.0 – 29.9 kg/m2) or obese (> 30 kg/m2) according to criteria 
of the World Health Organization[210]. To further explore the relationship between PYY 
and body composition, participants were divided into tertiles according to baseline fasting 
serum PYY concentrations (pg/ml) as follows: Low (Bottom 33.3%), Medium (middle 
33.3%) and High (top 33.3%) PYY concentration.  The range of serum PYY for the Low, 
Medium and High groups were 23.85-90.73 pg/ml, 97.69-131.36 pg/ml, and 133.52-
347.52 pg/ml respectively. 
 
Differences in variables between the three adiposity groups in response to 
overfeeding were analyzed by using a mixed model repeated two-way analysis of 
variance and baseline values between the three adiposity groups were analyzed using a 
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one-way analysis of variance.  The Bonferroni post-hoc test was run after the one-way 
ANOVA and the two-way ANOVA displaying a significant overfeeding by adiposity 
interaction (p < 0.05). Within group analysis on the response to overfeeding was 
performed with a student paired t-test performed on variables that displayed a significant 
overfeeding by adiposity interaction effect.  Pearson’s correlation analyses were 
performed to screen for potential factors related to fasting PYY concentrations followed 
by partial correlation analyses after controlling for age.  Bonferroni testing was applied to 
correct for multiple comparisons.  Three correlation analyses were performed as follows: 
1) PYY at baseline was compared with all variables at baseline; 2) PYY at baseline was 
compared with changes in all variables in response to overfeeding to investigate whether 
baseline PYY could predict the changes in related markers; and 3) Changes in PYY were 
compared with changes in all variables in response to overfeeding. SPSS software 
version 17.0 (SPSS Inc, Chicago, IL, USA) was used for all analyses. Statistical analyses 
were 2-sided and p < 0.05 was considered to be statistically significant. 
 
3.3 - RESULTS 
 
Comparison of characteristics at baseline and in response to short-term overfeeding 
Physical and biochemical characteristics of subjects at baseline are shown in 
Table 3.1.The body composition, glucose and lipid metabolism differences found 
between normal weight, overweight and obese young health males have been previously 
described by us [90-92]. Fasting serum PYY concentrations at baseline for normal weight 
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(121.47 ± 60.8 pg/ml), overweight (109.90 ± 53.8 pg/ml) and obese (118.93 ± 56.54 
pg/ml) subjects were not significantly different from one another.  PYY concentrations 
were also analyzed according to BMI criteria where no significant differences were found 
(data not shown).   
 
Changes in body composition and phenotypes of glucose metabolism and lipids in 
response to the 7-day overfeeding are also described in Table 3.1.Our 7-day positive 
energy challenge for normal weight, overweight and obese young healthy males 
significantly increased body composition, serum lipids, insulin resistance and β cell 
function.  These findings have been previous described by us as well [90-92].  The only 
significant overfeeding x adiposity status interactions found from our analysis were for 
%BF and %TF, indicating that normal weight subjects experienced a greater significant 
increase in body fat percentage than overweight and obese (Table 3.1).  Regarding whole 
PYY, there was no significant difference in concentration between normal weight, 
overweight and obese young men after overfeeding (p = 0.758). However, the main effect 
for overfeeding did reach significance demonstrating that PYY concentration was 
significantly increased due to the 7-day positive energy challenge (p = 0.013).  
 
Correlations of PYY with phenotypes of glucose and lipid metabolism 
Correlations between baseline PYY and baseline phenotypes were assessed 
(Table 3.2).  In the entire cohort at baseline, PYY was negatively correlated with BMI. 
However, when these analyses were repeated according to adiposity status the correlation 
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was only found in normal weight and overweight subjects. PYY was not significantly 
correlated with %BF for the entire cohort, but was found to be negatively correlated with 
%BF within the normal weight subjects.  Baseline PYY was negatively correlated with 
baseline %AF within the normal weight group. Correlations between baseline PYY and 
the changes in phenotypes were also assessed to determine if PYY could act as a 
predictor of these parameters under conditions of an energy surplus (Table 3.3).Three 
significant negative correlations were found within the normal weight group between 
baseline PYY and the changes in total cholesterol, LDL-cholesterol and HDL-cholesterol 
due to overfeeding.  Also, baseline PYY was negatively correlated with the changes in 
glucose for overweight subjects.  Correlations between changes in baseline PYY and the 
changes in phenotypes were also assessed (Table 3.4).  There were only two positive 
partial correlations found between the changes in PYY with the changes in phenotype 
markers due to overfeeding which were HDL-cholesterol and glucose for normal weight 
subjects (Table 3.4). 
 
Comparison of body composition measures in low, medium and high baseline fasting 
serum PYY concentrations.   
Lastly, we wanted to investigate the relationship between Low, Medium, and 
High baseline fasting serum PYY concentrations and markers of body composition. The 
between group comparison demonstrated that there were no significant differences in the 
any of the body composition variables at baseline nor after the overfeeding protocol 
(body weight, BMI, %BF, %TF, %AF). %BF at baseline stratified in the Low, Medium, 
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and High PYY concentrations was 24.54 ± 8.2%, 22.6 ± 8.9% and 22.13 ± 8.5% 
respectively and were not significantly different from one another (p = 0.606). BMI at 
baseline stratified in the Low, Medium, and High PYY concentrations were 26.66 ± 4.8 
kg/m
2
, 24.80 ± 4.7 kg/m
2
 and 25.14 ± 4.4 kg/m
2 
respectively and were also not 
significantly different from one another (p = 0.469). The two-way ANOVA again 
revealed that the 7-day overfeeding effectively increased whole PYY concentrations (p = 
0.002) and that there was a significant overfeeding by PYY concentration group 
interaction (p < 0.001). Sub-group analysis revealed that PYY significantly increased 
within the Low baseline PYY group from 61.87 ± 19.43 pg/ml to 103.51 ± 37.01 pg/ml 
(p < 0.05) and that the Medium (from 114.37 ± 10.30 pg/ml to 115.18 ± 43.37 pg/ml) and 
High (from 178.03 ± 50.14 pg/ml to 194.43 ± 85.72 pg/ml) baseline PYY concentration 
groups remained unchanged after overfeeding.    
 
 
 
 
 
 
 
 
 
68 
 
 
69 
 
 
70 
 
 
71 
 
 
72 
 
3.4 - DISCUSSION 
The gastrointestinal tract is the largest endocrine organ inthe human body and 
secretes several appetite regulating hormones including PYY.  The brainstem and 
hypothalamus receive neural and hormonal signals through a gut-brain communication 
pathway subsequently regulating food intake and energy homeostasis [214, 215].  
Although PYY is thought to be involved in the development of obesity [30], controversy 
exists regarding the definitive role that PYY plays in this regard [58, 66, 71].  Therefore, 
we sought to clarify whether fasting serum PYY varied before and after a positive energy 
challenge among normal weight, overweight and obese young men.   
Data from animal experiments indicate that endogenous PYY acts on the arcuate 
nuclei through the gut-hypothalamic pathway blocking various orexigenic effects which 
results in increased satiety and decreased gastric emptying [30, 53, 60].  It has been 
suggested that fasting serum PYY concentrations are lower in obese rodents as well as 
humans and that PYY infusion effectively reduces food intake and body weight [51, 53].  
However, many other studies have failed to reproduce these findings [66, 71].  In our 
study, we found no significant differences in fasting serum PYY concentrations between 
normal weight, overweight or obese men classified by %BF (DXA) or BMI.  
Furthermore, there were no significant differences between body composition 
measurements according to DXA or BMI when our subjects were stratified into Low, 
Medium and High fasting serum PYY concentrations.  Therefore, our data do not support 
the hypothesis that adiposity status, indexed by %BF or BMI, determines basal PYY 
concentrations.  Interestingly, we did observe an inverse correlation between circulating 
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PYY and markers of adiposity (%BF and BMI) among normal weight subjects.  Although 
the reason for this is unclear, it appears that PYY may have a weak effect on adiposity 
among normal weight men.  Nonetheless, without a number of large population-based 
studies on fasting serum levels of human PYY, strong conclusions regarding the role 
PYY plays in determining adiposity status and the development of obesity will remain 
controversial.   
The most important finding from the current study is that the concentration of 
fasting PYY significantly increased in all subjects after a 7-day overfeeding challenge.  In 
addition, the amount of PYY significantly increased in the low PYY concentration group 
and not in the medium and high concentration group suggesting a possible dose effect. 
This finding is difficult to interpret without further study. It was first suspected that the 
majority of the low baseline concentration PYY subjects experiencing an increase in 
PYY, from the positive energy challenge, would have been from the normal weight 
group. However, due to only 9 out of the 23 low PYY concentration subjects being of 
normal weight we doubt that this possible dose effect would be dependent upon adiposity 
status.  In addition, having divided our subjects into groups according to a baseline 
measurement it cannot be ignored that the regression to the mean may partially explain 
both the increase in PYY for the low PYY concentration group and the increase in 
percent body fat for the normal weight group after our intervention. Previous studies 
investigating the role of PYY in maintaining energy homeostasis have examined the 
response of this gut hormone to a negative energy balance [58, 89].  Specifically, a study 
by Essah et al [89] on 30 obese adults demonstrated that after an 8-week low-fat and low-
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carbohydrate hypocaloric diet there was a 9% reduction in body weight and a subsequent 
10% reduction in circulating PYY levels [89].  Although the study provides valuable 
insight into the regulation of PYY by a negative energy challenge, obesity is generally 
understood to be the result of a chronic energy surplus [86] triggering many complex 
hormonal changes [87, 88].  The current overfeeding study therefore provides a means in 
which the biochemical changes in circulating PYY that would be evident with extended 
overeating, such as in the development of obesity, could be examined.  The significant 
increase in PYY under a positive energy challenge in our study could be physiologically 
meaningful and act as a protective mechanism to counteract the hypercaloric diet.  
However, the increase in PYY due to overfeeding is not dependent upon adiposity status 
which suggests hope that PYY could potentially be helpful to overweight and obese 
individuals. Our results, combined with data from previous negative energy balance 
studies, suggest that PYY is involved in maintaining energy homeostasis however the 
level of contribution is yet to be determined.   
 
Aside from investigating the role PYY plays in body composition and energy 
homeostasis, we were also interested in investigating its association with parameters of 
glucose and lipid metabolism.  Interestingly, baseline PYY was found to be negatively 
correlated with the increase in cholesterol measurements (Total, LDL and HDL) in 
response to overfeeding in normal weight subjects.  This finding would suggest that 
individuals with lower baseline PYY concentrations experience a greater increase in 
serum lipids after overfeeding.  Although the parallel response between PYY and serum 
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lipids may be beneficial when under a positive energy balance, a causal relationship 
between these variables cannot be inferred.  More studies are warranted to further 
understand the possible physiological significance between fasting PYY and serum lipids 
under a positive energy challenge.   
 
The primary limitation of the present study is that we only studied young males 
(19-29 yr), which limits the application of our conclusions to other groups.  Larger 
population studies investigating the effects of overfeeding with a wider age distribution 
including females is warranted to determine the physiological role PYY plays in the 
modification of appetite and the development of obesity.  Furthermore, we only 
investigated whole human PYY rather than PYY3-36 which has been suggested to be the 
more significantly active form of PYY.  However, whole PYY levels are well positively 
correlated with PYY3-36[61] and both PYY3-36 and PYY1-36  have been found to decrease 
gastrointestinal motility [58].  
 
In summary, this is the first study of its kind to explore the response of fasting 
PYY to a short-term positive energy challenge.  We measured fasting serum whole PYY 
in 69 young men before and after a 7-day positive energy challenge.  Circulating PYY 
was similar among normal weight, overweight and obese young men at baseline before 
overfeeding.  We did, however, observe significant negative correlations with both BMI 
and %BF in normal weight subjects only.  Furthermore, PYY was significantly increased 
in response to the positive energy challenge in the entire cohort.  It would appear that 
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PYY acts as protective mechanism against the development of obesity.  The body seems 
to mount a counter regulatory reaction to prevent further weight gain in normal weight, 
overweight and obese subjects.  Therefore, PYY represents a likely target for further 
downstream studies related to the development of obesity.  
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4.1 - INTRODUCTION 
 
 The accumulation of white adipose tissue (WAT) is the product of a chronic 
positive energy balance in an obesogenic environment [91].  Numerous disorders such as 
insulin resistance, type 2 diabetes (T2D) and cardiovascular disease have shown a strong 
association with the accumulation of subcutaneous and visceral fat mass [216, 217].Once 
regarded as a site for energy storage, recent research has shown that WAT secretes a 
large number of physiologically active proteins [113-115] thus playing an integral role in 
human endocrinology and energy homeostasis [111, 112, 218].  Adiponectin, for 
example, is predominantly secreted into circulation from adipose tissue, which increases 
insulin sensitivity resulting in the effective disposal of glucose from circulation [116-
118].  Accumulating evidence suggests that adiponectin is strongly associated with 
glucose and lipid metabolism, although adiponectins role in the development of obesity 
and insulin resistance remains unclear.  
 Considering that adiponectin has been recognized as a significant insulin 
sensitizer it would be consistent to anticipate that circulating adiponectin levels would be 
considerable in the presence of an insulin resistant state such as obesity.  However, the 
puzzling actuality suggests that adiponectin is inversely associated with obesity [119-
124] and insulin resistance [122, 125-127].  Consequently if adiponectin is an anti-
obesigenic and anti-diabetic protein, expected to increase in circulation, it is perplexing 
that adiponectin levels are attenuated in both obese and diabetic populations.  
Nevertheless there is significant evidence that adiponectin does indeed play a beneficial 
role in both lipid and glucose metabolism [126, 127, 134,135].  Rodent studies have 
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shown that adiponectin gene knockout mice severely attenuate glucose disposal and [126, 
134] the administration of adiponectin can effectively ameliorate insulin resistance [127, 
135].  These findings demonstrate that adiponectin can protect or even reverse obesity 
related disease states.  However, the paradoxical inverse relationship of adiponectin with 
adiposity remains unclear.  
 Our laboratory and others have demonstrated that a short-term positive energy 
challenge affects glucose and lipid metabolism, which results in significant body weight 
gain and insulin resistance [84 , 91, 92, 207, 212].  Moreover, changes in nutritional 
status have also shown to significantly affect circulating adipokines[84, 91,92].  For this 
reason we propose that investigating the response of adiponectin, to adiposity 
development, will provide insight into the potential role that adiponectin may play in the 
development of obesity and diabetes.  The objective of our present investigation is to 
address the following as yet unanswered question: Does circulating adiponectin increase 
in response to a short-term positive energy challenge and is this potential response 
obesity status dependent.  To our knowledge this is the first study of its kind to 
investigate the effect of a 7-day positive challenge (70% above normal energy 
requirements) on circulating adiponectin among normal-weight, overweight and obese 
individuals.   
 
4.2 - SUBJECTS & METHODS 
 
Ethics Statement 
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 This study was approved by The Health Research Ethics Authority (HREA) for 
the Faculty of Medicine, Memorial University of Newfoundland and Labrador, St John’s, 
Canada.  All subjects provided written informed consent. Initial data collection for this 
study began October 2003.   
Subjects 
 Sixty-four young men, recruited from the city of St. John’s (Newfoundland and 
Labrador, Canada) and surrounding areas, participated in the current positive energy 
challenge (PEC) study.  The study inclusion criteria were as follows: 1) male; 2) non-
smoker, 3) 19–29 yr of age; 4) at least third-generation Newfoundlander; 5) healthy 
young men, without any serious metabolic, cardiovascular, or endocrine disease; 6) not 
receiving medication for lipid metabolism; 7) reported stable weight (±2.5 kg) in the 
previous 6 months and 8) subjects abstained from any alcoholic or additional calorie-
containing beverage consumption during the study period.  Participants refrained from 
taking any drugs/medications throughout the duration of the study.  All physical and 
biochemical measurements were collected, after a 12 hour fast, on the morning of the first 
day of overfeeding and one day after the 7
th
 and final day of overfeeding.  Study 
participants were free living throughout the experiment and were not restricted to an 
experimental environment, such as a hospital.  
Serum measurements 
Fasting blood samples were obtained from all subjects before and after the 
completion of the overfeeding intervention.  Serum was stored at -80 °C for subsequent 
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analyses.  The majority of biochemical markers [219] and adiponectin [220] remain 
stable under these storing conditions.  Adiponectin (Phoenix Pharmaceuticals, Belmont, 
California) concentrations were measured in duplicate utilizing enzyme-linked 
immunosorbentassays.  The intra-assay variation ranged from 4.8 – 5.4% and the inter-
assay variation was 5.1%.  The detection limit of the adiponectin ELISA kits used was 0. 
15ng/ml when using 100 μL diluted samples.  Serum insulin concentrations were 
measured with the use of an immunoassay analyzer (Immulite; DPC, Los Angeles, CA).  
The homeostasis model assessment (HOMA) was used as a measure of insulin resistance 
and beta cell function [213].  
 
)5.22/])/[cos_]/[_(( LmmoleGluFastingmlUInsulinFastingIRHOMA    
))5.3]/[cos_/(]/[_20((  LmmoleGluFastingmlUInsulinFastingHOMA 
 
Serum concentrations of glucose, triacylglycerols (TG), high-density lipoprotein 
(HDLc) cholesterol and total cholesterol were measured by an Lx20 analyzer (Beckman 
Coulter Inc, Fullerton, CA).  Low-density lipoprotein (LDLc) cholesterol was calculated 
as seen below. The LDL cholesterol calculation is reliable in the absence of severe 
hyperlipidemia. 
 
)]2.2/)/(lg()/(_)/(_[ LmmollycerolTriacyLmmollCholesteroHDLLmmollCholesteroTotalLDLc 
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Body composition measurements  
Height (nearest 0.1 cm) and weight (nearest 0.1 kg) measurements were collected 
and Body Mass Index (BMI) calculated.  BMI was defined as weight divided by height 
squared (kg/m
2
).  Percent body fat (%BF), percent trunk fat (%TF), and percent android 
(abdominal) fat (%AF), were measured utilizing dual-energy X-ray absorptiometry 
(DXA, Lunar Prodigy; GE Medical Systems, Madison, WI).  Measurements were 
performed on subjects in a supine position, after the removal of all metal accessories [91, 
208].  Version 12.2 of the enCORE (enCORE,Ver 12.2, 2008, GE Medical Systems, 
Madison, WI) software package was used for DXA analysis.  DXA measurements (fat 
weight, lean tissue weight and bone weight) are recorded to the nearest 0.001 kg.  
 
Overfeeding protocol 
Participants consumed 70% more calories than their normal energy requirements 
(hypercaloric), which consisted of 15% protein, 35% fat, and 50% carbohydrates to 
mimic the common daily diet in North America. Baseline energy requirements were 
determined from three 24-hr diet recalls and a 30-d dietary inventory. The average caloric 
intake per day was as follows: energy (baseline: 2969 kcal; overfeeding: 5471 kcal), 
protein (baseline: 106 g; overfeeding: 178 g), carbohydrates (baseline: 394 g; 
overfeeding: 713 g), fiber (baseline: 19 g; overfeeding: 33 g), total fat (baseline: 105 g; 
overfeeding: 221 g), saturated fat (baseline: 38 g; overfeeding: 71 g), and cholesterol 
(baseline: 304 mg; overfeeding: 735 mg). Subjects were offered meals at 0900, 1200, and 
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1700h every day, and energy values and macronutrient content of the food were 
measured by using FOOD PROCESSOR SQL software (version 9.5.0.0; ESHA 
Research, Salem, OR).  The actical physical activity monitor (Mini Mitter Co, Inc, Bend, 
OR) was used to determine the total energy expenditure.  Physical activity levels were 
controlled below 15% between the baseline and overfeeding period. Full details of our 
overfeeding protocol have been previously described and all of the participants in this 
study were members of these studies [91, 92,207].  On average, subjects gained 2.2 ± 1.4 
kg body weight, of which 44.1 ± 30.4% (0.842 kg ± 0.531) was body fat. A 7-day 
overfeeding protocol, 70% above normal energy requirements, was chosen for this study 
to ensure that the intervention would induce metabolic changes[91, 92,207]. 
 
Statistical analysis  
Data are presented as means ± SDs unless otherwise stated.  Before any statistical 
analysis was performed, data that were not normally distributed were logarithmically 
transformed (TG, insulin, HOMA-IR and HOMA-β) to approximate normal distribution.  
Sixty-four young men were used for the analysis of this paper.  Subjects were classified 
on the basis of %BF as normal weight (8 – 20.9%), overweight (21 – 25.9%) or obese (> 
26%) according to criteria recommended by Bray [3].  Statistical analysis was also 
performed on adiposity groups classified by BMI according to the WHO criteria [210].  
To further explore the relationship between adiponectin and body composition, 
participants were divided into tertiles according to baseline fasting serum adiponectin 
concentrations (µg/ml) as follows: Low (Bottom 33.3%), Medium (middle 33.3%) and 
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High (top 33.3%) adiponectin concentration.  The range of serum adiponectin at baseline 
for the Low, Medium and High adiponectin concentration groups were 1.60-8.15µg/ml, 
8.20-13.80µg/ml, and14.20-27.10µg/ml respectively. 
 
Differences in variables between the three adiposity groups in response to 
overfeeding were analyzed by using a mixed model repeated two-way analysis of 
variance.  Baseline values between the three adiposity groups were analyzed using a one-
way analysis of variance.  The Bonferroni post-hoc test was run after the one-way 
ANOVA and the two-way ANOVA displaying a significant overfeeding by adiposity 
interaction.  Within group analysis on the response to overfeeding was performed with a 
student paired t-test on variables that displayed a significant overfeeding by adiposity 
interaction effect.  Pearson’s correlation analyses were performed to screen for potential 
factors related to fasting adiponectin concentrations followed by partial correlation 
analyses after controlling for age.  Bonferroni testing was applied to correct for multiple 
comparisons.  Two correlation analyses were performed as follows: 1) adiponectin at 
baseline was compared with all variables at baseline; and 2) adiponectin at baseline was 
compared with changes in all variables in response to overfeeding to investigate whether 
baseline adiponectin could predict the changes in related markers. SPSS software version 
18.0 (SPSS Inc, Chicago, IL, USA) was used for all analyses.  Statistical analyses were 2-
sided and p < 0.05 was considered to be statistically significant. 
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4.3 - RESULTS 
 
Comparison of characteristics at baseline and in response to short-term overfeeding 
Physical and biochemical characteristics of subjects at baseline are shown in 
Table 4.1.Fasting serum adiponectin concentrations at baseline for normal weight (11.60 
± 6.3 µg/ml), overweight (12.84 ± 4.6 µg/ml) and obese (10.69 ± 6.3 µg/ml) subjects 
were not significantly different from one another. Adiponectin concentrations were also 
analyzed according to BMI criteria where no significant differences were found (data not 
shown).   
Changes in body composition and phenotypes of glucose metabolism and lipids in 
response to the 7-day overfeeding are also described in Table 4.1.The 7-day positive 
energy challenge protocol significantly increased subcutaneous body fat, serum lipids 
(except LDL cholesterol), insulin resistance and β cell function. The only significant 
overfeeding x adiposity status interactions found from our analysis were for %BF and 
%TF, indicating that normal weight subjects experienced a greater significant increase in 
body fat percentage than overweight and obese (Table 4.1). The analysis of variance 
revealed that adiponectin concentrations were significantly increased due to the 7-day 
positive energy challenge (p < 0.0001).  Fasting adiponectin levels increased by 18.9% 
within the entire cohort after overfeeding while increasing by 20.3%, 15.4% and 19.9% 
among normal-weight, overweight and obese young men respectively. With a ~19% 
change in adiponectin due to overfeeding with 64 subjects the calculated power was 0.81.  
 
Correlations of adiponectin with phenotypes of glucose and lipid metabolism 
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Correlations between baseline adiponectin and baseline phenotypes were assessed 
(Table 4.2).  In the entire cohort at baseline, adiponectin was negatively correlated with 
weight and BMI along with a positive correlation with HDLc.  However, when these 
analyses were repeated according to adiposity status no correlation between adiponectin 
and these variables were found.  In addition, when insulin and HOMA-IR were controlled 
for during partial correlation analysis on the entire cohort the relationship between 
adiponectin with weight and BMI were nullified.  Adiponectin was significantly inversely 
correlated with %TF, glucose, insulin, and HOMA-IR in the obese group.  Correlations 
between baseline adiponectin and the changes in phenotypes were also assessed to 
determine if adiponectin could act as a predictor of these parameters under conditions of 
an energy surplus (Table 4.3).  Only two significant negative correlations between 
baseline adiponectin and the change in phenotypes due to overfeeding were found among 
the adiposity groups.  The first inverse relationship was found between adiponectin and 
insulin in the normal weight group and the second inverse relationship was found 
between adiponectin and triacyglycerol in the obese group. 
 
Comparison of body composition and lipid profile measures in low, medium and high 
baseline fasting serum adiponectin concentrations. 
Lastly, we wanted to investigate the relationship between low, medium, and high 
baseline fasting serum adiponectin concentrations and markers for lipids and body 
composition.  The between group comparison at baseline demonstrated that there were no 
significant differences in body composition measurements among the low, medium and 
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high adiponectin concentration groups. Total %BF stratified in the low, medium, and 
high adiponectin concentrations were 23.9 ± 9.4%, 21.9 ± 8.4% and 22.85 ± 6.8% 
respectively (p = 0.735).  BMI values at baseline were also not significantly different 
among the low, medium, and high adiponectin concentrations groups.  It would seem that 
only HDL cholesterol was significantly different between the low and medium (p = 
0.044) as well as the low and high (p = 0.01) baseline adiponectin concentration groups.  
The two-way ANOVA revealed that the 7-day overfeeding effectively increased whole 
adiponectin concentrations (p < 0.0001) and in addition that there was a significant 
overfeeding by adiponectin concentration group interaction (p = 0.002).  Sub-group 
analysis revealed that adiponectin significantly increased within the low baseline 
adiponectin group from 5.39 ± 2.0 µg/ml to 9.11 ± 3.75 µg/ml (p < 0.001) and the 
medium baseline adiponectin group from 10.61 ± 1.7 µg/ml to 13.05 ± 3.1 µg/ml (p < 
0.001), but did not significantly increase within the high baseline adiponectin group 
(18.24 ± 3.6 µg/ml to 18.71 ± 2.8 µg/ml).   
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4.4 - DISCUSSION 
 
The noteworthy finding of the present investigation is that circulating adiponectin 
levels are significantly increased by a short-term positive energy challenge independent 
of adiposity status.  Taking into consideration that the majority of human cross-sectional 
studies show that circulating adiponectin is diminished among the obese population [119, 
122-124],  and significantly promoted after weight reduction [124, 125, 128, 129], the 
increase in circulating adiponectin we observed after weight gain in overweight and 
obese subjects was unexpected.  White adipose tissue being the primary location for the 
adiponectin production, together with the paradoxical inverse relationship between 
adiponectin and obesity, advocates that circulating adiponectin may be regulated by an 
adiposity feedback inhibition [124].  Rodent studies, observing a suppression of 
adiponectin in obese and ob/ob mice [127, 130,131], support the notion of an adiposity 
regulated feedback mechanism.  However adiponectin transgenic ob/ob mice effectively 
ameliorating insulin resistance but not obesity [132, 133] and adiponectin knockout mice 
developing insulin resistance without affecting weight or adiposity [126, 134], provides 
the strongest evidence that adiponectin is not mediated by adiposity alone.  In addition, 
the administration of adiponectin to ob/ob, db/db, and adiponectin knockout mice can 
ameliorate the development of insulin resistance without significantly influencing 
adiposity [127, 135].  In the present study adiponectin concentration significantly 
increased within the entire cohort and the normal-weight, overweight, and obese 
subgroups due to overfeeding.  However, there was no significant difference in the 
increase of circulating adiponectin between the three obesity groups due to overfeeding.  
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To further explore this unique finding we stratified our subjects into a low, medium and 
high adiponectin concentration groups to determine whether adiponectin concentration 
was associated with the increase in adiposity due to the positive energy challenge.  
Consequently, there was no significant difference in the increase of our adiposity 
measurements among adiponectin concentration groups before or after overfeeding.  
These findings would suggest that there is a definite capacity, regardless of obesity status, 
for the human body to significantly synthesize and secrete more adiponectin into 
circulation after being exposed to a short-term overfeeding.  To our knowledge this is the 
first study of its kind to demonstrate that adiponectin levels will significantly increase 
after a short-term positive energy challenge independent of obesity status. 
 
Our laboratory has demonstrated that a short-term positive energy challenge can 
significantly affect both physical and biochemical obesity-related phenotypes [91, 
92,207].  However, to date, very few other overfeeding studies have been performed due 
to the inherent difficulty to carry out this type of study.  One 5-day high-fat (60% fat, 
32.5% carbohydrates and 7.5% protein) overfeeding (50% greater than normal caloric 
intake) investigation on 26 normal-weight young men observed a significant increase in 
adiponectin concentration [84]. Although the age and body weight of these subjects were 
comparable to the normal-weight group from our current study, the overfeeding 
intervention and diet composition were considerably different. This study also did not 
contain any overweight and/or obese subjects.   Nevertheless our findings, with those of 
Bron et al. [84], provide evidence that the significant increase of adiponectin due to 
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overfeeding is likely driven by an increase in total caloric intake rather than 
macronutrient composition.  A 4-week positive energy challenge on 18 young normal-
weight adults (12 male and 6 female) did not induce a significant increase in circulating 
adiponectin [85].  Although no explanation was provided, low statistical power due to the 
small number of subjects could be a potential reason.  Finally, a long-term (100-day) 
overfeeding study investigated the influence of chronic food intake on circulating 
adiponectin in 12 pairs of young male identical twins [93].  Study participants were 
overfed by 840 kcal for 100 days and adiponectin concentration was found to have 
decreased.  However there was no relationship between baseline adiponectin and 
adiposity before or after prolonged overfeeding.  A replication study would be favored 
since this is the only long-term positive energy challenge study containing a fairly small 
sample size.  Overall, the current human overfeeding studies demonstrate that 
adiponectin concentrations are up regulated during a short-term positive energy 
challenge.  Our findings would suggest that adiponectin plays a protective role during 
obesity development and its role is more potent during the early stages of the chronic 
positive energy balance.  This assumption is supported by data from an animal 
experiment which found that circulating adiponectin concentrations significantly 
increased in C57BL/6J mice on a high-fat diet during the initial stages of adiposity 
development [221] and decreased after the full 18 week diet.  
 
The present investigation did not find a significant difference in baseline 
adiponectin concentration among normal-weight, overweight and obese subjects nor were 
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any associations found between adiponectin concentration and adiposity measurements 
for these groups.  In addition, no significant difference was observed for any body 
composition measurement among the low, medium and high adiponectin concentration 
groups.  The data from this investigation does not support the hypothesis that adiposity 
status is a strong contributing factor to circulating adiponectin concentration.  We did 
observe that circulating adiponectin was inversely correlated with BMI and weight for the 
entire cohort along with %TF in obese subjects.  However, recent studies have advocated 
that the inverse relationship between adiponectin and adiposity phenotypes is solely 
dependent upon the development of insulin resistance [116, 120, 123,139]. Therefore, 
after controlling for fasting insulin and/or HOMA-IR in our analysis the significant 
partial correlation between adiponectin and aforementioned body composition 
measurements were nullified.  Therefore, our data supports the hypothesis that the 
paradoxical relationship between adiposity and circulating adiponectin is not dependent 
upon the accumulation of adipose tissue but rather the concomitant increase in insulin 
resistance during obesity development  [120, 121, 139]. 
 
The primary limitation of the present study is that we only studied young males 
(19-29 yr), which limits the application of our conclusions to other groups.  Larger 
population studies investigating the effects of overfeeding on a wider age distribution 
which includes females is warranted.  In addition, only total circulating adiponectin was 
measured in this investigation.  It has been suggested that high molecular weight 
adiponectin is the primary physiologically active isoform [222] of adiponectin.  However, 
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it has also been shown that low, medium and high molecular weight adiponectin respond 
to nutritional regulation and exercise the same as total circulating adiponectin [128].  In 
addition, the influence of inflammatory markers (such as TNF-α, IL-6 and hs-CRP, etc.) 
on adiponectin regulation is a noteworthy consideration [223]. Therefore, future short-
term overfeeding studies investigating influence of inflammatory markers on the 
regulation and circulation of adiponectin in adipose tissue and peripheral circulation are 
warranted. 
 
In summary, we investigated the response of circulating adiponectin to a 7-day 
positive energy challenge mimicking a North American diet in 64 healthy young men.  
The relationship between adiponectin and adiposity status was also analyzed.  The 
current study revealed that endogenous adiponectin concentration significantly increased 
within the entire cohort and all three adiposity groups in response to short-term 
overfeeding.  Fasting serum adiponectin levels were found to be similar among normal-
weight, overweight and obese young men at baseline and were not associated with 
adiposity. Negative correlations of adiponectin with %TF, body weight and BMI was 
observed, but likely arbitrated to insulin resistance.  Our data suggests for first time that 
the increase in adiponectin, in the face of short-term positive energy challenge, may act 
as a protective mechanism during periods of weight gain against insulin resistance 
independent of adiposity status and diet composition. 
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5.1 - INTRODUCTION 
 
 Type 2 diabetes comprises 90% of all diabetic cases and has become an ever 
increasing   healthcare challenge as the number of people affected reaches epidemic 
proportions [1].  The prevalence of this condition is expected to reach over 438 million 
people globally by the year 2030 and carries with it a significant fiscal burden [145].  
This is especially relevant to the Canadian province of Newfoundland and Labrador 
considering it has one the highest rates of diabetes and obesity in Canada. Currently, 9% 
of the population of Newfoundland and Labrador struggle with diabetes which 
corresponds to an annual cost of $254 million dollars [11].  The Canadian Diabetes 
Association has projected that by the year 2020 over 15% of Newfoundland and 
Labradorean’s will be diabetic with an annual health care cost exceeding $360 million 
dollars [11].  Although there is currently no medical intervention capable of preventing 
the development of diabetes, simple lifestyle modifications (such as increased physical 
activity, moderate weight loss, and eating behavior modifications) have been shown to 
attenuate the onset of type 2 diabetes [1, 146].  However few studies to date have 
investigated the association between dietary micronutrient intake and insulin function in 
the general population. 
  
 Magnesium, a cofactor required in over 300 enzymatic reactions, is the fourth 
most abundant cation in the human body involved with both glucose metabolism and 
insulin homeostasis [140, 141].  Although recent evidence has suggested that dietary 
magnesium intake may play an important role in enhancing insulin sensitivity, population 
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based studies have found conflicting evidence regarding the potential benefit of dietary 
magnesium intake.  Several studies have correlated low dietary magnesium intake [147-
149] and serum magnesium [224] with increased insulin resistance [150-152].  However, 
other studies do not support the proposed protective effect that dietary magnesium can 
attenuate the development of diabetes [154-156].  Of note, most studies have not 
adequately controlled for adiposity in their analysis.  Instead of controlling for relative 
body fat, the majority of studies have utilized the body mass index (BMI) which cannot 
accurately distinguish fat mass from and fat-free mass [16].  Since adiposity is the 
parameter most closely linked with the development of insulin resistance [157], 
controlling for this important confounding factor is critical.  Therefore we designed the 
present study to investigate the association between magnesium intake and insulin 
resistance in the Canadian province of Newfoundland and Labrador, taking into 
consideration age, gender, caloric intake, physical activity, medication use, smoking 
status, menopause and adiposity. 
 
5.2 - SUBJECTS & METHODS 
 
Ethics Statement 
Ethics approval was obtained from the Human Investigation Committee, Faculty 
of Medicine, Memorial University, St. John’s, Newfoundland, Canada.  All subjects 
provided written and informed consent before participation in this study. 
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Subjects 
All 2330 subjects (600 men 1725 women) from the current study are volunteers 
from the general population of Newfoundland and Labrador and the cohort for our 
ongoing CODING (Complex Diseases in the Newfoundland Population: Environment 
and Genetics) Study.  The CODING study is a large-scale nutrigenomics investigation 
[15, 16,225].  Eligibility of participants for the CODING study are based upon the 
following inclusion criteria: 1) > 19 yrs of age; 2) at least a third generation 
Newfoundlander; and 3) healthy, without any serious metabolic, cardiovascular, or 
endocrine diseases.  The primary method of subject recruitment for the CODING study 
was the use of posters and handouts.  This literature was distributed throughout public 
facilities (offices, hospitals, and gyms) in the city of St. John's, Newfoundland and 
Labrador.  All subjects completed screening questionnaires providing information about 
physical characteristics, physical activity, health status, and dietary practices.  
Anthropometrics, body composition, and biochemical measurements were collected 
following a 12 hour fast. 
 
Physical Activity 
Physical activity patterns were measured using the ARIC-Baecke Questionnaire, 
which consists of a Work Index, Sports Index, and Leisure Time Activity Index [226]. 
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Dietary magnesium assessment 
 Dietary intake patterns of each participant were assessed using a 124 item  
semi-quantitative Willett Food Frequency Questionnaire (FFQ) [227].  The Willett FFQ 
is one of the most commonly used dietary questionnaires for large-scale epidemiologic 
studies [228]. The Willett FFQ obtains from subjects, the number of weekly servings 
consumed of specific food item(s).  NutriBase Clinical Nutrition Manager (version 8.2.0; 
Cybersoft Inc, Phoenix, AZ) software package was used to convert weekly serving values 
into mean daily serving values to calculate the total daily intake of magnesium(mg/day) 
for each individual. The nutritional information, including dietary magnesium intake, was 
computed for all subjects in the CODING study [225]. 
 
Anthropometric and body composition measurements 
 Subjects were weighed (Health O Meter, Bridgeview, IL) to the nearest 0.1 kg in 
standardized clothing (hospital gown).  Height was measured using a fixed stadiometer 
(nearest 0.1 cm).  Body mass index (kg/m
2
) was calculated as weight in kilograms 
divided by participants’ height in meters squared.  Whole body composition 
measurements including fat mass, lean body mass, and bone mineral densities were 
measured using dual-energy X-ray absorptiometry (DXA) Lunar Prodigy (GE Medical 
Systems, Madison, WI).  DXA can produce an accurate measurement of adipose tissue 
within the body with a low margin of error.  For this reason, DXA is considered to be one 
of the most accurate measurements of adiposity.  DXA measurements were performed on 
subjects following the removal of all metal accessories, while lying in a supine position 
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as previously described by us [15, 16, 225].  Body fat percentage (%BF) is determined as 
a ratio of fat mass to total body mass (Version 12.2 of the enCORE software).  Quality 
assurance was performed on our DXA scanner daily and the typical CV was 1.3% during 
the study period.  
 
Biochemical measurements 
 Serum concentrations of glucose and magnesium were measured on an Lx20 
analyzer (Beckman Coulter Inc., Fullerton, CA) using Synchron reagents.  Serum insulin 
was measured on an Immulite Immunoassay analyzer.  Insulin resistance and beta cell 
function were determined with the homeostasis model assessment (HOMA), as described 
by Matthews et al [213]. 
 
 HOMA-IR =  [(Fasting Insulin (mU/L) x Fasting Glucose (mmol/L))/22.5] 
 HOMA-β =  [(20x Fasting Insulin (mU/L)) /(Fasting glucose (mmol/L) – 3.5)] 
 
Smoking, Medication and Menopausal Status 
 A self-administered screening questionnaire was used to collect information about 
the subjects’ demographics, personal and family medical history, medication use (yes or 
no), and smoking status (yes or no).  Women completed an additional questionnaire 
regarding menstrual history and menopausal status (pre- or post-menopausal) [16, 225]. 
 
Statistical analysis 
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 All data are reported as mean ± standard deviation (SD) unless otherwise stated. 
Participants with daily total caloric intake (kcal/day) falling outside the range of ± 3SDs 
were considered outliers and excluded from further analyses to account for possible 
errors associated with over- or under-reporting of food intake on the FFQ.  Insulin, 
HOMA-IR, and HOMA-β were log-transformed to normalize distributions and meet the 
assumptions of statistical tests.  The sample size for the study was 2295 participants (590 
men, 1705 women).  Differences in physical, biochemical, and dietary patterns between 
men and women were assessed using one-way ANOVA.  Subjects were subdivided by 
adiposity into Normal-Weight (NW), Overweight (OW), and Obese (OB) groups based 
on %BF measured by DXA according to the age and gender-specific criteria 
recommended by Bray [3].  Differences in physical, biochemical, and dietary patterns 
among adiposity groups was assessed using a one-way ANCOVA controlling for age, 
gender, total caloric intake, physical activity, medication use and smoking and 
menopause.  As the number of underweight subjects was too low (n=28) to perform 
effective statistical analysis, they were excluded from these analyses.  To initially explore 
the relationship between dietary magnesium and IR (fasting glucose (mmol/l), insulin 
(pmol/l), HOMA-IR, HOMA-β), participants were divided into a tertile (low, medium, or 
high) based upon dietary magnesium intake (mg/day) which were assessed using an 
ANCOVA controlling for age, gender, total caloric intake, physical activity, medication 
use, smoking, menopause and %BF.  Subsequently, multiple regression analyses were 
used to more rigorously explore the potential association of dietary magnesium intake 
(g/kg body weight) with insulin resistance (HOMA-IR) within the entire cohort and 
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among men and women adjusting for age, gender, caloric intake, physical activity, 
medication use, smoking, menopause and %BF or BMI.  However, only caloric intake, 
physical activity, medication use, menopause and %BF or BMI were statistically 
considered as confounding variables within the regression models.  In addition, due to the 
significant interaction of adiposity and menopause on the association between dietary 
magnesium intake and insulin resistance, multiple regression analysis was performed 
among normal-weight, overweight and obese subjects along with pre-menopausal (n = 
834) and post-menopausal (n = 577) women.  Multiple regression analyses were 
performed on subjects stratified into tertiles (low, medium, or high) based upon both BMI 
and %BF measured from DXA to assess the difference in their adjustments on the 
relationship between dietary magnesium intake and insulin resistance.  Lastly, Binary 
logistic analysis was also performed to explore the association between magnesium 
intake (g/kg/day) and diabetes status.  Diabetes status was defined by a fasting glucose 
cutoff (glucose > 7.0 mmol/L) together with those individuals who reported they were 
diabetics.  Under the aforementioned definition, 102 subjects were labeled as diabetics 
for this analysis.  Age, gender, caloric intake, physical activity, medication use, 
menopausal status, and smoking status were used as covariates.  However, only caloric 
intake, medication status and age were statistically considered as confounding variables 
within the binary logistic model. Some subjects had missing data in one or more 
measurements.  Five subjects did not disclose their smoking status and eight subjects did 
not respond to the medication use question.  1981 participants had all complete dataset 
for all variables measured to be used for the ANCOVA and multiple regression analysis.  
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All statistical analyses were performed with and without diabetic subjects; however none 
of the results were not affected.  All statistical analyses were performed using PASW 
19.0 (SPSS Inc., Chicago, IL).  All tests were two-sided and a p-value <0.05 was 
considered to be statistically significant. 
5.3 - RESULTS 
 
Physical, biochemical, and dietary characteristics of normal-weight, overweight, and 
obese participants 
 Physical, biochemical, and dietary characteristics for men and women along with 
those for normal-weight, overweight and obese participants are presented in Table 5.1.  
Glucose, insulin, and HOMA-IR were significantly greater for men than women, but 
HOMA-β was significantly greater among women.  In terms of dietary intake, male 
participants had a significantly higher total daily caloric and magnesium intake than 
females.  However, women had significantly greater magnesium intake (mg/day/kg) per 
kilogram body weight than men.  Insulin, glucose, HOMA-β, and HOMA-IR values were 
greater among overweight and obese subjects, which we have previously described [15, 
16,225].  Individuals with the highest insulin, HOMA-IR and HOMA-β had the highest 
levels of adiposity.  In addition, subjects with highest levels of adiposity had the lowest 
levels of magnesium intake (mg/day), and magnesium intake per kilogram of body 
weight (mg/day/kg). The findings remained significant after controlling for total age, 
gender, caloric intake, physical activity, medication use, menopausal status and smoking 
status.  Serum magnesium was not significantly different among adiposity groups (Table 
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5.1).  
 
Insulin resistance among low, medium, and high dietary magnesium intake groups 
 Physical, biochemical, and dietary characteristics were assessed among a tertile 
(low, medium, or high) based upon dietary magnesium intake (mg/day) (Table 5.2).  
Those individuals with the highest magnesium intake had the lowest insulin, HOMA-IR 
and HOMA-ß.  Individuals with the lowest magnesium intake had the highest fasting 
insulin levels, HOMA-IR, and HOMA-ß. The findings remained significant after 
accounting for age, gender, caloric intake, physical activity, medication use, smoking, 
menopause and %BF.  The dietary magnesium intake ranged from; 33.06 to 270.83 
mg/day in the low dietary magnesium intake group, 270.84 to 393.66 mg/day in the 
medium dietary magnesium intake group, and 394.07 to 2493.01 mg/day in the high 
dietary magnesium intake group.  Dietary magnesium intake per kilogram of body weight 
ranged from; 0.43 to 5.3mg/kg/day in the low dietary magnesium intake group, 2.0 to 
8.18 mg/kg/day in the medium dietary magnesium intake group, and 3.17 to 44.84 
mg/kg/day in the high dietary magnesium intake group. 
 
Relationship between dietary magnesium and insulin resistance 
 Unadjusted and adjusted linear regression analysis results of dietary magnesium 
intake on insulin resistance are shown in Table 5.3. There was a significant negative 
association between dietary magnesium intake (g/day/kg) with HOMA-IR in the entire 
cohort before and after adjusting for caloric intake, physical activity, medication use, 
106 
 
menopausal status and %BF or BMI.  In addition, the negative association between 
magnesium intake and insulin resistance was greater having adjusted for adiposity (%BF) 
over adjusting for BMI (Table 5.3).  Multiple regression analysis of the entire study 
cohort also revealed a significant interaction of adiposity (%BF & BMI) with the 
negative association of magnesium intake with insulin resistance.  Therefore, multiple 
regression analysis was performed on NW, OW and OB groups based upon %BF 
according to the Bray Criteria (Table 5.3).  Magnesium intake was found to be 
significantly negatively associated with HOMA-IR among all adiposity groups.  This 
inverse relationship was greater among overweight and obese subjects and pre-
menopausal women.  
 
Relationship between dietary magnesium and insulin resistance among low, medium 
and high %BF and BMI. 
 Unadjusted and adjusted linear regression analysis results of dietary magnesium 
intake (g/day/kg) on insulin resistance among low, medium and high BMI and %BF 
groups are shown in Table 5.4.  Magnesium intake was increasingly more negatively 
associated with HOMA-IR the greater the adiposity (%BF) or body mass index (BMI). 
Moreover, the negative association between dietary magnesium intake and insulin 
resistance was more prevalent according to a %BF classification than a BMI 
classification (Table 5.4). 
  
Relationship between dietary magnesium and diabetes status  
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 Binary logistic analysis, performed to explore the association between magnesium 
intake (g/kg/day) with diabetes status, revealed that magnesium intake (g/kg/day) was 
significantly negatively associated with diabetes status (n = 102, Unstandardized β = -
499.80, standard error 79.45, p < 0.0001).  Caloric intake, medication status and age were 
statistically considered as confounding variables within the binary logistic model. 
 
Serum magnesium and markers of insulin resistance 
 The relationship between serum magnesium and insulin resistance was also 
explored. Although serum magnesium concentration concomitantly increased with 
dietary magnesium intake, it was not found to be significantly associated with insulin 
resistance in the Newfoundland population (data not shown). 
 
 
 
 
 
 
 
 
108 
 
 
109 
 
 
 
110 
 
 
111 
 
 
112 
 
5.4 - DISCUSSION 
 
 The noteworthy finding of the present investigation was a beneficial dose 
dependent relationship between dietary magnesium intake and insulin resistance, 
independent of age gender, total caloric intake, physical activity, medication use, 
menopause, and adiposity. However, this favorable association was more significant in 
overweight and obese subjects suggesting that this population may be more sensitive to 
the beneficial effects of dietary magnesium intake.  Obesity, as a disorder, is a well-
known condition which can place individuals at a significantly elevated risk for impaired 
insulin action [144] and various metabolic abnormalities such as hypertension, 
dyslipidemia, and a reduction in glucose tolerance [144].  The functional relationship 
between various hormones and obesity-related conditions is a significant focus of obesity 
research, however diet composition has become increasingly recognized and studied 
[145, 146].  One study specifically demonstrated that an increase in dietary magnesium 
can significantly improve insulin sensitivity [153].  Magnesium has been proposed to be 
functionally related to glucose metabolism through an interaction with tyrosine-kinase 
activity on the insulin receptor which is associated with the development of insulin 
resistance and type 2 diabetes [142].  Studies have suggested that the effect of dietary 
magnesium on decreasing markers of IR [150, 151] and development of type 2 diabetes is 
more pronounced in overweight patients [150, 151]. However, body fat percentage was 
not measured in these studies. This is an especially important point to consider when the 
relative amount and distribution of adipose tissue, both important determinants of insulin 
sensitivity, cannot be determined by the body mass index [158-160].  
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In fact the majority of studies evaluating the association between dietary magnesium and 
insulin resistance have only utilized BMI when attempting to control for adiposity, 
bearing in mind that percent body fat and BMI likely represent different physiological 
entities.  Having adjusted for the influence of %BF and BMI on the association of dietary 
magnesium intake with insulin resistance, we observed that this inverse association was 
stronger after having adjusted for %BF than for BMI which further supports our 
hypothesis.  Considering that our laboratory and others have revealed that BMI is not an 
accurate measure of body fat due to its inability to differentiate fat mass from fat free 
mass [15, 186, 229], it is implicit that BMI cannot represent adiposity.  We found that 
overweight and obese individuals, defined by a high resolution adiposity measurement, 
are more sensitive to the beneficial effect of magnesium intake on insulin resistance.  Our 
current findings, taken together with others of others [150, 151] provides strong evidence 
that overweight individuals, classified by either %BF or BMI, could potentially benefit 
from an increase in magnesium intake.  It is possible that overweight and obese 
individuals are better able to absorb and metabolize magnesium, thereby enhancing its 
action at the insulin receptor and promoting insulin sensitivity.  To our knowledge, this 
study is the first large cross-sectional study to systematically control for major 
confounding factors including %BF when analyzing the relationship between dietary 
magnesium intake and markers of insulin resistance. This study is also the first 
investigation to observe that dietary magnesium is more strongly associated with insulin 
resistance when adjusting for %BF than BMI.  
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The association between dietary magnesium intake and insulin resistance was 
examined with regards smoking [230], menopause [151]and medication [231, 232] as 
possible confounding factors for this relationship.  Evidence suggests that nicotine intake 
may increase insulin resistance, however we did not find a significant association of 
smoking status with HOMA-IR or magnesium intake.  In addition, during the regression 
model development smoking status failed to reach statistical significance and was not 
included in the regression model.  Our data would suggest that smoking is not a critical 
confounding factor regarding the beneficial effect of dietary magnesium intake on insulin 
resistance in the Newfoundland population.  However, this finding may be due to the 
significantly smaller sample size of smokers (n = 222) to non-smokers (n = 1754) in our 
study cohort.  Further study is needed to elucidate the potential interaction of smoking on 
the relationship of dietary magnesium intake and insulin resistance.  Medication status 
was significantly associated with insulin resistance and there is evidence to suggest that 
various medications inhibit magnesium re-absorption in the kidney which can result in 
magnesium deficiency [231, 232]. However, we were unable to find a significant 
interaction of medication use on the inverse association with magnesium intake and 
insulin resistance.  Pre-menopausal women were more significantly associated the 
beneficial effects of magnesium intake on insulin resistance than post-menopausal 
women.  This finding is strengthened by the Shanghai Women’s Health Study, designed 
to assess the prospective risk of type 2 diabetes, which found a statistically significant 
negative correlation between magnesium intake and type 2 diabetes risk in pre-
menopausal women only [151].  We considered, since over 68% of our post-menopausal 
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women are medication users, that the lack of association of magnesium intake with 
insulin resistance could be drug related interference.  However, this relationship remained 
absent among post-menopausal women whether or not medication status was included in 
the regression model.  Therefore, our data would suggest that the beneficial effects of 
magnesium intake are less sensitive among post-menopausal women and further study is 
needed to explore the physiological mechanism involved.  Lastly, we discovered that 
magnesium intake was significantly negatively associated with diabetes.  Considering 
that insulin resistance is a significant clinical symptom of diabetes and that insulin 
resistance was significantly inversely associated with magnesium intake this, finding was 
not surprising.  Our results suggest that the potential beneficial influence of magnesium 
intake exists in a wide range of populations from the general population to insulin 
resistance and to those people struggling with diabetes in Newfoundland and Labrador.    
 
Aside from investigating the influence of %BF and BMI on the association 
between magnesium intake and insulin resistance in the general population and the 
influence that an adiposity status defined by %BF has on this relationship, we also 
investigated whether an adiposity status defined by BMI would have a different effect 
than %BF on this association. Considering that the adiposity status criteria for the World 
Health Organization (WHO) is considerably different from that developed by Bray et al. 
[3], the association between dietary magnesium intake and insulin resistance was 
examined among low, medium and high tertiles according to %BF and BMI. Our data 
revealed that the inverse relationship between dietary magnesium intake and insulin 
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resistance was progressively stronger the greater the %BF or BMI. However, the 
aforementioned association was more significantly pronounced for concomitant increases 
in %BF over BMI. Consider that %BF is a more direct measure of adiposity than BMI, 
together with our current findings, we recommend that %BF be used when considering 
adiposity as a factor.   
  
The apparent protective role of magnesium on IR and type 2 diabetes has not been 
fully explained but is likely due to enhanced insulin sensitivity through multiple 
mechanisms. For example, phosphorylation of the tyrosine kinase enzyme of the insulin 
receptor, required for post-receptor insulin sensitivity and subsequent insulin-mediated 
glucose uptake, is dependent on adequate intracellular concentrations of magnesium 
[143]. As such, we also chose to investigate the relationship between serum magnesium 
and markers of IR; no significant association between them was observed. 
Inconsistencies have been present in previous studies examining this relationship, some 
supporting a negative correlation [233, 234] and others not [224].  One possible 
explanation for these differences is that serum magnesium may not accurately reflect 
intracellular magnesium levels, which may be low, even when serum levels are within the 
normal range [154]. Additional studies are warranted to further clarify the relationship 
between serum magnesium and markers of IR. 
 
 Our study had certain limitations, many of which were due to its cross-sectional 
design.  Firstly, our use of a FFQ to evaluate patterns of dietary intake raises the 
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possibility of recall bias by subjects.  However, the Willett FFQ chosen for this study is 
one of the most commonly applied tool for the evaluation of dietary intake in 
epidemiologic population-based studies [227, 228].  In addition, dietary magnesium is 
highly correlated with other micronutrients and dietary components believed to affect 
insulin sensitivity, such as vegetables, fruits, potassium, calcium, and fiber. Thus, it is 
very difficult to separate their independent effects [147, 151]. In addition, to avoid over-
adjustment, we opted not to control for every available nutrient in our analysis.  We did 
not measure or account for magnesium supplementation regarding daily magnesium 
intake, which could have potentially reduced the strength of the inverse association found 
between magnesium intake and IR makers.  Furthermore, the reliability of serum 
magnesium levels in recognizing total body magnesium deficiency is unclear. Although 
intracellular magnesium concentrations are believed to provide a more accurate 
estimation of magnesium status, they are not generally easily measured [233]. Finally, 
our study enrolled Caucasian Newfoundlanders, so our findings may not be applicable to 
those from other ethnicities [156, 235]. 
 
 In summary, our cross-sectional study investigated the relationship between 
dietary magnesium intake and insulin resistance among 2295 Newfoundlanders and 
Labradoreans. To our knowledge this study is the most comprehensive of its kind having 
controlled for major confounding factors, most specifically being dual energy x-ray 
absorptiometry (DXA) determined body fat percentage.  Our findings suggest that higher 
dietary magnesium intake is associated with improved insulin sensitivity and this effect is 
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particularly beneficial for overweight and obese individuals in the general population 
along with pre-menopausal women.  We also provide the first evidence that the 
association between dietary magnesium and insulin resistance is more strongly associated 
with %BF than BMI and the concomitant increase in %BF over BMI.  Due to the fact that 
%BF more accurately represents adiposity than BMI, caution should be taken when 
attempting to utilize BMI as a measure of adiposity.  Further large-scale prospective 
studies, where body fat is adequately accounted for and which enroll various ethnic 
groups, are needed to further elucidate the role of dietary magnesium in improving 
insulin function and preventing diabetes. 
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6.1 - INTRODUCTION 
 
With the rapid increase of obesity prevalence worldwide, attempts to develop a 
simple and low cost method to estimate adiposity more accurately than body mass index 
(BMI) are being made [170-172].  The body mass index [(Weight-kg)/(height-m)
2
] was 
designed over 100 years ago [166] and due to its low cost and availability is the most 
commonly accepted method for estimating human adiposity by health professionals and 
the general population world-wide.   In addition, BMI is currently the method utilized for 
the World Health Organization’s (WHO) annual reports regarding obesity.  However, 
although BMI is the most cost effective method to evaluate adiposity, it has been shown 
to have significant weaknesses in accurately determining adiposity.  One such weakness 
of the BMI is that there are no sex specific criteria even though gender differences for 
body fat percentage have been well documented[167-169].  BMI also does not reflect 
neither the clear accumulation of body fat with age nor the inter-individual difference of 
body fat percentage among people within the same BMI category [15].  According to 
dual energy x-ray absorptiometry (DXA) body fat percentage measurements, BMI scores 
can mis-classify by one or even two obesity categories [14, 15].  Lastly, due to the fact 
that BMI was originally developed in Caucasian populations, the accuracy within various 
ethnic populations is problematic [176].   
 A study by Bergman et al. [170] recently proposed a new method to determine 
body fat percentage which has been named the body adiposity index (BAI).  The BAI is 
calculated from two anthropometric measurements, height and hip circumference 
measurements were measured in meters (m) and centimeters (cm) respectively.  The BAI 
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equation [ BAI = Hip circumference (cm) / height(m)
1.5
 – 18 ] was derived from the 
concordance between the body fat percentage of an Mexican-American population with 
resultants from proposed formulas utilizing various anthropometric measurements.  
Bergman et al. claim that their BAI equation can estimate percent body fat more reliably 
than BMI. However, like the BMI equation, it is unknown if BAI reflects the gender 
differences of both height and hip circumference measurements [180, 181] along with 
various dynamic anatomical measurements utilized to evaluate adiposity.  Our laboratory 
and others have shown that equations such as BMI, which ignore gender differences for 
body fat percentage and the accumulation of body fat with age will, inaccurately estimate 
relative body fat and adiposity status [15, 167, 186, 236].  In addition to gender, obesity 
status can be a critical factor affecting the accuracy of methods that depend on bone 
structure measurements because there is little change of the skeletal measurement with 
changes in body weight or adiposity.  At present there is very little data available 
regarding the influence of these two important factors on the performance of BAI.   
Although, Bergman et al.[170]  presuppose that BAI could be a better adiposity 
status measure than BMI, few studies to date have attempted to validate the BAI equation 
on a Caucasian population. Barreira et al.[182] letter to the editor was the first published 
material regarding the validation of the BAI equation on a Caucasian population against 
relative body fat. They found that the correlation between body fat percentage with BAI 
was very similar to that with BMI (r = 0.82 and r = 0.83 respectively) in women. 
However, the correlation of body fat percentage with BAI was not as similar BMI (r = 
0.75 and r = 0.81) for men. Barreira et al. conclude that BAI equation was an effective 
122 
 
method for predicting body fat percentage for a Caucasian population, although further 
studies are required to support these findings. Therefore the objectives of the present 
study were to further investigate the performance of BAI according to sexes and obesity 
statuses (defined by body fat percentage) in our Caucasian population. 
 
6.2 - SUBJECTS & METHODS 
 
 A total of 2660 subjects were recruited from an ongoing large-scale nutritional 
genetics study of human complex diseases called the CODING study [15, 16]. As BMI 
and %BF criteria are designed for individuals ≥ 20 yr, we excluded all participants below 
this age leaving us with a cohort of 2601 (1939 females, 663 men).  Each individual 
completed a screening questionnaire that included information regarding physical 
characteristics, dietary habits, and physical activity levels.  Dietary information was 
obtained from each participant completing the Willett Food Frequency Questionnaire 
(FFQ), which is a semi-quantitative method for the assessment of dietary intake patterns. 
The Willett FFQ is the most widely used dietary intake questionnaire for the study of 
nutritional information at the population level [237].  Physical activity was measured 
using the ARIC-Baecke Questionnaire, which consists of a Work Index, Sports Index, 
and Leisure Time Activity Index [226].  The primary method of subject recruitment was 
the use of posters and handouts. This literature was distributed throughout public 
facilities (offices, hospitals, and gyms) in the city of St. John's, Newfoundland.  Inclusion 
criteria in the present study were as follows: (i) greater than 19 years age (ii) at least 
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third-generation Newfoundlander; (iii) healthy, without any serious metabolic, 
cardiovascular, or endocrine disease.  This study was approved by The Human 
Investigations Committee for the Faculty of Medicine, Memorial University of 
Newfoundland and Labrador, St John’s, Canada.  All subjects provided written informed 
consent.  Anthropometrics, body composition, and biochemical measurements were 
collected following a 12 hour fasting period.  
 
Measurements of BAI, BMI and %BF 
Subjects were weighed to the nearest 0.1 kg in standardized clothing as previously 
described by us (Health O Meter, Bridgeview, IL) [15-17]. Height was measured using a 
fixed stadiometer (nearest 0.1 cm).  Hip circumference was measured as the largest 
circumference between the waist and thighs. Waist circumference was measured as the 
horizontal distance around the abdomen at the level of the umbilicus. Hip and waist 
measurements were recorded to the nearest 0.1 cm using a flexible metric measuring tape 
while the participant was in a standing position.  BAI was calculated based on the 
equation reported in the Bergman paper [170]. BMI was calculated as weight in 
kilograms divided by participants height in meters squared. Whole body composition 
measurements including fat mass, lean body mass, and bone mineral densities were 
measured using DXA Lunar Prodigy (GE Medical Systems, Madison, WI). DXA can 
produce an accurate measurement of adipose tissue within the body with a low margin of 
error. For this reason, DXA is considered to be one of the most accurate measurements of 
adiposity and is commonly used as a standard compared to less accurate field methods 
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such as BMI. DXA measurements were performed on subjects following the removal of 
all metal accessories, while lying in a supine position as previously described by us [15-
17]. Body fat percentage is determined as a ratio of fat mass over total body mass 
(including bone mineral densities) through the manufacturer’s DXA software.  Quality 
assurance was performed on our DXA scanner daily and the typical CV was 1.3% during 
the study period.   
 
Statistical analysis 
 All data are reported as mean ± sd. The gender differences of variables measured 
were determined by an independent t test. Pearson correlation analysis was performed to 
compare the concordance between both BAI and BMI with body fat percentage (%BF) 
measured by DXA taking in consideration both gender and adiposity status. Adiposity 
status (normal weight, overweight, or obese) was determined by the Bray criteria (age 
and gender specific) [3] according to body fat percentage (%BF) measured DXA.  The 
Lin’s concordance correlation method was applied for both BAI and BMI with %BF, 
although the correlation coefficients were very poor for both.  The Lin’s concordance 
correlation coefficient represents the strength-of-agreement between two continuous 
variables, which if is lower than 0.90 is considered to be poor. Both of the BAI vs. %BF 
and BMI vs. %BF concordance correlation coefficients were much lower than the lowest 
acceptable coefficient, Pearson correlation analysis was used as the main validation 
method in this study. SPSS version 17.0 (SPSS, Chicago, IL) was used for all analyses. 
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Statistical analyses were two-sided and a P value <0.05 was to be statistically significant.  
 
6.3 - RESULTS 
 
 Body composition characteristics of subjects in the study are shown in Table 6.1. 
Women on average were 3.7 years older than men. As most population studies have 
shown, women had lower body weight, height, BMI and waist circumference but higher 
%BF and hip circumference than men.  DXA measurements on body composition 
revealed an average of 12.8% higher percent body fat in women than men. Interestingly, 
BAI estimation only demonstrates an average of 6.4% difference between women and 
men.  Pearson correlations of both BAI and BMI with adiposity measurements within the 
entire study and each gender are shown in Table 6.2.  In the entire cohort, the correlation 
coefficient between BMI and %BF (r = 0.56) was found to be lower than the correlation 
coefficient between BAI and %BF (r = 0.78).  When analyses were performed according 
to gender the Pearson correlation coefficients of BAI with %BF were slightly lower than 
those of BMI with %BF.  Pearson correlations of both BAI and BMI with adiposity 
measurements among normal-weight, overweight, and obese groups within the entire 
study and each gender are shown in Table 6.3. Normal-weight or overweight men and 
women had BAI vs. %BF correlation coefficients higher than the BMI vs. %BF 
correlation coefficients.  However, BMI vs. %BF performed better than BAI vs. %BF in 
obese males and females.  
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6.4 - DISCUSSION 
 
 To date, few studies have attempted to validate the Body Adiposity Index within a 
Caucasian population[182, 238]. To our knowledge this is the first study to attempt to 
validate the accuracy of the Body Adiposity Index against DXA measured percentage 
body fat among normal-weight, overweight, and obese Caucasian men and women.  
Simple adiposity assessment methods, such as BMI, are usually used to either evaluate 
obesity status at an individual level in clinics and health clubs or to estimate the adiposity 
of a sample population within a research investigation.  In the entire cohort of this study, 
in which male and female subjects of all ages were mixed, the correlation coefficient 
between BAI and %BF was indeed much higher than that between BMI and %BF.  This 
is generally consistent with the finding obtained in the Mexican-American and African-
American populations, but the correlation coefficient between BAI and %BF in our 
CODING study was not as high as that shown in these two populations [170].  This result 
is more than likely due to the differences among the physical characteristics of these 
populations.  The data from our large Caucasian population demonstrates that the BAI 
method is more strongly associated with DXA (the current gold standard for adiposity 
measurement) body fat percentage than BMI.  
 Although our data showed that the BAI performs better in estimating adiposity 
compared with BMI in a large population based study (men and women combined), what 
is of concern is that both of the BAI equation variables (hip circumference and height 
measurements) are  essentially bone structure dependent.  In addition, data from the adult 
population of our CODING study shows that women are generally shorter in height, have 
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smaller waist and larger hip circumferences than men.  Therefore, longitudinal studies on 
measurement sensitive to the changes in adiposity similar for both men and women are 
warranted to aid in the development of an equation to accurately estimate adiposity.  Our 
measurements of percent body fat in the CODING study indicate a large gender 
difference of adiposity.  In the CODING study, women on average had 12.8% more total 
body fat than men.  Due to the findings from our population studies we believe it is also 
important to further evaluate the efficiency of the BAI to predict %BF in women and men 
separately.  
 
 To have an equation that can accurately estimate adiposity for both men and 
women in the general population would be ideal due to the inherent gender differences.  
However, considering that hip circumference, the primary measure in the BAI equation, 
is larger in females than in men [15] it could potentially reflect gender differences to 
some degree.  Conversely BAI adiposity scores are lower for men than women, and more 
closely represent the body fat percentage.  Although the estimation of gender difference 
from the BAI measure is about half of the real range measured by DXA, this ability of 
BAI to properly reflect the gender differences in adiposity is certainly an advantage over 
BMI.   
 
 Finally, we were also interested in investigating the potential influence of 
adiposity on the accuracy of BAI and the comparison with BMI through DXA as a gold 
criterion.  Therefore, the question that we wished to address was whether or not the two 
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skeletal system dependent variables would correctly reflect adiposity within various 
obesity statuses and if gender could be an important factor under these conditions.  We 
found that the BAI method performed better than BMI among normal weight, overweight 
and obese groups when both women and men were combined.  However, when women 
and men were analyzed separately the BAI only remained more strongly associated for 
the normal and overweight subjects.  The BAI vs. %BF correlation coefficients for obese 
men and women were less than that of those for the BMI vs. %BF.  Our findings indicate 
that caution should be taken when BAI is used to measure adiposity when obese women 
and men are separately evaluated.  This finding indicates the weakness of BAI as a new 
evaluation method of adiposity in obese subjects.  This weakness could be caused by the 
lack of measurement necessary to reflect adiposity and that the change in adiposity does 
not rely on height and hip circumference alone.  The poor ability to evaluate adiposity in 
obese women and men is a problem that should be addressed in future study.   
  
 In summary, the present study attempted to validate the accuracy by which BAI 
estimates adiposity among over 2600 Caucasian men and women (from the CODING 
study) along with various adiposity statuses defined by percentage body fat measured by 
DXA. Firstly, BAI can reflect the gender difference in total body fat percentage between 
men and women. Secondly, our data indicates that the BAI method is a better estimate of 
adiposity than BMI in non-obese Caucasian subjects. Meaning, from our Caucasian 
population, body fat percentage evaluated by BAI correlates better than BMI in normal-
weight and overweight men and women.  BAI was less associated with percent body fat 
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than that of BMI in obese men and women.  Therefore, caution should be taken when the 
BAI is used to evaluate adiposity in obese individuals.  However, more studies evaluating 
the concordance of BAI with DXA body fat percentage among normal-weight, 
overweight and obese subjects are needed.  We suggest that a measurement sensitive to 
the changes in adiposity for both men and women be incorporated into the present BAI 
equation to increase accuracy.  
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7.1 - INTRODUCTION 
 
 Obesity, characterized by excessive fat accumulation, is currently one of the top 
five leading risk factors for global mortality [18]. In Canada, the prevalence of obesity 
has tripled from 1985 to 2011, increasing from 6.1% to 18.3% [12]. The rise in obesity is 
mirrored by the rise of numerous obesity-related comorbidities including diabetes and 
cardiovascular disease [7-10]. This is especially relevant to the Canadian province of 
Newfoundland and Labrador, considering it has the highest rates of diabetes and obesity 
in Canada[12, 162]. The Canadian Diabetes Association has projected that by the year 
2020 over 15% of Newfoundland and Labradorean’s will be diabetic with an annual 
health care cost exceeding $360 million dollars[162].  However due to the excessive 
implementation of BMI, for obesity assessment, and its inability to differentiate fat mass 
from fat-free, the association of obesity with health risk factors has come into question 
[16, 239]. Air-displacement plethysmograohy (ADP), underwater weighing, magnetic 
resonance imaging (MRI) and/or dual-energy X-ray absorptiometry (DXA) are among 
the most precise measurements of body fat, conversely these methods are both expensive 
and impractical to assess obesity at the population level[163-165]. Therefore, recent 
focus has been placed on developing more accurate and cost effective methods of 
assessing adiposity for studying body fat associated disease risk [170, 188, 189].Due to 
its practicality and affordability the body mass index [(Weight (kg) / Height (m)²] has 
become the most well-known and commonly used predictors of adiposity and was 
developed well over 100 years ago [166]. However a number of limitations, such as body 
fat content, body fat distribution, gender and age, have been recognized as weaknesses of 
135 
 
adiposity assessment for by BMI [14, 15, 167-169, 183-186]. Moreover, previously 
published studies from our laboratory have demonstrated that BMI significantly 
misclassifies obesity status and that risk for cardiometabolic disease revealed by %BF 
increases can be missed by inappropriately normal obesity status by BMI[15, 16, 207, 
239].  
 
 Due to these limitations, the body adiposity index (BAI) was recently proposed as 
an alternative body composition estimate [170]. Unlike BMI, the BAI (hip circumference 
(cm)/[(height (cm)
1.5
)-18]) was derived from %BF measured by DXA and does not 
involve the measurement of body weight.  They reported that the BAI equation was more 
robust than BMI and required no statistical correction for gender or ethnicity [170]. 
However, regarding its prediction of %BF, it remains inconclusive whether BAI is a 
better predictor of %BF than BMI [170, 173-179].  Caution must be taken when 
interpreting the association of BAI with %BF as not all studies have employed a high 
resolution measure of body fat, such as DXA, which further adds to the controversial 
findings.  Despite the current criticisms of the BAI equations to predict %BF, an equally 
important question is; Does BAI more closely represent the association of %BF with 
obesity-related CRFs than BMI.   
To date, only a small number of studies have investigated the association of BAI 
and BMI with cardiometabolic metabolic risk factors (CRF)[190-194].Even fewer studies 
have included both insulin resistance and cardiovascular disease risk factors [190, 191].  
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Current studies have indicated that BAI is inferior to BMI as a predictor of CRFs. 
However, to the best of our knowledge, no large cross-section study has compared the 
association of insulin resistance and cardiovascular disease risk factors with BMI and 
BAI against their association with a high resolution measurement of body fat.  Therefore, 
the objectives of the current study were to assess the relationship of CRFs with BAI, BMI 
and %BF and to also determine whether the association of BAI, or BMI, with CRFs was 
more concordant with the associated with %BF (measured by DXA) with CRFs in the 
Newfoundland Population.  
  
7.2 - SUBJECTS & METHODS 
 
Ethics Statement  
 Ethics approval for this study was received from the Human Investigation 
Committee, Faculty of Medicine, Memorial University, St. John’s, Newfoundland, 
Canada. All subjects provided informed consent before taking part in this study. 
Subjects 
 All of the 3059 subjects (852 men 2207 women) from this current study 
are volunteers of the general population of Newfoundland and Labrador and are 
participants in the ongoing cohort CODING (Complex Diseases in the Newfoundland 
Population: Environment and Genetics) study. Eligibility criteria inclusion criteria in the 
CODING study included: 1) at least a third generation Newfoundlander; 2) 19 years of 
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age or older; and 3) healthy, without any documented serious medical conditions.  The 
primary method of subject recruitment for the CODING study was the use of posters and 
handouts.  This literature was distributed throughout public facilities (offices, hospitals, 
and gyms) in the city of St. John's, Newfoundland and Labrador.  All subjects completed 
screening questionnaires providing information about physical characteristics, physical 
activity, health status, and dietary practices.  Anthropometrics, body composition, and 
biochemical measurements were collected following a 12 hour fast. 
 
Anthropometric and Body Composition Measurements 
 Subjects were weighed (Health O Meter, Bridgeview, IL) to the nearest 0.1 kg in 
standardized clothing (hospital gown). Height was measured using a fixed stadiometer 
(nearest 0.1 cm). Hip circumference was measured as the largest circumference between 
the waist and thighs. Waist circumference was measured as the horizontal distance 
around the abdomen at the level of the umbilicus. Hip and waist measurements were 
recorded to the nearest 0.1 cm using a flexible metric measuring tape while the 
participant was in a standing position. Body mass index (BMI) was calculated by 
dividing the participant’s weight in kilograms by their height in meters squared (kg/m2). 
The body adiposity index (BAI) was calculated according to the equation [hip 
circumference (cm)/ height(m)
1.5– 18][170]. Percent body fat (%BF) was measured, in a 
supine position, utilizing dual-energy X-ray absorptiometry (DXA, Lunar Prodigy; GE 
Medical Systems, Madison, WI).DXA produces an accurate measurement of adipose 
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tissue within the body with a low margin of error. For this reason, DXA is considered to 
be one of the most accurate measurements of adiposity and is commonly used as a 
standard compared to less accurate field methods such as BMI. DXA measurements were 
performed on subjects following the removal of all metal accessories, while lying in a 
supine position [15-17].  Quality assurance was performed daily and the typical CV was 
1.3% during the study period.   
 
Biochemical measurements 
 Serum insulin concentrations were measured with the use of an immunoassay 
analyzer (Immulite; DPC, Los Angeles, CA).Insulin resistance and beta cell function 
were determined with the homeostasis model assessment (HOMA), as described by 
Matthews et al.[213]. 
 
HOMA-IR = [(Fasting Insulin (mU/L) x Fasting Glucose (mmol/L))/22.5] 
HOMA- = [(20x Fasting Insulin (mU/L))/(Fasting glucose (mmol/L) - 3.5)] 
 
 The serum concentrations of glucose, triacylglycerols (TG), high-density 
lipoprotein (HDLc) cholesterol and total cholesterol were measured by an Lx20 analyzer 
(Beckman Coulter Inc, Fullerton, CA) and the C16000 Architech Clinical Chemistry 
Analyzer (Abbott Diagnostics).  Low-density lipoprotein (LDLc) cholesterol was 
calculated by the Friedewald equation (see below).  The LDL cholesterol calculation is 
reliable in the absence of severe hyperlipidemia (TG > 4.6 mmol/L). 
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Statistical analysis 
 All data are reported as mean ± standard deviation (SD) unless otherwise 
stated. TG, insulin, HOMA-IR, and HOMA-β were log-transformed to normalize 
distributions for application of parametric statistical tests.  Differences in biochemical 
and body composition measurements between men and women were assessed using one-
way ANOVA.  Pearson correlation analysis was performed to compare the relationship of 
BAI and BMI with CRFs to the relationship %BF with CRFs within the entire cohort and 
among men and women separately.  BMI, BAI, and %BF were divided into tertiles (low, 
medium, or high) to study the relationship with cardiometabolic risk factors (Resting 
heart rate, systolic and diastolic blood pressure, total cholesterol, HDLc, LDLc, TG, 
glucose, insulin, HOMA-IR, and HOMA-β ).The differences in CRFs among body 
composition tertiles were assessed using a one-way ANOVA.  All statistical analyses 
were performed using PASW 19.0 (SPSS Inc., Chicago, IL). All tests were two-sided and 
a p value < 0.05 was considered to be statistically significant. 
 
7.3 - RESULTS 
 
Biochemical and body composition measurements for men, women, and the entire cohort 
)]2.2/)/(lg()/(_)/(_[ LmmollycerolTriacyLmmollCholesteroHDLLmmollCholesteroTotalLDLc 
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are presented in Table 7.1. 
 
Anthropometric and Body Composition Measurements 
 Height, weight, BMI, waist circumference, and waist-to-hip ratio were all 
significantly greater for men compared to women. However, Age, %BF, and BAI were 
significantly greater in women than men (Table 7.1).  
 
Cardiometabolic Risk Factors Measurements 
 TG, diastolic blood pressure, systolic blood pressure, glucose, insulin, HOMA-IR, 
and HOMA-β were significantly greater for men compared to women.  However, total 
cholesterol,  HDLc, and resting heart rate were significantly greater in women than men 
(Table 7.1). 
Cardiometabolic Risk Factors according to BMI, BAI and %BF tertiles.  
 Cardiometabolic risk factors were assessed among tertiles (low, medium, or high) 
of BMI, BAI and %BF results within the entire cohort and presented in Table 7.2.  The 
association of cholesterol, HDLc, LDLc, resting heart rate, glucose, and HOMA-β with 
BAI were concordant with their association with %BF (Table 7.2).  The association of 
TG and insulin with BAI and BMI were concordant with their association with %BF. 
However, the association of HOMA-IR with BMI was concordant with its association 
with %BF (Table 7.2).  Additionally, the association of systolic blood pressure with BAI 
and/or BMI were not concordant with their association with %BF or each other, and the 
141 
 
association of diastolic blood pressure with BAI was only concordant with its relationship 
to BMI (Table 7.2).  
 
 Cardiometabolic risk factors assessed among tertiles according to BMI, BAI and 
%BF among men and women are presented in Table 7.3. The association of HDLc and 
insulin with BAI were concordant with their association with %BF and the association of 
cholesterol with BMI was concordant with their association with %BF in men (Table 
7.3).  Additionally, the association of LDLc, TG, diastolic blood pressure with BMI and 
BAI were concordant with their associations with %BF in men. However, the association 
of systolic blood pressure, resting heart rate, glucose, HOMA-IR, and HOMA- β with 
BAI and/or BMI were not concordant with their associations with %BF in men (Table 
7.3).  Regarding women, the association of cholesterol, LDLc, glucose, insulin, HOMA-
IR, and HOMA-β with BMI were similar to their association with %BF (Table 7.3). The 
association of HDLc, TG, diastolic blood pressure and systolic blood pressure with BMI 
and BAI are concordant with their associations with %BF in women. However, the 
association of resting heart rate with BAI and/or BMI was not associated with %BFin 
women (Table 7.3).  
 
Pearson Correlation Analysis of Cardiometabolic Riskfactors with BMI, BAI and %BF 
 
 The Pearson correlation analyses of cardiometabolic risk factors with BMI, BAI 
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and %BF are presented in Table 7.4.  The association of HDLc, TG, diastolic blood 
pressure, systolic blood pressure, glucose, insulin, HOMA-IR, and HOMA-β with BMI 
was stronger than their association with BAI and/or %BF(Table 7.4).  However, the 
association of cholesterol and LDLc with %BF and/or BAI were stronger than their 
association and BMI and the correlation coefficient of resting heart rate with %BF was 
stronger than BMI and BAI (Table 7.4).Among men the correlation coefficient of TG, 
diastolic blood pressure, glucose, insulin, and HOMA-IR with BAI were greater than 
their association with BMI and/or %BF(Table 7.4). Conversely, the association of HDLc, 
systolic blood pressure, and insulin with BMI were greater than their association with 
BAI and/or %BF and the association of cholesterol, LDLc, resting heart rate and HOMA-
β with %BF were stronger than BMI and/or BAI (Table 7.4). 
 
 Among women the Pearson correlation coefficient of HDLc, TG, diastolic blood 
pressure, systolic blood pressure, glucose, insulin, HOMA-IR and HOMA-β with BMI 
were greater than their association with BAI and/or %BF (Table 7.4).  Conversely, the 
Pearson correlation coefficient of cholesterol and LDLc with BMI were greater than their 
association of BAI and/or %BF and the association of resting heart rate with %BF was 
stronger than both BMI and/or BAI (Table 7.4). 
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7.4 - DISCUSSION 
 
 To date, few studies have explored the association of the body adiposity index 
(BAI), a new predictive equation for adiposity, with cardiometabolic risk factors 
(CRFs)[190-194].  To our knowledge this is the largest cross-sectional study to determine 
whether BAI, or BMI, is more closely associated with the relationship of adiposity (%BF 
measured by DXA) with cardiovascular disease and type-2 diabetes risk factors while 
taking in to consideration both gender and the severity of obesity.  We found that BMI 
was more significantly associated with CRFs than either BAI or %BF in the 
Newfoundland population independent of sex.  However, the association of CRFs with 
BAI was more strongly concordant with %BF than BMI in both the general population 
and when men and women were examined separately.  Regarding the severity of 
adiposity, the influence of increasing BAI on CRFs was more strongly concordant with 
the increase in %BF than BMI.  Conversely, sex stratified analysis revealed that the 
influence of increasing BMI on CRFs was more concordant with the increase of %BF 
than BAI in women.  Although our results show that BMI has a stronger association with 
CRFs, the BAI more closely represents the association of CRFs with adiposity. 
 
The association of CRFs with obesity are not well established. The majority of 
epidemiological studies evaluating the association of CRFs with obesity assume the BMI 
accurately predicts adiposity.  The advent of new high resolution measurements of 
adiposity has allowed our laboratory [15-17, 178] and others [14, 15, 167-169, 183-
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186]to have demonstrate that BMI is a very poor predictor of adiposity and obesity status.  
In attempts to overcome the poor concordance of BMI with %BF and the impractically of 
DXA to evaluate obesity at the population level, a study by Bergman et al. [170] recently 
described a new predictive equation for adiposity called the body adiposity index (BAI).  
The BAI is calculated from two anthropometric measurements, height and hip 
circumference measurements measured in meters (m) and centimeters (cm) respectively.  
The BAI equation [ BAI = Hip circumference (cm) / height(m)
1.5
 – 18 ] was derived from 
the concordance between the %BF measured by DXA anthropometric measurements in a 
Mexican-American population. A recent study from our large Caucasian population [178] 
found that BAI was a stronger predictor of DXA %BF than BMI.  However, the 
predictive power of BAI is significantly attenuated when evaluating adiposity among 
men and women separately.  Additionally, BAI was more strongly associated with DXA 
%BF than BMI among normal-weight, overweight and obese individuals, but the 
predictive power of BMI was stronger than BAI in obese men and women when 
evaluated within the sexes separately.  Our findings[178], along with those of others[173, 
175, 178, 179, 194, 197, 200, 201, 203, 204], clearly demonstrate that the sexual 
dimorphism of body fat distribution presents a challenge to the BAI equation in %BF.  
Few studies to date have investigated the association of BAI with cardiometabolic risk 
factors[190-192, 195-198], and even fewer have included both insulin resistance and 
cardiovascular disease risk factor measurements[190, 191].  More importantly, no large 
cross sectional study to date has thoroughly compared the associations of BAI and BMI 
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with CRFs, and against the association of DXA %BF with CRFs while taking into 
consideration potential effects of gender and adiposity. 
 
 The current study, and others [190-192, 195-198], demonstrate that BMI 
significantly over estimates the association of obesity with CRFs.  Within the entire 
cohort or among men and women separately, BMI was more strongly associated CFRs 
than BAI or %BF.  Only total cholesterol, LDLc and resting heart rate were more 
significantly associated with %BF than BMI. Since a number of studies have shown that 
body weight shows greater association with CRF than hip circumference independent of 
sex, it is not surprising that BMI, which includes body weight as one of its determinants,  
was found to be more strongly associated with CRFs than BAI.  Studies by Snijder et al. 
[198] and Freedman et al. [199]showed that BMI and waist circumference more strongly 
correlated than BAI with LDLc, HDLc, TG, glucose, systolic blood pressure and diastolic 
blood pressure.  While an investigation from the Salzburg Atherosclerosis Prevention 
Program in Subjects at High Individual Risk (SAPHIR) study found that BMI was a 
better predictor of circulating lipids and glucose than BAI.  BMI was more strongly 
associated with HDLc, TG, glucose, insulin, and HOMA-IR than BAI [192]. Another 
study reported that BMI was more significantly associated with glucose, systolic blood 
pressure and diastolic blood pressure[195].  A weight loss study on obese post-
menopausal women by Elisha et al. [196] found that the reduction in BAI was not 
associated with changes in CRFs (total cholesterol, HDLc, TG, glucose, systolic blood 
pressure and diastolic blood pressure).  Although the findings from these investigations 
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are similar to our own, none of these have evaluated which of BMI and BAI more closely 
associates with %BF.  We found that BAIs relationship with CRFs more closely 
resembled that of  %BF's with CRFs.  These findings are supported by a recent study on 
698 Mexican Americans, which showed that BMI was more strongly associated with 
CRFs than either BAI or %BF[191]. More importantly, although they did not show nor 
describe the data in detail, the authors state that the association of CRFs with BAI more 
closely resembled that of DXA %BF than BMI. Our findings would suggest that since 
strength of association of BMI with CRFs is greater than that of %BF, adiposity is not the 
only determinate of BMI's association with CRFs. Considering that BMI is a poor 
predictor of adiposity, and an even worse predictor of obesity status, it must be 
recognized that the association of BMI with CRFs is fairly independent of adiposity. This 
finding suggests that BAI maybe more closely representative of the association of CFRs 
with adiposity and should be explored further.  Although, BMI has a stronger association 
with CRFs than does BAI, these findings should not lead to the claim that BMI is a more 
accurate predictor of adiposity associated CRFs than BAI.  
 We previously described the BAI as a stronger predictor of %BF in the general 
population [178]. The current study shows that BAI more closely resembles %BF in its 
relationship with CRFs. Considering this BAI could indeed be a useful tool in the study 
of obesity. The application of BAI in population based studies, where higher resolution 
assessments of adiposity are not available, could more accurately reflect the impact of 
obesity with CRFs, than BMI.  However, our current study and others [173, 175, 178, 
189, 194, 197, 200, 201] have clearly shown that BAI, like BMI, is not an effective 
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method for evaluating adiposity among men and women when sexes are examined 
separately.  Due to the BAI not accounting for the sexual dimorphism of body fat 
distribution, caution must be exercised if BAI is to be used in male/female populations 
separately.  Considering that obesity is growing rapidly across the globe, uncovering the 
association relative body fat with CRFs should also be investigated.   
 
 We were also interested in investigating the potential influence of adiposity on the 
association of CRFs and whether BMI or BAI would be more closely associated with the 
association of %BF (DXA as a gold standard criterion) with CRFs and if gender is an 
important factor. To account for adiposity we compared the association of increasing 
body fat percentage (tertile according to %BF measured by DXA) with CRFs against the 
association of increasing BMI and BAI on CRFs. The influence of increasing BAI on 
CRFs was more strongly concordant with that of increase in %BF than with BMI.  
However when the males and females were analyzed separately, the influence of 
increasing BMI on CRFs was more concordant with that of increase of %BF than BAI in 
women.  Interestingly, the influence of increasing %BF on cardiovascular disease 
biomarkers was similar to the influence of increasing BAI and BMI, but the association 
of insulin resistance risk factors with increasing %BF were different from either BMI or 
BAI in men.  This finding is not surprising.  The BAI maybe a better predictor of CRFs 
for men due to this region being more sensitive to fat accumulation than women. This 
means that women can accumulate significantly more body fat in this region than men 
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before experiencing a significant increase in cardiovascular risk. Additionally, other 
studies have hypothesized that body fat may not reflect health risk in women as larger hip 
circumferences in overweight/obese women may provide some protection against 
accumulating CRFs and cardiovascular risk with obesity.  If true, this could explain the 
stronger associations between BMI compared to BAI with the CRFs in the present study.  
Data from our laboratory supports this postulation having found that the accumulation of 
gynoid fat (body fat around the hips) is significantly more associated with CRFs in 
women than in men (data not shown).  Also, waist circumference of men had stronger 
concordance with DXA %BF than that of the hip circumference measurement used in the 
BAI equation[178, 197].The weakness of BAI stems from height and hip circumferences 
not accurately estimating adiposity or its association with CRFs in both women and men 
equally.  The association of BAI with CRFs is more closely %BF than BMI independent 
of sex.  Therefore we believe that developing sex specific adiposity equation(s), to better 
predict %BF among men and women, would more accurately calculate adiposity and its 
association with CRFs. Having such an equation would allow for a higher resolution 
assessment of obesity in very large populations along with a more accurate influence of 
body fat accumulation on morbidity and mortality at the population level.  
 
 The primary limitation of the current study is that all the findings were derived 
only from Caucasian men and women. Validation of our findings by other studies using 
subjects of other ethnicities should be carried out before applying our conclusions to 
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other populations. Additionally, confounding variables such as: age, dietary intake of 
micro- and macronutrients, medications use, menopausal status, physical activity levels 
and smoking have not been accounted for.  Although, the Pearson correlation analysis is 
adequate to support the findings in the present study, these aforementioned factors must 
be considered when attempting to further explore the physiological influence of adiposity 
on cardiometabolic risk factors.  For example it is well known that both physical 
activity[240, 241] and dietary intake [153, 239] play a significant role 
development/attenuation of insulin resistance.  
 
 In summary, we investigated the associations of BAI and BMI with CRFs against 
the association of DXA %BF with CRFs while taking into consideration both gender and 
adiposity.  The current study, which included 3059 subjects (852 men 2207 women) from 
the CODING study, revealed that BAI is more closely association with the relationship of 
%BF than BMI when subjects are not sub-categorized by gender. Our study also 
suggests, when considering adiposity, that the influence of increasing BAI on CRFs is 
similar to that of %BF in the general population.  However, this association is 
significantly attenuated when assessing the influence of increasing BAI on CRFs 
amongst men and women examined separately.  It is clear that BAI, like BMI, does not 
accommodated for the sexual dimorphism of body fat and significantly limits its ability to 
predict adiposity and its subsequent association with CRFs among men and women. We 
suggest that implementing measurements sensitive to the accumulation of body fat in 
men and women would aid in producing sex specific equations with greater predictive 
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power of adiposity and its association with CRFs.  Our data suggests for the first time 
that BAI maybe a more meaningful predictor of adiposity associated CRFs than BMI in 
populations studies where separate examination of male and female data is not warranted.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
 
8 
 
Chapter 8:A New Sex Specific Predictive Equation for an Evaluationof 
Body Fat PercentageMore Accurate Than BMI and BAI 
 
 
Farrell Cahill
1
, Yunqi Ji
1
, Yanqing Yi
1
, Pardis Pedram
1
, Mike Wahl
1
,  Guang Sun
1
 
 
1
 Division of Medicine, Faculty of Medicine, Memorial University of Newfoundland,  
  St. John’s, NL, Canada 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
This manuscript was not yet been submitted for publication 
 
 
156 
 
8.1 - INTRODUCTION 
 
 The high prevalence of obesity and obesity-related comorbities have grown to 
epidemic proportions and are critically important global health issues [161].  Currently, 
34.9% of the United States [4] and 18.3% of Canadians [12] are obese representing an 
annual health cost of ~$147 billion[5] and ~$7 billion [6], respectively.  These fiscal 
burdens are principally attributable to the strong concordance of adiposity with serious 
chronic health conditions such as; type 2 diabetes, hypertension, cardiovascular disease, 
and various forms of cancer [6].  This is especially pertinent to the Canadian province of 
Newfoundland and Labrador considering it has the highest rates of obesity and diabetes 
in Canada [12].  Currently, 27.7% of Newfoundlanders and Labradorians are obese [12] 
and approximately 10% of the general population struggle with diabetes [162], which 
corresponds to an annual cost of $254 million dollars.  Data from the Canadian 
Community Health Survey (CCHS) and the Canadian Diabetes Association (CDA) 
project that by the year 2020 over 71% on Newfoundland and Labradorians will be 
overweight/obese and the prevalence of diabetes will exceed 15%.   
The body mass index (BMI), calculated as weight (kg) divided by height squared 
(m
2
), is the most widely known and commonly used measure of obesity.  In fact, the 
World Health Organization (WHO) defines obesity as the abnormal or excessive fat 
accumulation represented by a BMI value greater than or equal to 30 kg/m
2
[18].  
However, numerous studies have shown that BMI has many weaknesses and does not 
accurately predict fat accumulation in a substantial portion of the general population.  
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Specifically, BMI does not account for the well documented gender differences in 
weight, adiposity and body fat distribution [167-169].  Also, since does not BMI 
accurately distinguish fat mass from and fat-free mass[16], it often mis-classifies obesity 
status by up to two obesity categories compared with more accurate methods [14, 15].  
More importantly, the false-negative classification of BMI defined obesity status reduces 
the identification of those at higher risk of cardiometabolic diseases with lower body fat 
content [187].  In fact, the WHO now admits that caution must be taken when utilizing 
BMI to classify obesity status[18].   
In a recent attempt to address the limitations of BMI, and the impracticality of 
magnetic resonance imaging (MRI) and dual-energy x-ray absorptiometry (DXA) to 
measure percent body fat (%BF), Bergman et al. [170] developed an equation which 
could accurately predict %BF body fat percent measured by DXA.  Regression analysis 
of anthropometric measurements with body fat produced the following formula for Body 
Adiposity Index (BAI), [hip circumference (cm)/ [(height (m)
1.5
] – 18] [170].  However, 
like the BMI, it is unknown if BAI will reflect the gender differences of height and hip 
circumference measurements [180, 181] along with various dynamic anatomical 
measurements utilized to evaluate adiposity.  Numerous studies to date, having evaluated 
the performance of BAI, have discovered that BAI is a strong predictor of percent body 
fat [173, 175, 178, 189, 194, 197, 200, 201].  However, these same studies also describe a 
significant reduction in the predictive power of BAI in evaluating adiposity when 
performed among men and women separately.  The BAI tends to over-estimate, and 
underestimate DXA %BF among men and women, respectively [174, 189,201].  
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Additionally, the waist circumference of men had stronger concordance with DXA %BF 
than that of the hip circumference measurement used in the BAI equation [178, 197]. 
Recent, studies have also revealed that the predictive power of BAI significantly 
decreases among underweight and obese individuals [173, 174, 178,201-204].  Our 
previous findings [178], and those of others [173, 175, 178, 179, 194, 197, 200, 201, 203, 
204], clearly demonstrate that not accounting for the sexual dimorphism of adiposity is 
the fundamental weakness of the BAI equation in predicting body fat percentage. This 
must be addressed to improve the development of future adiposity equations. 
 As the incidence of obesity and obesity-related diseases continues to increase, the 
need for an inexpensive and accurate assessment of adiposity has become of great 
importance to both clinical and epidemiological research.  To date few sex specific 
adiposity equations, which accurately predict high resolution %BF measured by DXA, 
have been developed.  Since BAI does not overcome the weakness of the BMI in 
predicting adiposity, the purpose of current study was to develop an equation(s) to more 
accurately predict body fat percentage among men and women in order to better define 
obesity status.  An equation such as this would be of critical importance to study the 
biomarkers related to obesity development and obesity-related comorbidities at the 
population level.  
8.2 - SUBJECTS & METHODS 
 
Ethics Statement 
 This study was approved by The Health Research Ethics Authority (HREA) for 
159 
 
the Faculty of Medicine, Memorial University of Newfoundland and Labrador, St John’s, 
Canada.  All subjects provided written informed consent. 
 
Subjects 
 A total of 3097 subjects (Male 881, Female 2254) were recruited from our 
ongoing large-scale Complex Diseases in the Newfoundland population: Environment 
and Genetics (CODING) study [15-17].  Anthropometric and body composition 
measurements were utilized to construct sex specific Body Fat Indices (BFIm and BFIf) to 
predict dual-energy x-ray absorptiometry (DXA).  Sixty percent of entire cohort (male 
518, female 1340) were randomly selected to construct the body fat percentage indices 
(BFIm and BFIf) and the remaining 40% (Male 363, Female 914) were implemented as a 
validation population.  All participants of this current study were from the Canadian 
province of Newfoundland and Labrador.  Inclusion criteria in the present study were as 
follows: (i) greater than 19 years age (ii) at least third-generation Newfoundlander; (iii) 
healthy, without any serious metabolic, cardiovascular, or endocrine disease.   The 
primary method of subject recruitment involved the use of posters and handouts.  This 
literature was distributed throughout public facilities (offices, hospitals, and gyms) in the 
city of St. John's, Newfoundland.  Anthropometrics, body composition, and biochemical 
measurements were collected following a 12 hour fasting period.  
 
Anthropometric and body composition measurements 
 Height (nearest 1.0 cm) and weight (nearest 0.1 kg) measurements were collected 
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and Body Mass Index (BMI) calculated.  BMI was defined as weight divided by height 
squared (kg/m
2
).  Waist circumference (cm) was measured as the horizontal distance 
around the abdomen at the level of the umbilicus, and hip circumference (cm) was 
measured as the largest circumference between the waist and thighs.  Height, waist and 
hip measurements were recorded to the nearest 0.1 cm. The body adiposity index (BAI) 
was calculated based on the equation reported in the Bergman paper [170].  Percent body 
fat (%BF) was measured utilizing a dual-energy X-ray absorptiometry (DXA, Lunar 
Prodigy; GE Medical Systems, Madison, WI).  The current version of the enCORE 
software for the DXA data presented within this manuscript cannot differentiate visceral 
from subcutaneous fat.  Therefore the %BF represents the summation of both 
subcutaneous and visceral fat.  DXA produces an accurate measurement of adipose tissue 
within the body with a low margin of error.  For this reason, DXA is considered to be one 
of the most reliable measurements of adiposity and is commonly used as a standard 
compared to less accurate field methods such as BMI.  The enCORE (Ver 12.2, 2008, GE 
Medical Systems, Madison, WI) software package was used for DXA data acquisition.  
DXA measurements were performed on subjects following the removal of all metal 
accessories, while lying in a supine position in standardized clothing as previously 
described by us [15-17, 90]. Quality assurance was performed on the DXA scanner daily 
and the typical CV during the study period was 1.4%.  
 
Statistical analysis 
 Creating Equation From Equation Dataset 
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 All data are reported as mean ± SD. The gender differences of variables measured 
were determined by an independent t test.  Pearson and partial (controlling for age) 
correlation analyses were performed to assess the association of anthropometric 
measurements with %BF measured by DXA.  Due to the significant sex difference found 
of anthropometric measurements, and their association with %BF, the body fat index 
(BFI) was modeled for both males (BFIm) and females (BFIf) separately. This was done 
by determining the value of ‘q’ that maximizes the partial correlation (control age) 
between U / [Height(m)]q  and  %BF where ‘U’ is represented as one of the following 
anthropometric measurements; Waist, Hip, or Weight. Pearson's correlation, partial 
correlation (controlling for age), and Lin's concordance correlation were employed to 
compare the predictive power of BFIm and BFIf with %BF against that of BMI and BAI.  
The Lin’s concordance correlation coefficient represents the strength-of-agreement 
between two continuous variables, which if it is lower than 0.90 is considered to be poor.   
 Validating Equation From Validation Dataset 
Pearson's correlation, Lin's concordance and Lin’s correlation coefficient of BFI 
(BFIm ,BFIf), BMI and BAI with percentage of body fat (%BF) measure by DXA from 
the equation and validation datasets were used to validate the BFI (BFIm ,BFIf) and 
compare the performance of each equation to predict %BF.  Pearson's correlation, Lin's 
concordance and Lin’s correlation coefficient of BFI (BFIm ,BFIf), BMI and BAI with 
percentage of body fat (%BF) measured by DXA among tertiles according to %BF in the 
validation dataset was used to compare the performance of each equation. Lastly, subjects 
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were stratified into tertiles (low, medium, high) based upon BFI, BMI, BAI, and %BF in 
the validation dataset to determine the correct classification counts/rates which 
determined by the number of subjects from each tertile group (BFI, BMI, and BAI), 
which corresponds to the tertile for %BF.R statistical software package version 2.15.2 (R 
development core team) was used for all analyses.  Statistical analyses were two-sided 
and a P value < 0.05 was considered to be statistically significant.  
8.3 - RESULTS 
 
Anthropometric and body composition 
 Anthropometric and body composition characteristics of the entire cohort, 
equation cohort, and validation cohort are shown in Table 8.1.  Weight, height, waist 
circumference, waist-to-hip ratio and BMI were significantly greater in men than women 
in all three cohorts.  Age, hip circumference, BAI, %BF, %TF, %AF, and %GF were 
significantly greater in women than men.  
 
Pearson and Partial Correlations of Anthropometric Measurements With DXA %BF  
 Pearson correlation analysis revealed that age, weight and waist and hip 
circumference were positively associated with DXA %BF and that height and sex were 
negatively associated with DXA %BF (Table 8.2).   Partial correlation analysis, 
controlling for age, demonstrated a very little overall effect on the significant association 
of anthropometric measurements with DXA %BF.  However, partial correlation analysis, 
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controlling for age and sex increased the correlation of weight, and waist and hip 
circumference with DXA %BF, while diminishing its significant association with height.   
 
Pearson and Partial Correlation of Anthropometric Measurements With DXA %BF 
Among Men and Women. 
 Pearson and partial (controlling age) correlation display that weight and waist and 
hip circumference are all positively associated with DXA %BF (Table 8.3).  However, 
weight and hip circumference are more positively associated with DXA %BF in women 
but waist circumference correlates more positively with it in men.  Moreover, the 
anthropometric measurement most positively associated with %BF in women was 
weight.   
 
Partial Correlation of Anthropometric Measurements (Adjusted For Height) With 
DXA %BF Among Men and Women. 
 To determine the maximum partial correlation (controlling for age) of 
anthropometric measurements (waist, hip, and weight), while adjusting for height, with 
%BF we had to determine the value for the power coefficient 'q' for height.  The value of 
'q' that maximizes the partial correlation between the anthropometric measurements with 
%BF was q = 0.46415 (r = 0.73572) for [Waist / (Height)q], q = 0.49054 (r = 0.76197) for 
[Hip / (Height)
q
], and q = 1.70150 (r = 0.76375) for [Weight / (Height)q] (Table 8.4).Among 
men the value of  'q' to maximize the partial correlation between the anthropometric 
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measurements with %BF was q = 0.43530 ( r = 0.78995) for [Waist / (Height)
q
], q = 
0.45750 (r = 0.75227) for [Hip / (Height)
q
], and q = 1.68880 (r = 0.73880) for [Weight / 
(Height)
q
] (Table 8.4).  Among women the value of  'q' to maximize the partial 
correlation between the anthropometric measurements with %BF was q = 0.60588 ( r = 
0.71883) for [Waist / (Height)
q
],  q = 0.57666 (r = 0.77634) for [Hip / (Height)
q
], and q = 
1.81496 (r = 0.77699) for [Weight / (Height)
q
].  For simplicity and efficiency of the new 
BFI, based on the analysis above, we choose Waist/Height
(q = 0.5)
 , Hip/Height
(q = 0.5)
 and 
Weight/Height
(q = 2.0) 
. 
 
The Association of BFIm and BFIf with DXA %BF 
 With the variables now in place Waist/Height
(q = 0.5)
 , Hip/Height
(q = 0.5)
 and 
Weight/Height
(q = 2.0) 
 with the optimal weights and/or powers determined we now had to 
determine the coefficients for each variable and the constant which would maximize the 
Lin's concordance of the resultant of both the BFIm and BFIF equations with %BF 
measured by DXA.  The Pearson's correlation coefficient  (r) is a measure of precision 
and the bias correction factor (C_b) is a measure of accuracy. The product of r and C_b is 
the concordance correlation coefficient.  The coefficients of 0.253819 for Waist/Height
(q 
= 0.5)
, 0.3920474 for Hip/Height
(q = 0.5)
 and 0.3541336 for Weight/Height
(q = 2.0)  
along with 
a constant of 32.68815 resulted in the highest Lin's concordance (0.990683) and Lin's 
concordance coefficient (0.8155655) for the BFIm with %BF in men (Table 8.5).  The 
coefficients of 0.3695107 for Waist/Height
(q = 0.5)
, 0.0683482 for Hip/Height
(q = 0.5)
 and 
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0.5621411 for Weight/Height
(q = 2.0)  
along with a constant of 11.45299 resulted in the 
highest Lin's concordance (0.9965971) and Lin's concordance coefficient (0.8047347) for 
the BFIf with %BF in women (Table 8.5).  Therefore the simplified sex specific predict 
equations for %BF are;  
 
{
 
 0.25
Hip(cm)
[Height(m)]
1/2+0.39
Waist(cm)
[Height(m)]
1/2+0.36
Weight(kg)
[Height(m)]
2−33 
0.37 Hip(cm)
[Height(m)]
1/2+0.07
Waist(cm)
[Height(m)]
1/2+0.56
Weight(kg)
[Height(m)]
2−11 
 
 
Association of BFI (BFIm ,BFIf), BMI and BAI with percentage of body fat (%BF) in 
the equation and validation dataset. 
 The Pearson's correlation for BFI with %BF was significantly greater than the 
correlation for BMI and/or BAI with %BF within the entire cohort or among men and 
women separately in both the equation and validation dataset (Table 8.6).  The Lin's 
concordance and Lin's concordance coefficient of BFI with %BF was also significantly 
greater than that for BMI and/or BAI with %BF within the entire cohort or among men 
and women separately in both the equation and validation dataset.  In addition, the 
Pearson's correlation, Lin's concordance and Lin's concordance coefficient of BFI with 
%BF within the entire cohort or among men and women separately for the equation 
dataset was similar that on the validation dataset (Table 8.6). 
 
BFI 
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Association of BFI (BFIm ,BFIf), BMI and BAI with percentage of body fat (%BF) 
among a tertiles according %BF in the validation dataset. 
 The Pearson's correlation, Lin's concordance and Lin's concordance coefficient of 
BFI with %BF was significantly greater than BMI and/or BAI with %BF at low, medium 
or high %BF (Table 8.7).  The Pearson's correlation, Lin's concordance and Lin's 
concordance coefficient of BMI and/or BAI with %BF were inconsistent and in 
inaccurate among the tertiles according to %BF.  This is especially prevalent for Lin's 
concordance and Lin's concordance coefficient of BMI and/or BAI with %BF in women 
in the medium and high %BF groups(Table 8.7).  
 
The classification counts of tertiles of BFI (BFIm BFIf),BMI, and BAI according to 
tertiles of percent body fat (%BF) measured by DXA in the validation dataset. 
 The classification counts for the low, medium, and high BFI with the low, 
medium, and high %BF were significantly greater than either of the counts of BMI and/or 
BAI tertiles with the %BF tertiles within the entire cohort or among men and women 
separately in the validation dataset (Table 8.8). Therefore, the low, medium and high BFI 
tertiles groups each had the highest inclusion counts of subjects from the low, medium 
and high %BF groups. 
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The classification rates of tertiles of BFI (BFIm BFIf),BMI, and BAI according to 
tertiles of percent body fat (%BF) measured by DXA in the validation dataset. 
 The concordant classification of low, medium, and high BFI with the low, 
medium, and high %BF were significantly greater than either of the concordance for BMI 
and/or BAI tertiles with the %BF tertiles within the entire cohort or among men and 
women separately in the validation dataset. Therefore, the low, medium and high BFI 
tertiles groups each had the highest concordance of classification rates of subjects from 
the low, medium and high %BF groups. (Table 8.9) 
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8.4 - DISCUSSION 
 
 The current study introduces a unique sex specific equation that more accurately 
predicts relative body fat (%BF) measured by dual-energy x-ray absorptiometry (DXA).  
The BFIm and BFIf equations were derived from common clinical anthropometric 
measurements, taking into account dimorphic sex differences of adiposity, to more 
directly predict %BF then using the body mass index (BMI) or the body adiposity index 
(BAI).  We have demonstrated that accounting for gender specific body fat distribution in 
our BFI equations have effectively increased the predictive power of %BF over that of 
both BAI and BMI in the general population and among men and women at various 
extremes of adiposity. 
 
 Our laboratory [15, 16, 178] and others [167-169, 186] have shown that adiposity 
assessments, which ignore the gender differences of body fat and body fat distribution, 
will inaccurately estimate relative body fat and obesity status.  Since, BMI does not 
account for the well documented gender differences in weight, adiposity and body fat 
distribution [167-169], it would not be surprising that a sex specific equation would 
perform better than BMI at predicting adiposity.  However, a new predictive equation 
called the body adiposity index has been developed and claims to effectively overcome 
gender differences without addressing them directly.  We tested this association through a 
validation study of the BAI equation on the large Caucasian population found in our 
CODING study[178].  Within the study entire cohort, the correlation coefficient between 
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BAI and %BF was stronger than the association of BMI with %BF[178].  This has also 
found in the majority of other studies attempting to validate the BAI equation [173, 175, 
178, 189, 194, 197, 200, 201].  However, these studies also demonstrated that the BAI 
was not a better predictor of DXA %BF compared with BMI when men and women were 
investigated separately.  We concluded that a measurement sensitive to the sex specific 
changes in adiposity for both men and women separately must be used to increase the 
predictive power of BAI[178].  Considering our previous findings and the critical need 
for an equation to more accurately predict adiposity at the population level we decided to 
create sex specific equations to predict body fat percentage measured by DXA.  
 Many epidemiological studies, defining obesity by BMI, have claimed that a 
number of metabolic and cardiovascular risk factors are related to adipose tissue 
accumulation.  However, since our laboratory and others have shown that BMI cannot 
accurately predict adiposity nor define obesity, it is possible that the majority of 
epidemiological obesity studies on large populations inaccurately define obesity and 
therefore its association on metabolic and cardiovascular disease.  This fact is evident in a 
number large number of studies showing that body fat percentage is significantly higher 
among women than men having the same BMI values.  This is also one of the strongest 
pieces of evidence demonstrating the sexual dimorphism of body fat.  Not only does BMI 
fail to accurately predict adiposity associated risk factors, but it also does not consider 
sex-specific body fat distribution and its effect on adiposity associated health risk factors.  
It is imperative that a more accurate measurement of body fat in the field be developed to 
more accurately predict the effects of adiposity on various health risk factors in both men 
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and women.  The goal of the present study was to develop sex specific equations to more 
accurately predict relative body fat (determined using DXA) than BMI.  
 
 The initial steps taken to create our sex specific equation was to assess the 
association of typical clinical anthropometric measurements such as weight (kg), height 
(m), hip and waist circumferences (cm) within the entire cohort and among men and 
women separately. Pearson correlation and partial correlation analysis (controlling for 
age) revealed that weight, waist circumference and hip circumference had reasonable 
associations with %BF, and partial correlation analysis controlling for gender revealed an 
amplified positive association of these variables with %BF.  As was initially 
hypothesized the gender dimorphism of body fat has a significant influence on the 
association of anthropometric measurements with adiposity.  This was further supported 
by the fact that the above anthropometric measurements were also more strongly 
associated with %BF among men and women separately.  In addition, because height was 
significantly negatively associated with %BF and nullified due to the consideration of 
gender, height was also considered an important factor in the prediction of body fat.  This 
was further supported by the observation that the correlations of weight, waist 
circumference and hip circumference with %BF were improved when correcting for 
height.  
 The next step involved determining the exponential weighting, that when applied 
to height, would optimize correction of height for each of the anthropometric 
measurements and maximizing their relationship with %BF.  The following model was 
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employed to determine the exponential weighting.  We setup that the exponential 
weighting value 'q' upon height which maximizes the correlation between the 
anthropometric measurements value 'U' and %BF [%BF = U / (height)
q
].  Among men 
the optimal 'q' for weight, waist circumference and hip circumference was 1.68880 (r = 
0.73880, p < 0.001), 0.43530 (r = 0.78995, p < 0.001), and 0.45750 (r = 0.75227, p < 
0.001) respectively.  Among women the optimal 'q' for weight, waist circumference and 
hip circumference was 1.81496 (r = 0.77699, p < 0.001), 0.60588 (r = 0.71883, p < 
0.001), and 0.57666 (r = 0.77634, p < 0.001) respectively.  Due to minimal and the non-
significant impact, 'q' values for both men and women were modified to 2.0 (Men - r = 
0.73709, Women - r = 0.77652; p < 0.001) for weight, 0.5 (Men - r = 0.78983, Women - r 
= 0.71860; p < 0.001) for waist circumference, and 0.5 (Men - r = 0.75218, Women - r = 
0.77612; p < 0.001) for hip circumference, to simplify the equation.   
 
 The final step in the design of the equation was to determine the optimal 
weight/coefficients that would be applied to each anthropometric measurement 
(appropriately corrected for height) and the resulting constant which would produce a 
body fat percentage maximally concordant with %BF measured by DXA.  We set BFI 
(BFIm and/or BFIf) the sum of the product of the optimal coefficient (a1, a2, a3) applied to 
each height corrected anthropometric measurement minus a corresponding optimal 
constant (C). The corresponding model was;  [BFI = a1(hip/(height)
0.5
) + 
a2(waist/(height)
0.5
) + a3(Weight/(height)
2.0
) - C].  Among men the optimal coefficients 
were 0.3541336, 0.253819, and 0.3920474 for weight, waist circumference and hip 
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circumference respectively with a constant of 32.68815 resulting in an optimal Lin's 
concordance of 0.990683. Among women the optimal coefficients were 0.3695107, 
0.0683282, and 0.5621411 for weight, waist circumference and hip circumference 
respectively with a constant of 11.45299 resulting in an optimal Lin's concordance of 
0.9965971. Therefore, the resulting sex specific equations were;  
 
BFIm= 0.25[hip(cm)/Height(m)
0.5
]+0.39[Waist(cm)/Height(m)
0.5
]+0.36[Weight(kg)/Height(m)]
2 
- 33 
BFIf= 0.37[hip(cm)/Height(m)
0.5
]+0.07[Waist(cm)/Height(m)
0.5
]+0.56[Weight(kg)/Height(m)]
2 
- 11 
 
 With the sex specific equations now optimally design the final step was to 
validate the predictive power of these equations in the validation dataset.  Our results 
demonstrated that the Pearson's correlation, Lin's concordance and Lin's correlation 
coefficient of our new BFI (BFIm and BFIf) with DXA %BF were greater than for BMI 
and/or BAI in the entire cohort and among men and women separately within the 
equation and validation dataset. Most noticeably the association of BFI with %BF 
remained remarkably constant when assessed among men and women separately.  
Although, both BAIs and BMIs association with %BF become inconsistent when 
assessed among sexes, this finding is not surprising. A number of studies to date have 
evaluated the performance of BAI and discovered it is as good or better predictor of %BF 
than BMI in the general population [173, 175, 178, 189, 194, 197, 200, 201].  However, 
these studies also discovered a significant reduction in the predictive power of BAI when 
evaluating adiposity among men and women separately.  Generally, the BAI tends to 
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over-estimate, and underestimate DXA %BF among men and women, respectively[174, 
189,201].   
 The current study demonstrates that our new BFI equation effectively 
incorporates the significant differences in body fat distribution between men and women.  
Although we have designed and validated equations which can better predict %BF than 
BMI and BAI in the general population and among men and women separately it is not 
clear if BFI would better predict body fat at low or high levels of DXA %BF.  After 
stratifying subjects into tertiles (low, medium, high) according to %BF the Pearson 
correlation, Lin's concordance, and Lin's correlation coefficient of BFI with %BF were 
significantly greater than that of BMI and BAI with %BF at the low, medium and high 
%BF.  This suggests that the BFI equations are better predictors of %BF at the variable 
extremes/ranges of adiposity.  A number of studies have also shown that the predictive 
power of BAI and BMI significantly decreases among underweight and obese individuals 
[173, 174, 178,201-204].  Our current study also revealed a significant reduction in the 
predictive power of both BMI and BAI, especially in women.   
 Lastly, we explored whether the BFI equations will better classify %BF than BMI 
and BAI.  Subjects were stratified into tertiles (low, medium, high) based upon BFI, 
BMI, BAI, and %BF in the validation dataset.  The correct classifications counts were 
determined by the number of subjects from each tertile of BFI, BMI, and BAI, which 
corresponds to %BF tertiles.  Our results revealed that the classification counts and/or 
rates of BFI with %BF were greater than for the BAI and BMI for each corresponding 
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%BF tertile (low, medium, and high).  
 
 Although our equations are more complicated than either BAI or BMI, the sex 
specific BFI equations designed in the current study more accurate predict %BF.  Not 
only have we shown that accounting for the sexual dimorphism of body fat in our 
equation effectively increased the predictive power of adiposity, but it can also increase 
the predictive power of %BF among various extremes of adiposity.  This is a very 
important point to consider due to the fact that the primary purpose of the work is based 
upon the assumption that adiposity is a critical determinant to chronic disease 
development at the population level.  Meaning that if we are to further understand the 
influence of body fat on various health conditions, a method like BMI, which cannot 
predict relative body fat, must be replaced with a more accurate predictor of adiposity for 
population based studies.  Therefore, due to rising prevalence of obesity across the globe 
a methodology, such as the equations we have designed, are necessary and significant 
contribution to assess adiposity and its subsequent association with disease.  
 
 Our study had certain limitations, many of which were due to its cross-sectional 
design.  Firstly, the design and validation of the BFIm and BFIf we derived only from a 
Caucasian population. Therefore, before the BFIM and BFIf equations can be 
implemented globally large scale validation studies involving different or mixed 
ethnicities must be performed.   
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 In summary, our study has introduced two new equations to directly predict the 
body fat percentage of men and women without the need of expensive equipment.  The 
BFIm and BFIf, which accurately calculate %BF measured by DXA, were derived from 
the anthropometric measurements most strongly assorted with adiposity in men and 
women, respectively.  Considering that we addressed the sexual dimorphism of body fat 
distribution, over looked by both BMI and BAI, the results indicate that our new sex 
specific equations better predict relative body fat.  Additionally, having considered the 
sexual dimorphism of adiposity, we believe that our equations will be more sensitive to 
the change in %BF observed during weight gain/loss.  The BFIm and BFIf equations will 
be a valuable tool for physicians, and epidemiological researchers, wishing to accurately 
assess relative body fat and its association with chronic diseases. 
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Chapter 9: Summary & Conclusions 
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9.1 –  Summary & Conclusion 
 
 Obesity, defined by the excessive accumulation of adipose tissue, is one of the 
leading causes of death around the world.  The high prevalence of obesity and obesity-
related comorbities have grown to epidemic proportions and are critically important 
global health issues. This thesis has contributed to further our understanding of obesity by 
exploring: 1) the association of appetite regulating hormones with adiposity and obesity 
status; 2) the response of appetite and energy regulating hormones to a positive energy 
challenge; 3) the association of dietary magnesium intake with insulin resistance adjusted 
for critical confounding factors; 4) the validity of the body adiposity index (BAI) to 
predict adiposity in a Caucasian population; 5) the association of BAI with 
cardiometabolic risk factors (CRFs), and 6) the development of two new sex-specific 
equations to predict body fat measured by dual-energy x-ray absorptiometry (DXA) 
better than BMI or BAI.  By implementing a multifaceted approach, we provide a strong 
comprehensive overview of the etiology of obesity. 
 
In Chapter 2 we evaluated the association of PYY (appetite suppressant) with 
obesity and obesity-related phenotypes in the general population.  Against most 
previously reported data, we found that circulating PYY is not inversely associated with 
obesity status defined by BMI or %BF adjusting for age, sex, smoking, medication use, 
and menopause. Our data, the largest and most comprehensive study controlling for 
confounding factors, do not support the idea that adiposity status, indexed by %BF or 
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BMI, determines basal PYY concentrations.  In addition, contrary to the initial or current 
literature we have demonstrated for the first time that fasting circulating PYY was 
positively associated with %BF, percent trunk fat (%TF), and waist circumference in 
women.  Our study also provides strong evidence that there is an obvious sex difference 
regarding fasting PYY concentration and that age, smoking, medication use and 
menopausal status all significantly influence circulating PYY concentration in women, 
but not men.  Although the effect size of the positive association of PYY with adiposity 
in women is small, and potentially negligible, it may in fact represent a protective 
response to weight gain. 
  
 Aside for investigating the association of appetite regulating hormones with 
obesity in the general population, we also sought to explore the response in circulating 
PYY (Chapter 3) and adiponectin (Chapter 4) in normal-weight, overweight and obese 
individuals to a 7-day hypercaloric diet.  Regarding PYY before overfeeding we found no 
significant differences in fasting serum PYY concentrations between normal-weight, 
overweight or obese men classified by %BF (DXA) or BMI.  This finding was also not 
surprising since the much larger study described in chapter 2 did not find any significant 
association of circulating PYY with obesity status in men.  We also discovered that 
serum PYY was significantly increased due to short-term positive energy challenge 
independent of adiposity.  The significant increase in PYY, being an appetite suppressant, 
could be physiologically meaningful by acting as a protective mechanism to counteract 
the hypercaloric diet.  Regarding adiponectin before overfeeding, we also found no 
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significant differences in fasting adiponectin between normal-weight, overweight or 
obese men classified by %BF (DXA) or BMI.  We did observed an inverse relationship 
with percent trunk fat (%TF), but this relationship is likely dependent upon insulin 
resistance.  This is supported by the fact that after controlling for fasting insulin and/or 
homeostatic model assessment (HOMA-IR) the association of %TF with adiponectin was 
nullified.  Lastly, serum adiponectin was also significantly increased due to short-term 
overfeeding independent of adiposity.  Our data suggests that the increase in adiponectin, 
in the face of short-term positive energy challenge, may act as a protective mechanism 
during periods of weight gain against insulin resistance independent of obesity status.  
This was the first study to indicate that the human body preserves the ability to increase 
the level of adiponectin when challenged by positive energy balance in people with all 
range of obesity status.  This finding is important for the treatment of insulin resistance in 
overweight/obese people. 
 
 In Chapter 5 we revealed that the favorable effects of dietary intake of 
magnesium was significantly positively associated with adiposity.  We discovered a 
beneficial dose dependent relationship between magnesium intake and insulin resistance, 
independent of age, gender, total caloric intake, physical activity, medication use, 
menopause, and adiposity. Moreover, this favorable association was more significant in 
overweight and obese subjects, suggesting that they may be more sensitive to the 
beneficial influences of dietary magnesium intake.  Adding to these findings, pre-
menopausal women were more significantly associated with the beneficial effects of 
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magnesium intake on insulin resistance than post-menopausal women.  We considered, 
since over 68% of our post-menopausal women are medication users, that the lack of 
association of magnesium intake with insulin resistance could be drug related 
interference.  However, this relationship remained absent among post-menopausal 
women whether or not medication status was included in the regression model.  Lastly, 
we also provide the first evidence that the association between dietary magnesium and 
insulin resistance was more strongly associated with DXA %BF than BMI and the 
concomitant increase in DXA %BF over BMI.  Therefore, because %BF more accurately 
represents adiposity than BMI, caution should be taken when attempting to utilize BMI as 
a measure of adiposity.  Chapter 5 may seem slightly disconnected from the entirety of 
this thesis, but this could not be further from the truth.  This work was vital to the 
development of my comprehensive understanding of the complexity of obesity research.  
It also demonstrates the significant influence of confounding factors when investigating 
obesity and obesity related co-morbidities.  But more importantly it led to question the 
definition of obesity itself.  
 
 Our evaluation of the accuracy of the BAI method we first explored in Chapter 6 
to determine whether BAI, a new predictive equation for adiposity, was more concordant 
with percent body fat (%BF) measured by DXA than the BMI.  We found that the entire 
cohort, where male and female subjects were mixed, the BAI was significantly more 
concordant with %BF than BMI.  However, when these relationships were evaluated 
among men and women separately, BMI was now slightly more concordant with %BF 
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than BAI.  Adding to these results, we were also interested in investigating the potential 
influence of obesity status on the predictive power of BMI and BAI.  We found that the 
BAI was more concordant with %BF than BMI in normal-weight, overweight, and obese 
subjects for the entire cohort.  Conversely, when evaluated among men and women 
separately, the BAI remained more concordant with %BF than BMI for normal-weight 
and overweight subjects.  Therefore, BAI was found to be a better modality to predict 
adiposity than BMI in non-obese Caucasian populations.  Our findings indicate that BAI 
does have some advantages over the utilization of BMI, but caution should be taken when 
attempting to predict adiposity with BAI equation among obese women and men.  We 
believe the weakness of the BAI equation is that adiposity relies not only on height and 
hip circumference measurements alone.  The BAI equation lacks the marker(s) that can 
reflect the change of body fat, which is critical due to the fact constant changes are the 
main characteristics in the development of obesity.  This study strongly suggests that a 
measurement sensitive to the changes in adiposity for both men and women should be 
incorporated into a new method to increase accuracy which is exactly what we have 
developed and illustrated in Chapter 8. 
 
 In Chapter 7, we found that BMI was more significantly associated with CRFs 
than either BAI or %BF in the Newfoundland population independent of sex.  However, 
the association of CRFs with BAI was more strongly concordant with %BF than BMI in 
both the general population and when men and women were examined separately.  
Regarding the severity of adiposity, the influence of increasing BAI on CRFs was more 
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strongly concordant with the increase in %BF than BMI.  Although our results 
demonstrated that BAI more closely represents the association of %BF with CRFs than 
BMI, it is clear that BAI, like BMI, does not accommodate for the sexual dimorphism.  
By not taking the sex-specific differences in adiposity into consideration both the BMI 
and BAI equations are limited in their ability to predict adiposity and to subsequent 
represent the association of adiposity with CRFs.  Therefore, we again have suggested 
that implementing measurements sensitive to the accumulation of body fat in men and 
women would aid in producing sex-specific equations with greater predictive power of 
adiposity and its true association with CRFs.   
 
 Lastly, in Chapter 8, since we have demonstrated that the sexual dimorphism of 
adiposity significantly weakens the ability of both BAI and BMI to predict adiposity we 
developed sex-specific equations to more accurately predict body fat percentage and 
better define obesity status.  Our findings demonstrate that our body fat index (BFI) 
equations can predict %BF significantly better than BAI and BMI in the general 
population, and among men and women separately, at various extremes of adiposity.  
Additionally, having introduced waist circumference which is sensitive to weight change, 
we believe that our equations will be more sensitive to the change in %BF observed 
during weight gain/loss.  The BFIm and BFIf equations describe in Chapter 8 will be a 
valuable tool for physicians, and epidemiological researchers, wishing to accurately 
assess relative body fat and its association with chronic diseases. 
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 In conclusion, this thesis has produced various novel findings and provided many 
new insights into understanding the etiology of obesity and diabetes development.  The 
significant strength of the current thesis is that both cross-sectional (CODING study) and 
intervention (Overfeeding study) studies were performed to investigate and answered 
many important physical and biochemical obesity-related questions.  In addition, the 
availability of DXA data in a population-based study gave us the ability to validate the 
predictive power of various adiposity equations and the subsequent development of 
equations that better predict adiposity.  Ultimately, the goal of the thesis was to 
comprehensively increase our understanding of obesity and subsequently produce novel 
findings to further our understanding of this condition.  We believe that the work 
enclosed has accomplished this goal.  
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A3.1 - Peptide YY (PYY) Responses to a 7-Day Positive Energy Challenge in 
Normal-Weight, Overweight, and Obese Young Men. 
Cahill, F., Sheridan K., Randell, E., Vasdev, S., Sun,G. (2010) 28th Annual Obesity Society 
Scientific Meeting ABSTRACT ID: 762-P 
Background:Gut hormones are important factors affecting food intake and the maintenance of 
energy homeostasis through gut-brain communication. Peptide YY (PYY), a linear 36amino acid, 
inhibits appetite and has been linked to the development of obesity. Objective: Our study was to 
investigate the relationship between PYY and obesity related phenotypes before and after a 7-day 
overfeeding protocol (70% above normal energy requirement). Design: The study recruited 72 
participants. We analyzed the potential relationship between serum PYY before and after 
overfeeding and the PYY changes with baseline energy requirement measured by the Willet 
Frequent Food Questionnaire and three 24hr recalls, weight, BMI, %BF, waist circumference, 
glucose, insulin, insulin resistance and beta cell function evaluated by the Homeostasis Model 
Analysis (HOMA-IR, HOMA-β), total cholesterol, HDL, LDL. Results:  The PYY concentration 
was significantly increased after the 7-day positive energy challenge (118.3pg/ml ± 57.8 to 
135.8pg/ml ± 70.1, p = 0.010). However, no significant differences of serum PYY between 
normal weight, overweight and obese subjects based on BMI or Body Fat Percentage (%BF) 
measured by DXA. No significant correlation was found after controlling for age and %BF or 
BMI. The positive energy challenge was overwhelmingly strong and induced significant change 
in body composition related phenotypes, negative changes in lipids and insulin resistance in the 
entire cohort. Conclusion: To our knowledge, this is the first study on the regulation of PYY by 
positive energy challenge. The increase in PYY, likely a protective response to overfeeding, 
suggests its usefulness in the prevention/treatment of human obesity. 
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A3.2 - Concordance of Body Adiposity Index (BAI) and BMI with DXA. 
Sun, G., Cahill, F., Yi.Y.,Xie, Y., Bridger, T., Pace, D., Zhang, H. (2011) 29th Annual 
Obesity Society Scientific Meeting ABSTRACT ID: 774-P 
Background: A recent study created a new parameter called Body Adiposity Index (BAI) to 
evaluate body fat using hip circumference and height. The equation was developed using a 
Mexican-American population and has not been validated in any Caucasian population. 
Objective: Compare the BAI and BMI by comparing the concordance with the dual-energy x-ray 
absorptiometry (DXA). Design: A total of 2601 adults from the CODING study recruited from 
the Canadian Province of Newfoundland & Labrador were used in the analysis. The partial 
correlation analysis was used.  Comparison was performed in all subjects and in men and women 
separately. In addition, body fat percentage (%BF) was also compared. Results: The correlation 
coefficients of BAI and BMI with DXA were r = 0.78 and r = 0.56 respectively for the entire 
cohort. However, when analysis was performed according to gender the performance of BAI 
compared with BMI was lower (r = 0.67 BAI vs. r = 0.70 BMI and r = 0.74 BAI vs. r = 0.76 in 
men and women respectively). Conclusion: The performances of BAI for %BF were lower in 
obese men and women when analysis was performed according to sex. BAI is a simple and better 
method than BMI in evaluating adiposity in NW and OW people but worse than BMI in OB 
people. We would suggest that a measurement sensitive to the changes in adiposity for both men 
and women be incorporated into the present BAI equation to increase efficiency 
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A3.3 - No Association Between Serum Whole Peptide YY (PYY) and Adiposity 
Status was Found in the Newfoundland Population. 
Cahill,F.,Wadden,D., Gulliver,W., Randell,E., Vasdev,S., Sun, G. (2011) 29th Annual 
Obesity Society Scientific Meeting ABSTRACT ID: 507-P 
Background: PYY is an appetite suppressing gut hormone, and has been linked to obesity in 
humans. However, there is little data regarding the association between PYY with obesity at the 
population level. Objective: The present study explored the link between serum PYY and obesity 
related phenotypes among normal-weight(NW),overweight(OW) and obese(OB) men and 
women.  Design: 2358 CODING study subjects (Male=594 Female=1764) participated in this 
study.  Whole PYY was measured with an enzyme-linked immunosorbent assay (ELISA). 
Adiposity status (NW, OW & OB) was determined by the Bray Criteria (age and gender specific) 
according to percent body fat (%BF) measured by Dual-Energy X-ray Absorptiometry (DXA). 
Percent trunk fat (%TF), android fat (%AF) and gynoid fat (%GF) were also measured by DXA . 
Partial correlations and ANOVAs were used to determine relationships with and differences of 
PYY within and between adiposity groups. Age and physical activity were controlled for.  
Analyses were also done according to menopausal, smoking, and medication use status. All 
subjects fasted 12 hr before blood drawings and DXA scans.  Results: Serum PYY was higher in 
males than females (118.5±77.3 pg/ml  vs  108.4±73.7pg/ml,  p=0.001).  No significant 
difference in serum PYY among NW, OW and OB subjects in the   entire cohort.  No significant 
difference in serum PYY among NW, OW and OB within each gender. No significant 
correlations between PYY and any obesity measure including BMI. Conclusion:  To our 
knowledge, this is the first and largest population based study exploring the association of  serum 
PYY with obesity related phenotypes. Our data do not support the idea that PYY plays a major 
role in determining adiposity status. 
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A3.4 - Serum whole Peptide YY (PYY) is Inversely Associated with Dietary Protein 
and Essential Amino Acids (EAAs) for Men in the CODING STUDY. 
Cahill, F.,Wadden, D., Gulliver, W., Randell, E., Vasdev, S., Sun, G.(2011) 29th Annual 
Obesity Society Scientific Meeting ABSTRACT ID: 518-P 
Background: PYY is a gut hormone which encourages the cessation of food intake. It has been 
suggested that serum levels of PYY is related with dietary protein. However, data is missing 
regarding the association between macro-nutrient intake with circulating PYY in the general 
population.  Objective: Therefore, the purpose of this study was to investigate the relationship 
between PYY with dietary protein, carbohydrates, fat, EAAs and total caloric intake.  Design: 
2295 CODING study subjects (Male = 578, Female = 1717) participated in this study. Whole 
PYY was measured using an enzyme-linked immunosorbent assay (ELISA) method. Dietary 
intakes of the nutrients were collected from the Willett Food Frequency survey and rendered with 
the Nutribase 8 software package. ANCOVA analysis, controlling for age and physical activity 
(PA), was performed to determined differences between gender and medication status 
[Medication (MED) and non-Medication (NON-MED) user]. All subjects fasted 12 hr before 
blood drawings and DXA scans.  Results: Men had higher levels of PYY than women (Men 
118.00±77.4pg/ml, vs. Women 108.41±73.8 pg/ml,  p = 0.001) but women ingested more dietary 
protein (Men 1.30±0.96 g/kg/day vs Women=1.33±0.88g/kg/day,   p = 0.01) and EAAs than men. 
However, Partial correlations (controlling age and PA) revealed a negative relationship between 
PYY with protein(g/kg/day) intake(r = -0.11, p = 0.02) for men. Regarding medication use, NON-
MED men revealed stronger associations between PYY with protein(g/kg/day)(r  = -0.14, p = 
0.01) and a new association with 9 EAAs(mg/kg/day) (r = -0.15 to -0.14, p = 0.01 to <0.001). 
Conclusions: Our study found significant inverse correlations between serum PYY with dietary  
protein and 9 EAAs in men but not women. The effect of dietary protein on serum PYY could be 
interfered by medication use.  
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A3.5 - Fasting Serum Peptide YY (PYY) Concentration is Associated with Glucose 
and Insulin Resistance in pre-menopausal Women. 
Cahill,F.,Wadden,D., Gulliver,W., Randell,E., Vasdev,S., Sun, G.(2011) 29th Annual 
Obesity Society Scientific MeetingABSTRACTID:517-P 
Background: The appetite suppressing gut hormone PYY has been suggested to influence insulin 
sensitivity. However data at the population level is missing.  Objective: Our objective was to 
investigate the relationship between PYY with glucose (GLU), insulin (INS) and insulin 
resistance (IR) in the Newfoundland population. Design: 2077 CODING study subjects 
(Male=595 Female=1573) participated in this study.  PYY was measured by enzyme-linked 
immunosorbent assay (ELISA). Lx20 and immunoassay analyzers measured GLU and INS, 
respectively. The homeostatic model assessment (HOMA) method was used to quantify IR. 
Partial correlations (controlling for age and physical activity) were used to determine associations 
between PYY with GLU, INS and IR. Analyses were also done according to menopausal, 
smoking, and medication status. ANOVAs were used to evaluate PYY within and between 
groups.  All subjects fasted 12 hr before blood drawings and DXA scans. Results: Men have 
higher PYY levels than women (p=0.001). PYY was positively correlated with GLU (r = 0.09 
P=0.006), INS (r = 0.10 P=0.002 ), IR (r = 0.11; P=0.002) in pre-menopausal women. PYY was 
found to be positively correlated with GLU (r = 0.10 P=0.01), INS (r = 0.14 P=0.001), IR (r = 
0.15; P=0.001), INS and IR in obese men and in normal and obese women.  Conclusion: Our 
study suggests that PYY is involved in insulin resistance and glucose regulation among pre-
menopausal women. Due to the fact that the associations between PYY with insulin resistance 
and glucose regulation were gender dependent and adiposity status dependent, further study is 
warranted. 
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A3.6 - Association Between the Body Adiposity Index (BAI) and Cardiometabolic 
Risk Factors (CRFs) among normal-weight (NW), overweight (OW), and obese 
(OB) men and women in the CODING study. 
Cahill, F.,Wadden, D., Amini, P., Lee, A., Yi, Y., Randell, E., Vasdev, S., Sun, G. (2012) 30th 
Annual Obesity Society Scientific Meeting. CONTROL ID: 1374824 
Background: The Body Adiposity Index (BAI) is a newly proposed method, developed using 
Mexican-Americans, to predict adiposity. Although BAI has demonstrated some advantages over 
Body Mass Index (BMI) as a predictor of whole adiposity, there is very little data regarding its 
association with Cardiometabolic Risk Factors (CRFs) in Caucasian populations.  Objective: The 
purpose of this investigation was to evaluate the relationship between BAI with CRFs and 
compare the predictive power of both BMI and BAI with CRFs among normal-weight 
(NW),overweight (OW) and obese (OB).Design: 2876 CODING study subjects (Male=734 
Female=2052) All subjects fasted 12 hr before blood drawings and DXA scans. Anthropometric 
(height, weight, waist circumference, hip circumference), and biochemical (glucose, insulin, 
triglycerides, and LDL cholesterol) makers were measured. Body composition (%BF, %TF, 
%AF, and %GF) were measured by dual-energy X-ray absorptiometry (DXA). Insulin resistance 
and β-cell function were determined with the homeostasis model assessment (HOMA-IR, 
HOMA-β). Pearson correlations, from the entire cohort, along with men and women separately, 
were employed to compare the correlation of both BAI and BMI with CRFs. In addition, the 
correlation of both BAI and BMI with CRFs were measured among NW, OW, and OB groups. 
Adiposity status was determined by the Bray Criteria according to %BF.Results: BAI was 
positively associated with glucose, insulin, HOMA-IR, and triglycerides with higher correlation 
coefficients in men than BMI. However, glucose, insulin, HOMA-IR, and triglycerides had 
higher correlation coefficients with BMI than BAI in women. The correlation coefficients 
between glucose, insulin, HOMA-IR, and triglycerides with BAI remained stronger for men then 
with BMI after stratified into NW, OW and OB groups. The correlation coefficients between 
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glucose, insulin, HOMA-IR, and triglycerides with BMI remained stronger for women then with 
BMI after stratified into adiposity groups.BAI showed higher correlation coefficients with 
cardiometabolic risk factors in men while BMI had higher correlation with cardiometabolic risk 
factors in women.  Conclusion: Our data would suggest that both BMI and BAI have gender 
specific biases regarding their ability to predict CRFs in the Caucasian population.  
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A3.7 - The Response of Five Functionally Connected Gut Hormones (PP, PYY, 
CCK, GLP-1 and Ghrelin) to a Short-term Positive Energy Challenge. 
Cahill, F.,Wadden, D., Amini, P., Lee, A., Yi, Y., Randell, E., Sun, G. (2012) 30th Annual 
Obesity Society Scientific Meeting. CONTROL ID: 1375761 
Background: The gastrointestinal tract (Gut) secretes a number of hormones which regulate 
metabolism and appetite through the gut-brain axis. Theoretically gut hormones are functionally 
associated. However, few studies have investigated whether gut hormones together and how they 
work as a functionally clustered hormonal group.  Objective: The purpose of our study was to 
evaluate how 5 functionally associated gut hormones: PP, PYY,  CCK, GLP-1 and Ghrelin 
respond to a short term positive energy challenge among normal-weight (NW),overweight (OW) 
and obese (OB) young men.Design: The 7-day positive energy challenge was set to 70% above 
normal energy requirements. The 5 gut hormones were measured using an ELISA method. The 
NW(8-20.9%), OW(21-25.9%), and OB(>26%) groups were classified by the Bray criteria 
according to percent body fat measured by dual-emission X-ray absorptiometry (DXA). Partial 
correlations (controlling for age and %BF) were used to assess the relationships among the 5 gut 
hormones at baseline and after a 7-day positive energy challenge.  Results: All 5 gut hormones 
were positively correlated with one another at baseline (Table 2.) Interesting baseline CCK level 
is positively correlated with the increase of PYY and GLP-1, which may represent a beneficial 
joint response to cope with the challenge of overfeeding. PYY at baseline predicts a decreased 
level of GLP-1 after overfeeding and CCK predicts an increased level of both PP and GLP-1. The 
5 gut hormones at baseline were found positively correlated with each other.   Conclusion: PYY 
level at baseline predicted a reduced GLP-1 response after overfeeding. However CCK level at 
baseline predicted a double increases of PYY and GLP-1 in response to a short period of 
overfeeding. Further study is warranted to understand the cluster response of gut hormones as a 
functional group in the development of human obesity and diabetes. 
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A3.8 - Pancreatic Polypeptide (PP) Response to a 7-Day Overfeeding in Young Men. 
Cahill, F.,Wadden, D., Amini, P., Lee, A., Randell,  E., Vasdev, S., Sun, G. (2012) 30th 
Annual Obesity Society Scientific Meeting. CONTROL ID: 1374895 
Background: Pancreatic Peptide, an anorexigenic hormone released from the pancreas, is 
involved in energy regulation. The administration of pancreatic peptide in humans reduces food 
intake. However, little is known how pancreatic peptide responds to a short term positive energy 
challenge.  Objective: The purpose of our study was to investigate the nutritional regulation of 
Pancreatic Peptide in response to a 7-day positive energy challenge (PEC) among normal-weight 
(NW),overweight (OW) and obese (OB) young men.Design: 69 young men participated in the 
study.The 7-day positive energy challenge was set to 70% above normal energy intake. Fasting 
serum Pancreatic Peptide  was measured via enzyme-linked immunosorbent assay (ELISA). 
Partial correlations were used to explore the relationship between Pancreatic Peptide  levels with 
obesity makers such as weight, body fat percentage (%BF), trunk fat percentage (%TF), body 
mass index (BMI),  triglycerides, HDL-C, LDL-C, glucose, insulin, insulin resistance (HOMA-
IR) and β-cell function (HOMA-β) at baseline and after the positive energy challenge.Results: 
The PEC significantly affected body composition, lipids and insulin profiles, but PP levels were 
not affected (Table 1). Baseline PP was not associated with baseline obesity markers within the 
entire cohort or among normal-weight overweight, and obese subjects based on %BF measured 
by DXA (Table 2). However, baseline PP was negatively associated with the increase in %BF(r= 
-0.318, p=0.016), %TF(r= -0.309, p=0.020) and insulin resistance in response to the PEC. These 
relationships remained after controlling for obesity status.Conclusion: To our knowledge, this is 
the first study to explore the association between PP and obesity related phenotypes before and 
after a PEC. Our findings suggest that PP is not significantly affected by our PEC and is not 
associated with obesity markers independent of adiposity status. However, higher baseline levels 
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of PP were found to be inversely correlated with a lower increase of body fat and insulin 
resistance suggesting a protective role of PP when exposed to a PEC. 
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A3.9 - Significant Association of Dietary Macronutrient Intake with Serum 
Gastrointestinal Hormones in Obese Children. 
Cahill, F.,Wadden, D., Amini, P., Bridger, T., Gulliver, W., Sun, G. (2013) 31st Annual 
Obesity Society Scientific Meeting. CONTROL ID: 1754611 
Background: Gastrointestinal (gut) hormones play an important role in the regulation of food 
intake and metabolism. Dysregulation of gut hormones are often seen in obese children. 
However, there is very little data regarding the effect of macronutrient (fat, protein and 
carbohydrates) intake on circulating levels of gut hormones in childhood obesity. Objective: The 
purpose of this investigation was to evaluate the relationship of the dietary intake of fat, protein 
and carbohydrates with fasting serum ghrelin, PYY, GLP-1, and Leptin among 100 obese 
children recruited from the Newfoundland population.  Design: Circulatingghrelin, PYY, GLP-1, 
and leptin were measured implementing the Luminex MAGPIX platform employing Milliplex 
magnetic bead assays.  Macronutrient intake was evaluated using the Willet Food Frequency 
Questionnaire and computed with the Nutribase software suite.  Results: Stepwise multiple 
regression analysis was performed to assess the association of dietary macronutrient intake with 
circulating ghrelin, PYY, GLP-1, and leptin. One-way analysis of variance obese children were 
ranked and divided into tertiles (Low, Medium, High) based upon dietary intake of carbohydrates, 
fat, protein to further assess dietary macronutrient intake appetite regulating hormones. Dietary 
carbohydrate was positively associated with fasting ghrelin (β 2.67, S.E. 0.71) and negatively 
associated with GLP-1 (β -0.80, S.E. 0.30) and leptin (β -1.29, S.E. 0.48). Dietary fat intake was 
positively associated with fasting ghrelin (β 14.17, S.E. 3.93, p = 0.001) and negatively 
associated with GLP-1 (β -3.58, S.E. 1.65, p = 0.033) and PYY (β -0.26, S.E. 0.12, p = 0.033). 
Higher circulating levels of ghrelin (19.86±12.6 vs. 38.8±30.3pg/ml, P = 0.049) were found in 
those with high carbohydrate intake. High dietary fat intake was significantly lower levels of 
PYY (66.27±43.1 vs. 42.43±28.1pg/ml, P = 0.029), GLP1 (18.48±9.2 vs. 13.61±5.8pg/ml, P = 
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0.038), and leptin (26.98±14.3 vs. 19.67±9.9ng/ml, P = 0.04).  Conclusion: In summary,  our 
results provide evidence that lowering dietary fat and carbohydrate intakes may help to normalize 
circulating gut hormones which are associated with lower body fat. 
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A3.10 - The Response and Interaction of Adiponectin, Leptin, and TNF-α Due to a 
Short-term Positive Energy Challenge. 
Cahill,F.,Amini, P., Wadden, D., Ji, Y., Khalili, S., Randell, E., Vasdev, S., Sun, G. (2013) 
31st Annual Obesity Society Scientific Meeting. CONTROL ID: 1754590 
Background: Adiponectin, leptin, and TNF-α areadipokines which affect, insulin sensitivity, 
appetite and energy homeostasis. However little data are available regarding the response and 
interaction of these three adipokines under a positive energy challenge (PEC), which is a major 
factor in the development of obesity. Therefore, we investigated the response and potential 
interaction(s) of circulating adiponectin, leptin and TNF-α to a PEC along with the influence of 
obesity status.  Objective: The purpose of our study was measure serum adiponectin, leptin, 
TNF-α before and after 7-days of overfeeding to investigate their response to a positive energy 
challenge and the functional interaction which may exist between these peptides among normal-
weight (NW) and overweight/obese (OW/OB) young men.Design: The 7-day positive energy 
challenge was set to 70% above normal energy requirements. The NW (8-20.9 %BF), OW/OB 
(>21 %BF) groups were classified by the Bray criteria according to percent body fat measured by 
dual-emission X-ray absorptiometry (DXA). ANOVA and multiple regression analysis were used 
to assess the relationships among the three adipokines before and after the 7-days of overfeeding 
in NW and OW/OB young men.  Results: Adiponectin and TNF-α at baseline were not 
associated with body composition.  After overfeeding circulating TNF-α increased in NW men 
only (p=0.032) and adiponectin increased (p<0.001) independent of adiposity status.  Circulating 
leptin concomitantly increased with adiposity at baseline (p<0.001) and also increased in 
response to the PEC (p<0.001). Among OW/OB, baseline TNF-α was negatively associated with 
the change in adiponectin (β -4.21, S.E. 1.85, p = 0.028) while baseline leptin was positively 
associated with the change in TNF-α (β 0.14, S.E. 0.04, p<0.001) due to overfeeding after 
adjusting for adiposity at baseline. Among OW/OB, the change in TNF-α, due to overfeeding, 
275 
 
was negatively associated with the change in adiponectin (β -1.75,  S.E. 0.44, p = 0.01) 
overfeeding after adjusting for adiposity at baseline.  Conclusion: Circulating levels of 
adiponectin, leptin and TNF-α were increased by the PEC. Additionally, our results suggest that 
baseline levels of TNF-α and leptin predict an attenuated response in adiponectin and an 
facilitated response of TNF-α ,due to a PEC independent of adiposity, respectively. 
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